HEADER RECORD*******LIBRARY HEADER RECORD!!!!!!!000000000000000000000000000000 SAS SAS SASLIB 9.4 X64_SR12 19MAY21:19:08:2019MAY21:19:08:20 HEADER RECORD*******MEMBER HEADER RECORD!!!!!!!000000000000000001600000000140 HEADER RECORD*******DSCRPTR HEADER RECORD!!!!!!!000000000000000000000000000000 SAS IE SASDATA 9.4 X64_SR12 19MAY21:19:08:2019MAY21:19:08:20 Inclusion/Exclusion Criteria Not Met HEADER RECORD*******NAMESTR HEADER RECORD!!!!!!!000000001600000000000000000000 STUDYID Study Identifier DOMAIN Domain Abbreviation USUBJID Unique Subject Identifier  SUBJID Subject Identifier for the Study )IESEQ Sequence Number 2IETESTCDInclusion/Exclusion Criterion Short Name :ÇIETEST Inclusion/Exclusion Criterion @ IECAT Inclusion/Exclusion Category  IEORRES I/E Criterion Original Result  IESTRESCI/E Criterion Result in Std Format  VISITNUMVisit Number d VISIT Visit Name  VISITDY Planned Study Day of Visit ~(EPOCH Epoch † IEDTC Date/Time of Collection ®IEDY Study Day of Collection ¸HEADER RECORD*******OBS HEADER RECORD!!!!!!!000000000000000000000000000000 mRNA-1273-P301IEmRNA-1273-P301-US300-2028US3002028AEXC11AImmunosuppressive or immunodeficient state, including HIV infection, asplenia, recurrent severe infections. EXCLUSIONYYAScreening ÂSCREENING 2020-07-28.mRNA-1273-P301IEmRNA-1273-P301-US300-2056US3002056AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-07-29.mRNA-1273-P301IEmRNA-1273-P301-US300-2085US3002085AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-03.mRNA-1273-P301IEmRNA-1273-P301-US300-2086US3002086AEXC11AImmunosuppressive or immunodeficient state, including HIV infection, asplenia, recurrent severe infections. EXCLUSIONYYAScreening ÂSCREENING 2020-08-03.mRNA-1273-P301IEmRNA-1273-P301-US300-2147US3002147AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-11.mRNA-1273-P301IEmRNA-1273-P301-US300-2287US3002287AEXC01 Participants who are acutely ill or febrile 72 hours prior to or at Screening may be rescheduled. Afebrile participants with minor illnesses can be enrolled at the discretion of the investigator. EXCLUSIONYYAScreening ÂSCREENING 2020-09-11.mRNA-1273-P301IEmRNA-1273-P301-US300-2301US3002301AEXC07AKnown or suspected allergy or history of anaphylaxis, urticaria, or other significant adverse reaction to the vaccine or its excipients. EXCLUSIONYYAScreening ÂSCREENING 2020-09-14.mRNA-1273-P301IEmRNA-1273-P301-US300-2310US3002310AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-09-17.mRNA-1273-P301IEmRNA-1273-P301-US300-2362US3002362AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-10-13.mRNA-1273-P301IEmRNA-1273-P301-US300-2370US3002370AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-10-20.mRNA-1273-P301IEmRNA-1273-P301-US301-2006US3012006AINC01 Adults, >= 18 years of age at time of consent, who are at high risk of SARS-CoV-2 infection. INCLUSIONNNAScreening ÂSCREENING 2020-07-27.mRNA-1273-P301IEmRNA-1273-P301-US301-2020US3012020AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-07-28.mRNA-1273-P301IEmRNA-1273-P301-US301-2032US3012032AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-07-30.mRNA-1273-P301IEmRNA-1273-P301-US301-2037US3012037AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-07-30.mRNA-1273-P301IEmRNA-1273-P301-US301-2050US3012050AINC01 Adults, >= 18 years of age at time of consent, who are at high risk of SARS-CoV-2 infection. INCLUSIONNN. . .mRNA-1273-P301IEmRNA-1273-P301-US301-2067US3012067AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-06.mRNA-1273-P301IEmRNA-1273-P301-US301-2071US3012071AEXC05 Demonstrated inability to comply with the study procedures. EXCLUSIONYYAScreening ÂSCREENING 2020-08-06.mRNA-1273-P301IEmRNA-1273-P301-US301-2074US3012074AINC01 Adults, >= 18 years of age at time of consent, who are at high risk of SARS-CoV-2 infection. INCLUSIONNNAScreening ÂSCREENING 2020-08-06.mRNA-1273-P301IEmRNA-1273-P301-US301-2088US3012088AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂBLINDED TREATMENT 2020-08-10AmRNA-1273-P301IEmRNA-1273-P301-US301-2089US3012089AINC03 Able to comply with study procedures based on the assessment of the Investigator. INCLUSIONNNAScreening ÂSCREENING 2020-08-10.mRNA-1273-P301IEmRNA-1273-P301-US301-2120US3012120AEXC03 Known history of SARS-CoV-2 infection. EXCLUSIONYYAScreening ÂSCREENING 2020-08-12.mRNA-1273-P301IEmRNA-1273-P301-US301-2122US3012122AEXC05 Demonstrated inability to comply with the study procedures. EXCLUSIONYYAScreening ÂSCREENING 2020-08-12.mRNA-1273-P301IEmRNA-1273-P301-US301-2123US3012123AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-12.mRNA-1273-P301IEmRNA-1273-P301-US301-2125US3012125AINC03 Able to comply with study procedures based on the assessment of the Investigator. INCLUSIONNNAScreening ÂSCREENING 2020-08-12.mRNA-1273-P301IEmRNA-1273-P301-US301-2128US3012128AINC01 Adults, >= 18 years of age at time of consent, who are at high risk of SARS-CoV-2 infection. INCLUSIONNNAScreening ÂSCREENING 2020-08-13.mRNA-1273-P301IEmRNA-1273-P301-US301-2129US3012129AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-13.mRNA-1273-P301IEmRNA-1273-P301-US301-2134US3012134AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-13.mRNA-1273-P301IEmRNA-1273-P301-US301-2135US3012135AEXC05 Demonstrated inability to comply with the study procedures. EXCLUSIONYYAScreening ÂSCREENING 2020-08-13.mRNA-1273-P301IEmRNA-1273-P301-US301-2136US3012136AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-08-13.mRNA-1273-P301IEmRNA-1273-P301-US301-2140US3012140AINC03 Able to comply with study procedures based on the assessment of the Investigator. INCLUSIONNNAScreening ÂSCREENING 2020-08-14.mRNA-1273-P301IEmRNA-1273-P301-US301-2147US3012147AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-14.mRNA-1273-P301IEmRNA-1273-P301-US301-2155US3012155AINC01 Adults, >= 18 years of age at time of consent, who are at high risk of SARS-CoV-2 infection. INCLUSIONNNAScreening ÂSCREENING 2020-08-14.mRNA-1273-P301IEmRNA-1273-P301-US301-2162US3012162AINC01 Adults, >= 18 years of age at time of consent, who are at high risk of SARS-CoV-2 infection. INCLUSIONNNAScreening ÂSCREENING 2020-08-17.mRNA-1273-P301IEmRNA-1273-P301-US301-2165US3012165AEXC09AHas received or plans to receive a non-study vaccine within 28 days before/after any dose of IP (except for seasonal influenza vaccine which not permitted within 14 days before/after any dose of IP).EXCLUSIONYYAScreening ÂSCREENING 2020-08-17.mRNA-1273-P301IEmRNA-1273-P301-US301-2172US3012172AEXC14 Has donated >= 450 mL of blood products within 28 days prior to Screening. EXCLUSIONYYAScreening ÂSCREENING 2020-08-18.mRNA-1273-P301IEmRNA-1273-P301-US301-2176US3012176AEXC07AKnown or suspected allergy or history of anaphylaxis, urticaria, or other significant adverse reaction to the vaccine or its excipients. EXCLUSIONYYAScreening ÂSCREENING 2020-08-18.mRNA-1273-P301IEmRNA-1273-P301-US301-2178US3012178AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-19.mRNA-1273-P301IEmRNA-1273-P301-US301-2184US3012184AINC01 Adults, >= 18 years of age at time of consent, who are at high risk of SARS-CoV-2 infection. INCLUSIONNNAScreening ÂSCREENING 2020-08-19.mRNA-1273-P301IEmRNA-1273-P301-US301-2187US3012187AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-19.mRNA-1273-P301IEmRNA-1273-P301-US301-2192US3012192AINC01 Adults, >= 18 years of age at time of consent, who are at high risk of SARS-CoV-2 infection. INCLUSIONNNAScreening ÂSCREENING 2020-08-19.mRNA-1273-P301IEmRNA-1273-P301-US301-2193US3012193AINC01 Adults, >= 18 years of age at time of consent, who are at high risk of SARS-CoV-2 infection. INCLUSIONNNAScreening ÂSCREENING 2020-08-19.mRNA-1273-P301IEmRNA-1273-P301-US301-2199US3012199AINC03 Able to comply with study procedures based on the assessment of the Investigator. INCLUSIONNNAScreening ÂSCREENING 2020-08-20.mRNA-1273-P301IEmRNA-1273-P301-US301-2200US3012200AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-20.mRNA-1273-P301IEmRNA-1273-P301-US301-2202US3012202AEXC05 Demonstrated inability to comply with the study procedures. EXCLUSIONYYAScreening ÂSCREENING 2020-08-21.mRNA-1273-P301IEmRNA-1273-P301-US301-2210US3012210AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-21.mRNA-1273-P301IEmRNA-1273-P301-US301-2218US3012218AINC01 Adults, >= 18 years of age at time of consent, who are at high risk of SARS-CoV-2 infection. INCLUSIONNNAScreening ÂSCREENING 2020-08-24.mRNA-1273-P301IEmRNA-1273-P301-US301-2219US3012219AINC01 Adults, >= 18 years of age at time of consent, who are at high risk of SARS-CoV-2 infection. INCLUSIONNNAScreening ÂSCREENING 2020-08-24.mRNA-1273-P301IEmRNA-1273-P301-US301-2225US3012225AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-21.mRNA-1273-P301IEmRNA-1273-P301-US301-2231US3012231AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-08-26.mRNA-1273-P301IEmRNA-1273-P301-US301-2243US3012243AINC04 Female participants of nonchildbearing potential may be enrolled in the study. Nonchildbearing potential is defined as surgically sterile or postmenopausal. INCLUSIONNNAScreening ÂSCREENING 2020-08-28.mRNA-1273-P301IEmRNA-1273-P301-US301-2257US3012257AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-02.mRNA-1273-P301IEmRNA-1273-P301-US301-2258US3012258AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-02.mRNA-1273-P301IEmRNA-1273-P301-US301-2259US3012259AEXC05 Demonstrated inability to comply with the study procedures. EXCLUSIONYYAScreening ÂSCREENING 2020-09-02.mRNA-1273-P301IEmRNA-1273-P301-US301-2266US3012145AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-14ÂmRNA-1273-P301IEmRNA-1273-P301-US301-2269US3012269AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-03.mRNA-1273-P301IEmRNA-1273-P301-US301-2271US3012271AINC05 Female participants of childbearing potential may be enrolled in the study if the participant fulfills all the criteria listed in the protocol. INCLUSIONNNAScreening ÂSCREENING 2020-09-03.mRNA-1273-P301IEmRNA-1273-P301-US301-2282US3012282AEXC09AHas received or plans to receive a non-study vaccine within 28 days before/after any dose of IP (except for seasonal influenza vaccine which not permitted within 14 days before/after any dose of IP).EXCLUSIONYYAScreening ÂSCREENING 2020-09-09.mRNA-1273-P301IEmRNA-1273-P301-US301-2301US3012301AEXC09AHas received or plans to receive a non-study vaccine within 28 days before/after any dose of IP (except for seasonal influenza vaccine which not permitted within 14 days before/after any dose of IP).EXCLUSIONYYAScreening ÂSCREENING 2020-09-14.mRNA-1273-P301IEmRNA-1273-P301-US301-2311US3012311AINC01 Adults, >= 18 years of age at time of consent, who are at high risk of SARS-CoV-2 infection. INCLUSIONNNAScreening ÂSCREENING 2020-09-14.mRNA-1273-P301IEmRNA-1273-P301-US301-2314US3012314AEXC09AHas received or plans to receive a non-study vaccine within 28 days before/after any dose of IP (except for seasonal influenza vaccine which not permitted within 14 days before/after any dose of IP).EXCLUSIONYYAScreening ÂSCREENING 2020-09-14.mRNA-1273-P301IEmRNA-1273-P301-US301-2320US3012320AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-15.mRNA-1273-P301IEmRNA-1273-P301-US301-2343US3012343AEXC05 Demonstrated inability to comply with the study procedures. EXCLUSIONYYAScreening ÂSCREENING 2020-10-19.mRNA-1273-P301IEmRNA-1273-P301-US301-2351US3012351AEXC12AHas received systemic immunosuppressants or immune-modifying drugs for >14 days in total within 6 months prior to Screening (for corticosteroids = 20 mg/day of prednisone equivalent). EXCLUSIONYYAScreening ÂSCREENING 2020-10-20.mRNA-1273-P301IEmRNA-1273-P301-US301-2355US3012355AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-10-22.mRNA-1273-P301IEmRNA-1273-P301-US301-2357US3012357AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-10-22.mRNA-1273-P301IEmRNA-1273-P301-US302-2002US3022002AINC06 Male participants that could result in pregnancy of sexual partners must agree to practice adequate contraception and refrain from sperm donation from the 1st dose to 3 months after the second dose. INCLUSIONNNAScreening ÂSCREENING 2020-07-27.mRNA-1273-P301IEmRNA-1273-P301-US302-2037US3022037AEXC11AImmunosuppressive or immunodeficient state, including HIV infection, asplenia, recurrent severe infections. EXCLUSIONYYAScreening ÂSCREENING 2020-07-28.mRNA-1273-P301IEmRNA-1273-P301-US302-2048US3022048AEXC11AImmunosuppressive or immunodeficient state, including HIV infection, asplenia, recurrent severe infections. EXCLUSIONYYAScreening ÂSCREENING 2020-07-28.mRNA-1273-P301IEmRNA-1273-P301-US302-2048US3022048A EXC12 Has received systemic immunosuppressants/immune-modifying drugs for >14 days in total within 6 months prior to Screening. Topical tacrolimus is allowed if not used within 14 days prior to Screening. EXCLUSIONYYAScreening ÂSCREENING 2020-07-28.mRNA-1273-P301IEmRNA-1273-P301-US302-2048US3022048A0INC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-07-28.mRNA-1273-P301IEmRNA-1273-P301-US302-2051US3022051AEXC07 History of anaphylaxis, urticaria, or other significant adverse reaction requiring medical intervention after receipt of a vaccine. EXCLUSIONYYAScreening ÂSCREENING 2020-07-28.mRNA-1273-P301IEmRNA-1273-P301-US302-2061US3022061AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-07-28.mRNA-1273-P301IEmRNA-1273-P301-US302-2072US3022072AEXC07 History of anaphylaxis, urticaria, or other significant adverse reaction requiring medical intervention after receipt of a vaccine. EXCLUSIONYYAScreening ÂSCREENING 2020-07-29.mRNA-1273-P301IEmRNA-1273-P301-US302-2080US3022080AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-07-29.mRNA-1273-P301IEmRNA-1273-P301-US302-2095US3022095AINC06 Male participants that could result in pregnancy of sexual partners must agree to practice adequate contraception and refrain from sperm donation from the 1st dose to 3 months after the second dose. INCLUSIONNNAScreening ÂSCREENING 2020-07-31.mRNA-1273-P301IEmRNA-1273-P301-US302-2101US3022101AEXC11AImmunosuppressive or immunodeficient state, including HIV infection, asplenia, recurrent severe infections. EXCLUSIONYYAScreening ÂSCREENING 2020-07-31.mRNA-1273-P301IEmRNA-1273-P301-US302-2106US3022106AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-07-31.mRNA-1273-P301IEmRNA-1273-P301-US302-2107US3022107AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-07-31.mRNA-1273-P301IEmRNA-1273-P301-US302-2110US3022110AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-03.mRNA-1273-P301IEmRNA-1273-P301-US302-2112US3022112AEXC11AImmunosuppressive or immunodeficient state, including HIV infection, asplenia, recurrent severe infections. EXCLUSIONYYAScreening ÂSCREENING 2020-07-31.mRNA-1273-P301IEmRNA-1273-P301-US302-2114US3022114AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-04.mRNA-1273-P301IEmRNA-1273-P301-US302-2117US3022117AINC04 Female participants of nonchildbearing potential may be enrolled in the study. Nonchildbearing potential is defined as surgically sterile or postmenopausal. INCLUSIONNNAScreening ÂSCREENING 2020-08-04.mRNA-1273-P301IEmRNA-1273-P301-US302-2118US3022118AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-04.mRNA-1273-P301IEmRNA-1273-P301-US302-2120US3022120AEXC07 History of anaphylaxis, urticaria, or other significant adverse reaction requiring medical intervention after receipt of a vaccine. EXCLUSIONYYAScreening ÂSCREENING 2020-08-05.mRNA-1273-P301IEmRNA-1273-P301-US302-2133US3022133AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-10.mRNA-1273-P301IEmRNA-1273-P301-US302-2138US3022138AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-10.mRNA-1273-P301IEmRNA-1273-P301-US302-2141US3022141AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-11.mRNA-1273-P301IEmRNA-1273-P301-US302-2153US3022153AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-17.mRNA-1273-P301IEmRNA-1273-P301-US302-2157US3022157AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-17.mRNA-1273-P301IEmRNA-1273-P301-US302-2158US3022158AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-17.mRNA-1273-P301IEmRNA-1273-P301-US302-2162US3022162AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-17.mRNA-1273-P301IEmRNA-1273-P301-US302-2163US3022163AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-17.mRNA-1273-P301IEmRNA-1273-P301-US302-2164US3022164AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-17.mRNA-1273-P301IEmRNA-1273-P301-US302-2168US3022168AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-17.mRNA-1273-P301IEmRNA-1273-P301-US302-2169US3022169AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-19.mRNA-1273-P301IEmRNA-1273-P301-US302-2170US3022170AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-19.mRNA-1273-P301IEmRNA-1273-P301-US302-2189US3022189AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-20.mRNA-1273-P301IEmRNA-1273-P301-US302-2206US3022206AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-20.mRNA-1273-P301IEmRNA-1273-P301-US302-2230US3022230AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-20.mRNA-1273-P301IEmRNA-1273-P301-US302-2261US3022261AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-21.mRNA-1273-P301IEmRNA-1273-P301-US302-2265US3022265AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-21.mRNA-1273-P301IEmRNA-1273-P301-US302-2266US3022266AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-21.mRNA-1273-P301IEmRNA-1273-P301-US302-2267US3022267AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-21.mRNA-1273-P301IEmRNA-1273-P301-US302-2271US3022271AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-21.mRNA-1273-P301IEmRNA-1273-P301-US302-2277US3022277AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-21.mRNA-1273-P301IEmRNA-1273-P301-US302-2282US3022282AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-21.mRNA-1273-P301IEmRNA-1273-P301-US302-2286US3022286AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-21.mRNA-1273-P301IEmRNA-1273-P301-US302-2298US3022298AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-08-28.mRNA-1273-P301IEmRNA-1273-P301-US302-2301US3022301AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-03.mRNA-1273-P301IEmRNA-1273-P301-US303-2032US3032032AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-07-29.mRNA-1273-P301IEmRNA-1273-P301-US303-2044US3032044AINC03 Able to comply with study procedures based on the assessment of the Investigator. INCLUSIONNNAScreening ÂSCREENING 2020-07-29.mRNA-1273-P301IEmRNA-1273-P301-US303-2057US3032057AINC03 Able to comply with study procedures based on the assessment of the Investigator. INCLUSIONNNAScreening ÂSCREENING 2020-07-30.mRNA-1273-P301IEmRNA-1273-P301-US303-2057US3032057A INC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-07-30.mRNA-1273-P301IEmRNA-1273-P301-US303-2073US3032073AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-04.mRNA-1273-P301IEmRNA-1273-P301-US303-2097US3032097AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-05.mRNA-1273-P301IEmRNA-1273-P301-US303-2102US3032102AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-05.mRNA-1273-P301IEmRNA-1273-P301-US303-2107US3032107AEXC12 Has received systemic immunosuppressants/immune-modifying drugs for >14 days in total within 6 months prior to Screening. Topical tacrolimus is allowed if not used within 14 days prior to Screening. EXCLUSIONYYAScreening ÂSCREENING 2020-08-05.mRNA-1273-P301IEmRNA-1273-P301-US303-2116US3032116AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-06.mRNA-1273-P301IEmRNA-1273-P301-US303-2118US3032118AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-06.mRNA-1273-P301IEmRNA-1273-P301-US303-2121US3032121AINC01 Adults, >= 18 years of age at time of consent, who are at high risk of SARS-CoV-2 infection. INCLUSIONNNAScreening ÂSCREENING 2020-08-06.mRNA-1273-P301IEmRNA-1273-P301-US303-2130US3032130AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-06.mRNA-1273-P301IEmRNA-1273-P301-US303-2147US3032147AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-07.mRNA-1273-P301IEmRNA-1273-P301-US303-2150US3032150AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-07.mRNA-1273-P301IEmRNA-1273-P301-US303-2155US3032155AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-08.mRNA-1273-P301IEmRNA-1273-P301-US303-2156US3032156AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-08.mRNA-1273-P301IEmRNA-1273-P301-US303-2165US3032165AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-08.mRNA-1273-P301IEmRNA-1273-P301-US303-2168US3032168AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-10.mRNA-1273-P301IEmRNA-1273-P301-US303-2190US3032190AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-11.mRNA-1273-P301IEmRNA-1273-P301-US303-2210US3032210AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-18.mRNA-1273-P301IEmRNA-1273-P301-US303-2212US3032212AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-18.mRNA-1273-P301IEmRNA-1273-P301-US303-2224US3032224AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-19.mRNA-1273-P301IEmRNA-1273-P301-US303-2232US3032232AEXC14 Has donated >= 450 mL of blood products within 28 days prior to Screening. EXCLUSIONYYAScreening ÂSCREENING 2020-08-19.mRNA-1273-P301IEmRNA-1273-P301-US303-2246US3032246AEXC11BImmunosuppressive or immunodeficient state, asplenia, recurrent severe infections (HIVpositive participants on stable antiretroviral therapy are not excluded). EXCLUSIONYYAScreening ÂSCREENING 2020-08-19.mRNA-1273-P301IEmRNA-1273-P301-US303-2256US3032256AEXC12 Has received systemic immunosuppressants/immune-modifying drugs for >14 days in total within 6 months prior to Screening. Topical tacrolimus is allowed if not used within 14 days prior to Screening. EXCLUSIONYYAScreening ÂSCREENING 2020-08-19.mRNA-1273-P301IEmRNA-1273-P301-US303-2271US3032271AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-20.mRNA-1273-P301IEmRNA-1273-P301-US303-2272US3032272AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-20.mRNA-1273-P301IEmRNA-1273-P301-US303-2290US3032290AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-20.mRNA-1273-P301IEmRNA-1273-P301-US303-2291US3032291AEXC07AKnown or suspected allergy or history of anaphylaxis, urticaria, or other significant adverse reaction to the vaccine or its excipients. EXCLUSIONYYAScreening ÂSCREENING 2020-08-20.mRNA-1273-P301IEmRNA-1273-P301-US303-2295US3032295AEXC12 Has received systemic immunosuppressants/immune-modifying drugs for >14 days in total within 6 months prior to Screening. Topical tacrolimus is allowed if not used within 14 days prior to Screening. EXCLUSIONYYAScreening ÂSCREENING 2020-08-21.mRNA-1273-P301IEmRNA-1273-P301-US303-2298US3032298AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-21.mRNA-1273-P301IEmRNA-1273-P301-US303-2306US3032306AEXC07AKnown or suspected allergy or history of anaphylaxis, urticaria, or other significant adverse reaction to the vaccine or its excipients. EXCLUSIONYYAScreening ÂSCREENING 2020-08-21.mRNA-1273-P301IEmRNA-1273-P301-US303-2311US3032311AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-21.mRNA-1273-P301IEmRNA-1273-P301-US303-2314US3032314AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-21.mRNA-1273-P301IEmRNA-1273-P301-US303-2335US3032335AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-22.mRNA-1273-P301IEmRNA-1273-P301-US303-2338US3032338AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-25.mRNA-1273-P301IEmRNA-1273-P301-US303-2342US3032342AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-31.mRNA-1273-P301IEmRNA-1273-P301-US304-2007US3042007AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-07-28.mRNA-1273-P301IEmRNA-1273-P301-US304-2012US3042012AEXC14 Has donated >= 450 mL of blood products within 28 days prior to Screening. EXCLUSIONYYAScreening ÂSCREENING 2020-07-28.mRNA-1273-P301IEmRNA-1273-P301-US304-2019US3042019AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-07-29.mRNA-1273-P301IEmRNA-1273-P301-US304-2096US3042096AEXC13 Has received systemic immunoglobulins or blood products within 3 months prior to the day of screening. EXCLUSIONYYAScreening ÂSCREENING 2020-08-06.mRNA-1273-P301IEmRNA-1273-P301-US304-2137US3042137AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-11.mRNA-1273-P301IEmRNA-1273-P301-US304-2140US3042140AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-11.mRNA-1273-P301IEmRNA-1273-P301-US304-2159US3042159AINC01 Adults, >= 18 years of age at time of consent, who are at high risk of SARS-CoV-2 infection. INCLUSIONNNAScreening ÂSCREENING 2020-08-12.mRNA-1273-P301IEmRNA-1273-P301-US304-2161US3042161AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-12.mRNA-1273-P301IEmRNA-1273-P301-US304-2163US3042163AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-12.mRNA-1273-P301IEmRNA-1273-P301-US304-2193US3042193AEXC11BImmunosuppressive or immunodeficient state, asplenia, recurrent severe infections (HIVpositive participants on stable antiretroviral therapy are not excluded). EXCLUSIONYYAScreening ÂSCREENING 2020-08-14.mRNA-1273-P301IEmRNA-1273-P301-US304-2195US3042195AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-14.mRNA-1273-P301IEmRNA-1273-P301-US304-2201US3042201AEXC09AHas received or plans to receive a non-study vaccine within 28 days before/after any dose of IP (except for seasonal influenza vaccine which not permitted within 14 days before/after any dose of IP).EXCLUSIONYYAScreening ÂSCREENING 2020-08-14.mRNA-1273-P301IEmRNA-1273-P301-US304-2214US3042214AINC01 Adults, >= 18 years of age at time of consent, who are at high risk of SARS-CoV-2 infection. INCLUSIONNNAScreening ÂSCREENING 2020-08-17.mRNA-1273-P301IEmRNA-1273-P301-US304-2240US3042240AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-08-19.mRNA-1273-P301IEmRNA-1273-P301-US304-2245US3042245AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-19.mRNA-1273-P301IEmRNA-1273-P301-US304-2257US3042257AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-20.mRNA-1273-P301IEmRNA-1273-P301-US304-2284US3042284AEXC09AHas received or plans to receive a non-study vaccine within 28 days before/after any dose of IP (except for seasonal influenza vaccine which not permitted within 14 days before/after any dose of IP).EXCLUSIONYYAScreening ÂSCREENING 2020-08-21.mRNA-1273-P301IEmRNA-1273-P301-US304-2303US3042303AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-22.mRNA-1273-P301IEmRNA-1273-P301-US304-2313US3042313AEXC12 Has received systemic immunosuppressants/immune-modifying drugs for >14 days in total within 6 months prior to Screening. Topical tacrolimus is allowed if not used within 14 days prior to Screening. EXCLUSIONYYAScreening ÂSCREENING 2020-08-22.mRNA-1273-P301IEmRNA-1273-P301-US304-2317US3042317AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-22.mRNA-1273-P301IEmRNA-1273-P301-US304-2318US3042318AINC03 Able to comply with study procedures based on the assessment of the Investigator. INCLUSIONNNAScreening ÂSCREENING 2020-08-22.mRNA-1273-P301IEmRNA-1273-P301-US305-2017US3052017AEXC07 History of anaphylaxis, urticaria, or other significant adverse reaction requiring medical intervention after receipt of a vaccine. EXCLUSIONYYAScreening ÂSCREENING 2020-07-30.mRNA-1273-P301IEmRNA-1273-P301-US305-2017US3052017A INC03 Able to comply with study procedures based on the assessment of the Investigator. INCLUSIONNNAScreening ÂSCREENING 2020-07-30.mRNA-1273-P301IEmRNA-1273-P301-US305-2048US3052048AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-07-31.mRNA-1273-P301IEmRNA-1273-P301-US305-2072US3052072AEXC11AImmunosuppressive or immunodeficient state, including HIV infection, asplenia, recurrent severe infections. EXCLUSIONYYAScreening ÂSCREENING 2020-08-03.mRNA-1273-P301IEmRNA-1273-P301-US305-2091US3052091AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-04.mRNA-1273-P301IEmRNA-1273-P301-US305-2097US3052097AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-04.mRNA-1273-P301IEmRNA-1273-P301-US305-2105US3052105AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-06.mRNA-1273-P301IEmRNA-1273-P301-US305-2121US3052121AEXC12 Has received systemic immunosuppressants/immune-modifying drugs for >14 days in total within 6 months prior to Screening. Topical tacrolimus is allowed if not used within 14 days prior to Screening. EXCLUSIONYYAScreening ÂSCREENING 2020-08-07.mRNA-1273-P301IEmRNA-1273-P301-US305-2147US3052147AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-10.mRNA-1273-P301IEmRNA-1273-P301-US305-2163US3052163AEXC03 Known history of SARS-CoV-2 infection. EXCLUSIONYYAScreening ÂSCREENING 2020-08-11.mRNA-1273-P301IEmRNA-1273-P301-US305-2275US3052275AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-20.mRNA-1273-P301IEmRNA-1273-P301-US305-2286US3052286AEXC12 Has received systemic immunosuppressants/immune-modifying drugs for >14 days in total within 6 months prior to Screening. Topical tacrolimus is allowed if not used within 14 days prior to Screening. EXCLUSIONYYAScreening ÂSCREENING 2020-08-21.mRNA-1273-P301IEmRNA-1273-P301-US305-2340US3052340AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-01.mRNA-1273-P301IEmRNA-1273-P301-US305-2344US3052064AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-07-31Â!mRNA-1273-P301IEmRNA-1273-P301-US306-2060US3062060AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-08-04.mRNA-1273-P301IEmRNA-1273-P301-US306-2072US3062072AEXC05 Demonstrated inability to comply with the study procedures. EXCLUSIONYYAScreening ÂSCREENING 2020-08-04.mRNA-1273-P301IEmRNA-1273-P301-US306-2072US3062072A INC03 Able to comply with study procedures based on the assessment of the Investigator. INCLUSIONNNAScreening ÂSCREENING 2020-08-04.mRNA-1273-P301IEmRNA-1273-P301-US306-2159US3062159AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-07.mRNA-1273-P301IEmRNA-1273-P301-US306-2174US3062174AINC03 Able to comply with study procedures based on the assessment of the Investigator. INCLUSIONNNAScreening ÂSCREENING 2020-08-08.mRNA-1273-P301IEmRNA-1273-P301-US306-2178US3062178AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-08-08.mRNA-1273-P301IEmRNA-1273-P301-US306-2199US3062199AEXC05 Demonstrated inability to comply with the study procedures. EXCLUSIONYYAScreening ÂSCREENING 2020-08-10.mRNA-1273-P301IEmRNA-1273-P301-US306-2318US3062318AEXC09AHas received or plans to receive a non-study vaccine within 28 days before/after any dose of IP (except for seasonal influenza vaccine which not permitted within 14 days before/after any dose of IP).EXCLUSIONYYAScreening ÂSCREENING 2020-09-30.mRNA-1273-P301IEmRNA-1273-P301-US308-2013US3082013AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-10.mRNA-1273-P301IEmRNA-1273-P301-US308-2024US3082024AINC01 Adults, >= 18 years of age at time of consent, who are at high risk of SARS-CoV-2 infection. INCLUSIONNNAScreening ÂSCREENING 2020-08-13.mRNA-1273-P301IEmRNA-1273-P301-US308-2031US3082031AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-11.mRNA-1273-P301IEmRNA-1273-P301-US308-2032US3082032AEXC02 Is pregnant or breastfeeding. EXCLUSIONYYAScreening ÂSCREENING 2020-08-14.mRNA-1273-P301IEmRNA-1273-P301-US308-2035US3082035AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-11.mRNA-1273-P301IEmRNA-1273-P301-US308-2036US3082036AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-12.mRNA-1273-P301IEmRNA-1273-P301-US308-2039US3082039AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-17.mRNA-1273-P301IEmRNA-1273-P301-US308-2047US3082047AINC01 Adults, >= 18 years of age at time of consent, who are at high risk of SARS-CoV-2 infection. INCLUSIONNNAScreening ÂSCREENING 2020-08-18.mRNA-1273-P301IEmRNA-1273-P301-US308-2053US3082053AINC01 Adults, >= 18 years of age at time of consent, who are at high risk of SARS-CoV-2 infection. INCLUSIONNNAScreening ÂSCREENING 2020-08-18.mRNA-1273-P301IEmRNA-1273-P301-US308-2058US3082058AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-19.mRNA-1273-P301IEmRNA-1273-P301-US308-2070US3082070AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-20.mRNA-1273-P301IEmRNA-1273-P301-US308-2075US3082075AINC01 Adults, >= 18 years of age at time of consent, who are at high risk of SARS-CoV-2 infection. INCLUSIONNNAScreening ÂSCREENING 2020-08-20.mRNA-1273-P301IEmRNA-1273-P301-US308-2085US3082085AEXC09AHas received or plans to receive a non-study vaccine within 28 days before/after any dose of IP (except for seasonal influenza vaccine which not permitted within 14 days before/after any dose of IP).EXCLUSIONYYAScreening ÂSCREENING 2020-08-21.mRNA-1273-P301IEmRNA-1273-P301-US308-2089US3082089AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-21.mRNA-1273-P301IEmRNA-1273-P301-US308-2127US3082127AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-27.mRNA-1273-P301IEmRNA-1273-P301-US308-2155US3082155AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-31.mRNA-1273-P301IEmRNA-1273-P301-US308-2161US3082161AEXC09AHas received or plans to receive a non-study vaccine within 28 days before/after any dose of IP (except for seasonal influenza vaccine which not permitted within 14 days before/after any dose of IP).EXCLUSIONYYAScreening ÂSCREENING 2020-08-31.mRNA-1273-P301IEmRNA-1273-P301-US308-2175US3082175AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-01.mRNA-1273-P301IEmRNA-1273-P301-US308-2188US3082146AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-29ÁPmRNA-1273-P301IEmRNA-1273-P301-US308-2206US3082206AEXC03 Known history of SARS-CoV-2 infection. EXCLUSIONYYAScreening ÂSCREENING 2020-09-08.mRNA-1273-P301IEmRNA-1273-P301-US308-2223US3082223AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-10.mRNA-1273-P301IEmRNA-1273-P301-US308-2230US3082230AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-11.mRNA-1273-P301IEmRNA-1273-P301-US308-2232US3082232AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-11.mRNA-1273-P301IEmRNA-1273-P301-US308-2235US3082235AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-11.mRNA-1273-P301IEmRNA-1273-P301-US308-2250US3082168AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-01ÁðmRNA-1273-P301IEmRNA-1273-P301-US308-2256US3082256AEXC05 Demonstrated inability to comply with the study procedures. EXCLUSIONYYAScreening ÂSCREENING 2020-09-17.mRNA-1273-P301IEmRNA-1273-P301-US309-2145US3092145AEXC09AHas received or plans to receive a non-study vaccine within 28 days before/after any dose of IP (except for seasonal influenza vaccine which not permitted within 14 days before/after any dose of IP).EXCLUSIONYYAScreening ÂSCREENING 2020-08-15.mRNA-1273-P301IEmRNA-1273-P301-US309-2155US3092155AINC01 Adults, >= 18 years of age at time of consent, who are at high risk of SARS-CoV-2 infection. INCLUSIONNNAScreening ÂSCREENING 2020-08-19.mRNA-1273-P301IEmRNA-1273-P301-US309-2236US3092236AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-26.mRNA-1273-P301IEmRNA-1273-P301-US309-2250US3092250AINC01 Adults, >= 18 years of age at time of consent, who are at high risk of SARS-CoV-2 infection. INCLUSIONNNAScreening ÂSCREENING 2020-08-27.mRNA-1273-P301IEmRNA-1273-P301-US309-2251US3092251AINC01 Adults, >= 18 years of age at time of consent, who are at high risk of SARS-CoV-2 infection. INCLUSIONNNAScreening ÂSCREENING 2020-08-27.mRNA-1273-P301IEmRNA-1273-P301-US309-2253US3092253AINC01 Adults, >= 18 years of age at time of consent, who are at high risk of SARS-CoV-2 infection. INCLUSIONNNAScreening ÂSCREENING 2020-08-27.mRNA-1273-P301IEmRNA-1273-P301-US309-2254US3092254AINC01 Adults, >= 18 years of age at time of consent, who are at high risk of SARS-CoV-2 infection. INCLUSIONNNAScreening ÂSCREENING 2020-08-27.mRNA-1273-P301IEmRNA-1273-P301-US309-2270US3092270AINC01 Adults, >= 18 years of age at time of consent, who are at high risk of SARS-CoV-2 infection. INCLUSIONNNAScreening ÂSCREENING 2020-08-28.mRNA-1273-P301IEmRNA-1273-P301-US309-2271US3092271AEXC14 Has donated >= 450 mL of blood products within 28 days prior to Screening. EXCLUSIONYYAScreening ÂSCREENING 2020-08-28.mRNA-1273-P301IEmRNA-1273-P301-US309-2275US3092275AINC01 Adults, >= 18 years of age at time of consent, who are at high risk of SARS-CoV-2 infection. INCLUSIONNNAScreening ÂSCREENING 2020-08-29.mRNA-1273-P301IEmRNA-1273-P301-US309-2288US3092288AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-02.mRNA-1273-P301IEmRNA-1273-P301-US310-2013US3102013AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-07-28.mRNA-1273-P301IEmRNA-1273-P301-US310-2022US3102022AINC03 Able to comply with study procedures based on the assessment of the Investigator. INCLUSIONNNAScreening ÂSCREENING 2020-07-28.mRNA-1273-P301IEmRNA-1273-P301-US310-2032US3102032AINC03 Able to comply with study procedures based on the assessment of the Investigator. INCLUSIONNNAScreening ÂSCREENING 2020-07-29.mRNA-1273-P301IEmRNA-1273-P301-US310-2033US3102033AINC03 Able to comply with study procedures based on the assessment of the Investigator. INCLUSIONNNAScreening ÂSCREENING 2020-07-29.mRNA-1273-P301IEmRNA-1273-P301-US310-2037US3102037AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-07-29.mRNA-1273-P301IEmRNA-1273-P301-US310-2053US3102053AINC03 Able to comply with study procedures based on the assessment of the Investigator. INCLUSIONNNAScreening ÂSCREENING 2020-07-29.mRNA-1273-P301IEmRNA-1273-P301-US310-2100US3102100AEXC10 Has participated in an interventional clinical study within 28 days prior to the day of enrollment. EXCLUSIONYYAScreening ÂSCREENING 2020-08-04.mRNA-1273-P301IEmRNA-1273-P301-US310-2159US3102159AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-10.mRNA-1273-P301IEmRNA-1273-P301-US310-2265US3102265AEXC10 Has participated in an interventional clinical study within 28 days prior to the day of enrollment. EXCLUSIONYYAScreening ÂSCREENING 2020-08-26.mRNA-1273-P301IEmRNA-1273-P301-US310-2359US3102359AEXC11CImmunosuppressive or immunodeficient state, asplenia, recurrent severe infections (HIVpositive participants with CD4 count =350 cells/mm3 and an undetectable HIV viral load within the past year). EXCLUSIONYYAScreening ÂSCREENING 2020-09-14.mRNA-1273-P301IEmRNA-1273-P301-US310-2403US3102403AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-09-30.mRNA-1273-P301IEmRNA-1273-P301-US311-2001US3112001AINC01 Adults, >= 18 years of age at time of consent, who are at high risk of SARS-CoV-2 infection. INCLUSIONNNAScreening ÂSCREENING 2020-07-28.mRNA-1273-P301IEmRNA-1273-P301-US311-2015US3112015AEXC10 Has participated in an interventional clinical study within 28 days prior to the day of enrollment. EXCLUSIONYYAScreening ÂSCREENING 2020-07-29.mRNA-1273-P301IEmRNA-1273-P301-US311-2021US3112021AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-07-30.mRNA-1273-P301IEmRNA-1273-P301-US311-2044US3112044AEXC07 History of anaphylaxis, urticaria, or other significant adverse reaction requiring medical intervention after receipt of a vaccine. EXCLUSIONYYAScreening ÂSCREENING 2020-07-31.mRNA-1273-P301IEmRNA-1273-P301-US311-2098US3112019AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-07-30ÁPmRNA-1273-P301IEmRNA-1273-P301-US311-2102US3112102AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-05.mRNA-1273-P301IEmRNA-1273-P301-US311-2104US3112104AEXC12 Has received systemic immunosuppressants/immune-modifying drugs for >14 days in total within 6 months prior to Screening. Topical tacrolimus is allowed if not used within 14 days prior to Screening. EXCLUSIONYYAScreening ÂSCREENING 2020-08-05.mRNA-1273-P301IEmRNA-1273-P301-US311-2140US3112140AEXC02 Is pregnant or breastfeeding. EXCLUSIONYYAScreening ÂSCREENING 2020-08-06.mRNA-1273-P301IEmRNA-1273-P301-US311-2158US3112158AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-07.mRNA-1273-P301IEmRNA-1273-P301-US311-2174US3112174AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-08-10.mRNA-1273-P301IEmRNA-1273-P301-US311-2181US3112041AEXC14 Has donated >= 450 mL of blood products within 28 days prior to Screening. EXCLUSIONYYAScreening ÂSCREENING 2020-07-30Á°mRNA-1273-P301IEmRNA-1273-P301-US311-2196US3112196AINC06 INCLUSIONNNAScreening ÂSCREENING 2020-08-11.mRNA-1273-P301IEmRNA-1273-P301-US311-2200US3112022AEXC14 Has donated >= 450 mL of blood products within 28 days prior to Screening. EXCLUSIONYYAScreening ÂSCREENING 2020-07-30ÁÐmRNA-1273-P301IEmRNA-1273-P301-US311-2208US3112208AEXC11AImmunosuppressive or immunodeficient state, including HIV infection, asplenia, recurrent severe infections. EXCLUSIONYYAScreening ÂSCREENING 2020-08-12.mRNA-1273-P301IEmRNA-1273-P301-US311-2226US3112226AINC06 INCLUSIONNNAScreening ÂSCREENING 2020-08-13.mRNA-1273-P301IEmRNA-1273-P301-US311-2331US3112331AINC06 INCLUSIONNNAScreening ÂSCREENING 2020-08-20.mRNA-1273-P301IEmRNA-1273-P301-US311-2334US3112334AINC06 INCLUSIONNNAScreening ÂSCREENING 2020-08-20.mRNA-1273-P301IEmRNA-1273-P301-US311-2355US3112355AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-08-21.mRNA-1273-P301IEmRNA-1273-P301-US311-2390US3112390AINC06 INCLUSIONNNAScreening ÂSCREENING 2020-08-26.mRNA-1273-P301IEmRNA-1273-P301-US311-2392US3112052AEXC09 Has received or plans to receive a vaccine within 28 days prior to the first dose or plans to receive a non-study vaccine within 28 days prior to or after any dose of IP. EXCLUSIONYYAScreening ÂSCREENING 2020-07-31ÂmRNA-1273-P301IEmRNA-1273-P301-US311-2403US3112288AEXC11BImmunosuppressive or immunodeficient state, asplenia, recurrent severe infections (HIVpositive participants on stable antiretroviral therapy are not excluded). EXCLUSIONYYAScreening ÂSCREENING 2020-08-18ÁmRNA-1273-P301IEmRNA-1273-P301-US311-2416US3112416AINC06 INCLUSIONNNAScreening ÂSCREENING 2020-08-28.mRNA-1273-P301IEmRNA-1273-P301-US311-2421US3112421AINC06 INCLUSIONNNAScreening ÂSCREENING 2020-08-28.mRNA-1273-P301IEmRNA-1273-P301-US311-2427US3112427AINC06 INCLUSIONNNAScreening ÂSCREENING 2020-08-28.mRNA-1273-P301IEmRNA-1273-P301-US311-2441US3112441AINC06 INCLUSIONNNAScreening ÂSCREENING 2020-09-02.mRNA-1273-P301IEmRNA-1273-P301-US311-2453US3112453AEXC09AHas received or plans to receive a non-study vaccine within 28 days before/after any dose of IP (except for seasonal influenza vaccine which not permitted within 14 days before/after any dose of IP).EXCLUSIONYYAScreening ÂSCREENING 2020-09-08.mRNA-1273-P301IEmRNA-1273-P301-US311-2462US3112462AEXC05 Demonstrated inability to comply with the study procedures. EXCLUSIONYYAScreening ÂSCREENING 2020-09-10.mRNA-1273-P301IEmRNA-1273-P301-US311-2464US3112464AINC06 INCLUSIONNNAScreening ÂSCREENING 2020-09-10.mRNA-1273-P301IEmRNA-1273-P301-US311-2479US3112172AEXC11BImmunosuppressive or immunodeficient state, asplenia, recurrent severe infections (HIVpositive participants on stable antiretroviral therapy are not excluded). EXCLUSIONYYAScreening ÂSCREENING 2020-08-10Â%mRNA-1273-P301IEmRNA-1273-P301-US311-2483US3112483AEXC09AHas received or plans to receive a non-study vaccine within 28 days before/after any dose of IP (except for seasonal influenza vaccine which not permitted within 14 days before/after any dose of IP).EXCLUSIONYYAScreening ÂSCREENING 2020-09-16.mRNA-1273-P301IEmRNA-1273-P301-US311-2486US3112100AEXC11AImmunosuppressive or immunodeficient state, including HIV infection, asplenia, recurrent severe infections. EXCLUSIONYYAScreening ÂSCREENING 2020-08-04Â+mRNA-1273-P301IEmRNA-1273-P301-US312-2008US3122008AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-07-27.mRNA-1273-P301IEmRNA-1273-P301-US312-2009US3122009AINC06 Male participants that could result in pregnancy of sexual partners must agree to practice adequate contraception and refrain from sperm donation from the 1st dose to 3 months after the second dose. INCLUSIONNNAScreening ÂSCREENING 2020-07-27.mRNA-1273-P301IEmRNA-1273-P301-US312-2015US3122015AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-07-27.mRNA-1273-P301IEmRNA-1273-P301-US312-2016US3122016AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-07-27.mRNA-1273-P301IEmRNA-1273-P301-US312-2053US3122053AEXC14 Has donated >= 450 mL of blood products within 28 days prior to Screening. EXCLUSIONYYAScreening ÂSCREENING 2020-07-27.mRNA-1273-P301IEmRNA-1273-P301-US312-2063US3122063AEXC14 Has donated >= 450 mL of blood products within 28 days prior to Screening. EXCLUSIONYYAScreening ÂSCREENING 2020-07-28.mRNA-1273-P301IEmRNA-1273-P301-US312-2131US3122131AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-07-30.mRNA-1273-P301IEmRNA-1273-P301-US312-2140US3122140AEXC04 Prior administration of an investigational coronavirus (SARS-CoV, MERS-CoV) vaccine or current/planned simultaneous participation in another interventional study to prevent or treat COVID-19. EXCLUSIONYYAScreening ÂSCREENING 2020-07-30.mRNA-1273-P301IEmRNA-1273-P301-US313-2008US3132008AEXC12 Has received systemic immunosuppressants/immune-modifying drugs for >14 days in total within 6 months prior to Screening. Topical tacrolimus is allowed if not used within 14 days prior to Screening. EXCLUSIONYYAScreening ÂSCREENING 2020-08-10.mRNA-1273-P301IEmRNA-1273-P301-US313-2014US3132014AEXC12 Has received systemic immunosuppressants/immune-modifying drugs for >14 days in total within 6 months prior to Screening. Topical tacrolimus is allowed if not used within 14 days prior to Screening. EXCLUSIONYYAScreening ÂSCREENING 2020-08-13.mRNA-1273-P301IEmRNA-1273-P301-US313-2015US3132015AEXC12 Has received systemic immunosuppressants/immune-modifying drugs for >14 days in total within 6 months prior to Screening. Topical tacrolimus is allowed if not used within 14 days prior to Screening. EXCLUSIONYYAScreening ÂSCREENING 2020-08-13.mRNA-1273-P301IEmRNA-1273-P301-US313-2074US3132074AINC01 Adults, >= 18 years of age at time of consent, who are at high risk of SARS-CoV-2 infection. INCLUSIONNNAScreening ÂSCREENING 2020-09-18.mRNA-1273-P301IEmRNA-1273-P301-US313-2097US3132097AINC03 Able to comply with study procedures based on the assessment of the Investigator. INCLUSIONNNAScreening ÂSCREENING 2020-10-01.mRNA-1273-P301IEmRNA-1273-P301-US313-2099US3132099AINC01 Adults, >= 18 years of age at time of consent, who are at high risk of SARS-CoV-2 infection. INCLUSIONNNAScreening ÂSCREENING 2020-10-02.mRNA-1273-P301IEmRNA-1273-P301-US313-2104US3132104AINC01 Adults, >= 18 years of age at time of consent, who are at high risk of SARS-CoV-2 infection. INCLUSIONNNAScreening ÂSCREENING 2020-10-05.mRNA-1273-P301IEmRNA-1273-P301-US313-2126US3132126AEXC07AKnown or suspected allergy or history of anaphylaxis, urticaria, or other significant adverse reaction to the vaccine or its excipients. EXCLUSIONYYAScreening ÂSCREENING 2020-10-15.mRNA-1273-P301IEmRNA-1273-P301-US313-2155US3132155AEXC09AHas received or plans to receive a non-study vaccine within 28 days before/after any dose of IP (except for seasonal influenza vaccine which not permitted within 14 days before/after any dose of IP).EXCLUSIONYYAScreening ÂSCREENING 2020-10-22.mRNA-1273-P301IEmRNA-1273-P301-US314-2024US3142024AINC03 Able to comply with study procedures based on the assessment of the Investigator. INCLUSIONNNAScreening ÂSCREENING 2020-07-31.mRNA-1273-P301IEmRNA-1273-P301-US314-2032US3142032AEXC05 Demonstrated inability to comply with the study procedures. EXCLUSIONYYAScreening ÂSCREENING 2020-07-31.mRNA-1273-P301IEmRNA-1273-P301-US314-2032US3142032A INC03 Able to comply with study procedures based on the assessment of the Investigator. INCLUSIONNNAScreening ÂSCREENING 2020-07-31.mRNA-1273-P301IEmRNA-1273-P301-US314-2032US3142032A0INC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-07-31.mRNA-1273-P301IEmRNA-1273-P301-US314-2093US3142093AEXC12 Has received systemic immunosuppressants/immune-modifying drugs for >14 days in total within 6 months prior to Screening. Topical tacrolimus is allowed if not used within 14 days prior to Screening. EXCLUSIONYYAScreening ÂSCREENING 2020-08-04.mRNA-1273-P301IEmRNA-1273-P301-US314-2118US3142118AEXC07AKnown or suspected allergy or history of anaphylaxis, urticaria, or other significant adverse reaction to the vaccine or its excipients. EXCLUSIONYYAScreening ÂSCREENING 2020-08-05.mRNA-1273-P301IEmRNA-1273-P301-US314-2179US3142179AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-10.mRNA-1273-P301IEmRNA-1273-P301-US314-2181US3142181AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-08-10.mRNA-1273-P301IEmRNA-1273-P301-US314-2193US3142193AEXC05 Demonstrated inability to comply with the study procedures. EXCLUSIONYYAScreening ÂSCREENING 2020-08-11.mRNA-1273-P301IEmRNA-1273-P301-US314-2194US3142194AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-11.mRNA-1273-P301IEmRNA-1273-P301-US315-2021US3152021AINC03 Able to comply with study procedures based on the assessment of the Investigator. INCLUSIONNNAScreening ÂSCREENING 2020-07-28.mRNA-1273-P301IEmRNA-1273-P301-US315-2068US3152068AINC01 Adults, >= 18 years of age at time of consent, who are at high risk of SARS-CoV-2 infection. INCLUSIONNNAScreening ÂSCREENING 2020-08-03.mRNA-1273-P301IEmRNA-1273-P301-US315-2070US3152070AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-03.mRNA-1273-P301IEmRNA-1273-P301-US315-2074US3152074AINC03 Able to comply with study procedures based on the assessment of the Investigator. INCLUSIONNNAScreening ÂSCREENING 2020-08-03.mRNA-1273-P301IEmRNA-1273-P301-US315-2075US3152075AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-08-03.mRNA-1273-P301IEmRNA-1273-P301-US315-2091US3152091AINC03 Able to comply with study procedures based on the assessment of the Investigator. INCLUSIONNNAScreening ÂSCREENING 2020-08-05.mRNA-1273-P301IEmRNA-1273-P301-US315-2093US3152093AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-05.mRNA-1273-P301IEmRNA-1273-P301-US315-2097US3152097AEXC03 Known history of SARS-CoV-2 infection. EXCLUSIONYYAScreening ÂSCREENING 2020-08-05.mRNA-1273-P301IEmRNA-1273-P301-US315-2110US3152110AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-08-06.mRNA-1273-P301IEmRNA-1273-P301-US315-2125US3152125AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-10.mRNA-1273-P301IEmRNA-1273-P301-US315-2140US3152140AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-11.mRNA-1273-P301IEmRNA-1273-P301-US315-2143US3152143AINC01 Adults, >= 18 years of age at time of consent, who are at high risk of SARS-CoV-2 infection. INCLUSIONNNAScreening ÂSCREENING 2020-08-11.mRNA-1273-P301IEmRNA-1273-P301-US315-2186US3152186AINC03 Able to comply with study procedures based on the assessment of the Investigator. INCLUSIONNNAScreening ÂSCREENING 2020-08-13.mRNA-1273-P301IEmRNA-1273-P301-US315-2187US3152187AINC03 Able to comply with study procedures based on the assessment of the Investigator. INCLUSIONNNAScreening ÂSCREENING 2020-08-14.mRNA-1273-P301IEmRNA-1273-P301-US315-2198US3152198AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-14.mRNA-1273-P301IEmRNA-1273-P301-US315-2209US3152209AINC01 Adults, >= 18 years of age at time of consent, who are at high risk of SARS-CoV-2 infection. INCLUSIONNNAScreening ÂSCREENING 2020-08-14.mRNA-1273-P301IEmRNA-1273-P301-US315-2220US3152220AINC03 Able to comply with study procedures based on the assessment of the Investigator. INCLUSIONNNAScreening ÂSCREENING 2020-08-14.mRNA-1273-P301IEmRNA-1273-P301-US315-2241US3152241AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-14.mRNA-1273-P301IEmRNA-1273-P301-US315-2251US3152251AINC03 Able to comply with study procedures based on the assessment of the Investigator. INCLUSIONNNAScreening ÂSCREENING 2020-08-15.mRNA-1273-P301IEmRNA-1273-P301-US315-2260US3152260AEXC14 Has donated >= 450 mL of blood products within 28 days prior to Screening. EXCLUSIONYYAScreening ÂSCREENING 2020-08-15.mRNA-1273-P301IEmRNA-1273-P301-US315-2278US3152278AEXC11BImmunosuppressive or immunodeficient state, asplenia, recurrent severe infections (HIVpositive participants on stable antiretroviral therapy are not excluded). EXCLUSIONYYAScreening ÂSCREENING 2020-08-17.mRNA-1273-P301IEmRNA-1273-P301-US315-2278US3152278A EXC12 Has received systemic immunosuppressants/immune-modifying drugs for >14 days in total within 6 months prior to Screening. Topical tacrolimus is allowed if not used within 14 days prior to Screening. EXCLUSIONYYAScreening ÂSCREENING 2020-08-17.mRNA-1273-P301IEmRNA-1273-P301-US315-2280US3152280AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-17.mRNA-1273-P301IEmRNA-1273-P301-US315-2282US3152282AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-17.mRNA-1273-P301IEmRNA-1273-P301-US315-2287US3152287AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-17.mRNA-1273-P301IEmRNA-1273-P301-US315-2300US3152300AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-20.mRNA-1273-P301IEmRNA-1273-P301-US315-2305US3152305AEXC12 Has received systemic immunosuppressants/immune-modifying drugs for >14 days in total within 6 months prior to Screening. Topical tacrolimus is allowed if not used within 14 days prior to Screening. EXCLUSIONYYAScreening ÂSCREENING 2020-08-20.mRNA-1273-P301IEmRNA-1273-P301-US315-2314US3152314AINC01 Adults, >= 18 years of age at time of consent, who are at high risk of SARS-CoV-2 infection. INCLUSIONNNAScreening ÂSCREENING 2020-08-20.mRNA-1273-P301IEmRNA-1273-P301-US315-2340US3152340AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-21.mRNA-1273-P301IEmRNA-1273-P301-US315-2385US3152385AEXC14 Has donated >= 450 mL of blood products within 28 days prior to Screening. EXCLUSIONYYAScreening ÂSCREENING 2020-08-24.mRNA-1273-P301IEmRNA-1273-P301-US315-2398US3152398AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-04.mRNA-1273-P301IEmRNA-1273-P301-US315-2400US3152343AEXC09 Has received or plans to receive a vaccine within 28 days prior to the first dose or plans to receive a non-study vaccine within 28 days prior to or after any dose of IP. EXCLUSIONYYAScreening ÂSCREENING 2020-08-21ÁàmRNA-1273-P301IEmRNA-1273-P301-US315-2443US3152443AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-10-06.mRNA-1273-P301IEmRNA-1273-P301-US315-2444US3152444AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-10-06.mRNA-1273-P301IEmRNA-1273-P301-US315-2445US3152445AEXC01 Participants who are acutely ill or febrile 72 hours prior to or at Screening may be rescheduled. Afebrile participants with minor illnesses can be enrolled at the discretion of the investigator. EXCLUSIONYYAScreening ÂSCREENING 2020-10-06.mRNA-1273-P301IEmRNA-1273-P301-US315-2445US3152445A INC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-10-06.mRNA-1273-P301IEmRNA-1273-P301-US315-2451US3152451AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-10-07.mRNA-1273-P301IEmRNA-1273-P301-US315-2470US3152470AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-10-13.mRNA-1273-P301IEmRNA-1273-P301-US315-2482US3152482AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-10-14.mRNA-1273-P301IEmRNA-1273-P301-US315-2490US3152490AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-10-15.mRNA-1273-P301IEmRNA-1273-P301-US315-2495US3152495AEXC07AKnown or suspected allergy or history of anaphylaxis, urticaria, or other significant adverse reaction to the vaccine or its excipients. EXCLUSIONYYAScreening ÂSCREENING 2020-10-15.mRNA-1273-P301IEmRNA-1273-P301-US315-2503US3152503AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-10-16.mRNA-1273-P301IEmRNA-1273-P301-US315-2507US3152507AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-10-20.mRNA-1273-P301IEmRNA-1273-P301-US315-2524US3152524AINC01 Adults, >= 18 years of age at time of consent, who are at high risk of SARS-CoV-2 infection. INCLUSIONNNAScreening ÂSCREENING 2020-10-21.mRNA-1273-P301IEmRNA-1273-P301-US316-2014US3162014AEXC14 Has donated >= 450 mL of blood products within 28 days prior to Screening. EXCLUSIONYYAScreening ÂSCREENING 2020-07-29ÁÀmRNA-1273-P301IEmRNA-1273-P301-US316-2042US3162042AEXC14 Has donated >= 450 mL of blood products within 28 days prior to Screening. EXCLUSIONYYAScreening ÂSCREENING 2020-07-31ÂmRNA-1273-P301IEmRNA-1273-P301-US316-2092US3162092AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-10.mRNA-1273-P301IEmRNA-1273-P301-US316-2242US3162242AEXC12AHas received systemic immunosuppressants or immune-modifying drugs for >14 days in total within 6 months prior to Screening (for corticosteroids = 20 mg/day of prednisone equivalent). EXCLUSIONYYAScreening ÂSCREENING 2020-09-16.mRNA-1273-P301IEmRNA-1273-P301-US316-2260US3162260AEXC09AHas received or plans to receive a non-study vaccine within 28 days before/after any dose of IP (except for seasonal influenza vaccine which not permitted within 14 days before/after any dose of IP).EXCLUSIONYYAScreening ÂSCREENING 2020-10-02.mRNA-1273-P301IEmRNA-1273-P301-US316-2272US3162272AEXC03 Known history of SARS-CoV-2 infection. EXCLUSIONYYAScreening ÂSCREENING 2020-10-09.mRNA-1273-P301IEmRNA-1273-P301-US316-2281US3162281AEXC05 Demonstrated inability to comply with the study procedures. EXCLUSIONYYAScreening ÂSCREENING 2020-10-14.mRNA-1273-P301IEmRNA-1273-P301-US317-2004US3172004AINC03 Able to comply with study procedures based on the assessment of the Investigator. INCLUSIONNNAScreening ÂSCREENING 2020-08-07.mRNA-1273-P301IEmRNA-1273-P301-US317-2054US3172054AINC03 Able to comply with study procedures based on the assessment of the Investigator. INCLUSIONNNAScreening ÂSCREENING 2020-08-11.mRNA-1273-P301IEmRNA-1273-P301-US317-2068US3172068AINC03 Able to comply with study procedures based on the assessment of the Investigator. INCLUSIONNNAScreening ÂSCREENING 2020-08-12.mRNA-1273-P301IEmRNA-1273-P301-US317-2080US3172080AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-12.mRNA-1273-P301IEmRNA-1273-P301-US317-2081US3172081AEXC07 History of anaphylaxis, urticaria, or other significant adverse reaction requiring medical intervention after receipt of a vaccine. EXCLUSIONYYAScreening ÂSCREENING 2020-08-12.mRNA-1273-P301IEmRNA-1273-P301-US317-2097US3172097AINC03 Able to comply with study procedures based on the assessment of the Investigator. INCLUSIONNNAScreening ÂSCREENING 2020-08-13.mRNA-1273-P301IEmRNA-1273-P301-US317-2098US3172098AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-13.mRNA-1273-P301IEmRNA-1273-P301-US317-2099US3172099AINC03 Able to comply with study procedures based on the assessment of the Investigator. INCLUSIONNNAScreening ÂSCREENING 2020-08-13.mRNA-1273-P301IEmRNA-1273-P301-US317-2100US3172100AEXC07 History of anaphylaxis, urticaria, or other significant adverse reaction requiring medical intervention after receipt of a vaccine. EXCLUSIONYYAScreening ÂSCREENING 2020-08-13.mRNA-1273-P301IEmRNA-1273-P301-US317-2101US3172101AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-13.mRNA-1273-P301IEmRNA-1273-P301-US317-2104US3172104AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-14.mRNA-1273-P301IEmRNA-1273-P301-US317-2125US3172125AINC03 Able to comply with study procedures based on the assessment of the Investigator. INCLUSIONNNAScreening ÂSCREENING 2020-08-14.mRNA-1273-P301IEmRNA-1273-P301-US317-2127US3172127AEXC03 Known history of SARS-CoV-2 infection. EXCLUSIONYYAScreening ÂSCREENING 2020-08-14.mRNA-1273-P301IEmRNA-1273-P301-US317-2128US3172128AINC03 Able to comply with study procedures based on the assessment of the Investigator. INCLUSIONNNAScreening ÂSCREENING 2020-08-14.mRNA-1273-P301IEmRNA-1273-P301-US317-2130US3172130AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-17.mRNA-1273-P301IEmRNA-1273-P301-US317-2134US3172134AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-17.mRNA-1273-P301IEmRNA-1273-P301-US317-2143US3172143AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-17.mRNA-1273-P301IEmRNA-1273-P301-US317-2151US3172151AINC03 Able to comply with study procedures based on the assessment of the Investigator. INCLUSIONNNAScreening ÂSCREENING 2020-08-17.mRNA-1273-P301IEmRNA-1273-P301-US317-2158US3172158AEXC07 History of anaphylaxis, urticaria, or other significant adverse reaction requiring medical intervention after receipt of a vaccine. EXCLUSIONYYAScreening ÂSCREENING 2020-08-17.mRNA-1273-P301IEmRNA-1273-P301-US317-2176US3172176AEXC12 Has received systemic immunosuppressants/immune-modifying drugs for >14 days in total within 6 months prior to Screening. Topical tacrolimus is allowed if not used within 14 days prior to Screening. EXCLUSIONYYAScreening ÂSCREENING 2020-08-18.mRNA-1273-P301IEmRNA-1273-P301-US317-2206US3172206AINC03 Able to comply with study procedures based on the assessment of the Investigator. INCLUSIONNNAScreening ÂSCREENING 2020-08-19.mRNA-1273-P301IEmRNA-1273-P301-US317-2214US3172214AINC03 Able to comply with study procedures based on the assessment of the Investigator. INCLUSIONNNAScreening ÂSCREENING 2020-08-19.mRNA-1273-P301IEmRNA-1273-P301-US317-2227US3172227AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-19.mRNA-1273-P301IEmRNA-1273-P301-US317-2228US3172228AEXC12 Has received systemic immunosuppressants/immune-modifying drugs for >14 days in total within 6 months prior to Screening. Topical tacrolimus is allowed if not used within 14 days prior to Screening. EXCLUSIONYYAScreening ÂSCREENING 2020-08-18.mRNA-1273-P301IEmRNA-1273-P301-US317-2235US3172235AINC03 Able to comply with study procedures based on the assessment of the Investigator. INCLUSIONNNAScreening ÂSCREENING 2020-08-20.mRNA-1273-P301IEmRNA-1273-P301-US317-2236US3172236AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-20.mRNA-1273-P301IEmRNA-1273-P301-US317-2244US3172244AEXC07 History of anaphylaxis, urticaria, or other significant adverse reaction requiring medical intervention after receipt of a vaccine. EXCLUSIONYYAScreening ÂSCREENING 2020-08-20.mRNA-1273-P301IEmRNA-1273-P301-US317-2262US3172262AINC03 Able to comply with study procedures based on the assessment of the Investigator. INCLUSIONNNAScreening ÂSCREENING 2020-08-21.mRNA-1273-P301IEmRNA-1273-P301-US317-2263US3172263AINC03 Able to comply with study procedures based on the assessment of the Investigator. INCLUSIONNNAScreening ÂSCREENING 2020-08-21.mRNA-1273-P301IEmRNA-1273-P301-US317-2287US3172287AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-24.mRNA-1273-P301IEmRNA-1273-P301-US317-2309US3172309AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-25.mRNA-1273-P301IEmRNA-1273-P301-US317-2347US3172347AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-26.mRNA-1273-P301IEmRNA-1273-P301-US317-2351US3172351AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-26.mRNA-1273-P301IEmRNA-1273-P301-US317-2357US3172357AINC03 Able to comply with study procedures based on the assessment of the Investigator. INCLUSIONNNAScreening ÂSCREENING 2020-08-27.mRNA-1273-P301IEmRNA-1273-P301-US317-2364US3172364AEXC02 Is pregnant or breastfeeding. EXCLUSIONYYAScreening ÂSCREENING 2020-08-27.mRNA-1273-P301IEmRNA-1273-P301-US317-2364US3172364A INC03 Able to comply with study procedures based on the assessment of the Investigator. INCLUSIONNNAScreening ÂSCREENING 2020-08-27.mRNA-1273-P301IEmRNA-1273-P301-US317-2364US3172364A0INC05 Female participants of childbearing potential may be enrolled in the study if the participant fulfills all the criteria listed in the protocol. INCLUSIONNNAScreening ÂSCREENING 2020-08-27.mRNA-1273-P301IEmRNA-1273-P301-US317-2370US3172370AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-27.mRNA-1273-P301IEmRNA-1273-P301-US317-2373US3172373AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-27.mRNA-1273-P301IEmRNA-1273-P301-US317-2396US3172396AEXC10 Has participated in an interventional clinical study within 28 days prior to the day of enrollment. EXCLUSIONYYAScreening ÂSCREENING 2020-10-19.mRNA-1273-P301IEmRNA-1273-P301-US317-2401US3172401AINC03 Able to comply with study procedures based on the assessment of the Investigator. INCLUSIONNNAScreening ÂSCREENING 2020-10-19.mRNA-1273-P301IEmRNA-1273-P301-US317-2407US3172407AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-10-19.mRNA-1273-P301IEmRNA-1273-P301-US317-2411US3172411AINC03 Able to comply with study procedures based on the assessment of the Investigator. INCLUSIONNNAScreening ÂSCREENING 2020-10-19.mRNA-1273-P301IEmRNA-1273-P301-US317-2411US3172411A INC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-10-19.mRNA-1273-P301IEmRNA-1273-P301-US317-2421US3172421AINC03 Able to comply with study procedures based on the assessment of the Investigator. INCLUSIONNNAScreening ÂSCREENING 2020-10-20.mRNA-1273-P301IEmRNA-1273-P301-US317-2424US3172424AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-10-20.mRNA-1273-P301IEmRNA-1273-P301-US317-2428US3172428AINC03 Able to comply with study procedures based on the assessment of the Investigator. INCLUSIONNNAScreening ÂSCREENING 2020-10-20.mRNA-1273-P301IEmRNA-1273-P301-US317-2437US3172437AINC03 Able to comply with study procedures based on the assessment of the Investigator. INCLUSIONNNAScreening ÂSCREENING 2020-10-20.mRNA-1273-P301IEmRNA-1273-P301-US317-2445US3172445AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-10-21.mRNA-1273-P301IEmRNA-1273-P301-US317-2449US3172449AINC03 Able to comply with study procedures based on the assessment of the Investigator. INCLUSIONNNAScreening ÂSCREENING 2020-10-21.mRNA-1273-P301IEmRNA-1273-P301-US317-2453US3172453AINC03 Able to comply with study procedures based on the assessment of the Investigator. INCLUSIONNNAScreening ÂSCREENING 2020-10-21.mRNA-1273-P301IEmRNA-1273-P301-US317-2455US3172455AINC03 Able to comply with study procedures based on the assessment of the Investigator. INCLUSIONNNAScreening ÂSCREENING 2020-10-21.mRNA-1273-P301IEmRNA-1273-P301-US317-2478US3172478AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-10-22.mRNA-1273-P301IEmRNA-1273-P301-US318-2022US3182022AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-07-28.mRNA-1273-P301IEmRNA-1273-P301-US318-2156US3182156AINC01 Adults, >= 18 years of age at time of consent, who are at high risk of SARS-CoV-2 infection. INCLUSIONNNAScreening ÂSCREENING 2020-08-04.mRNA-1273-P301IEmRNA-1273-P301-US318-2232US3182232AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-07.mRNA-1273-P301IEmRNA-1273-P301-US318-2308US3182308AEXC12 Has received systemic immunosuppressants/immune-modifying drugs for >14 days in total within 6 months prior to Screening. Topical tacrolimus is allowed if not used within 14 days prior to Screening. EXCLUSIONYYAScreening ÂSCREENING 2020-08-12.mRNA-1273-P301IEmRNA-1273-P301-US318-2344US3182344AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-08-14.mRNA-1273-P301IEmRNA-1273-P301-US319-2057US3192057AEXC14 Has donated >= 450 mL of blood products within 28 days prior to Screening. EXCLUSIONYYAScreening ÂSCREENING 2020-08-04.mRNA-1273-P301IEmRNA-1273-P301-US319-2058US3192058AEXC12 Has received systemic immunosuppressants/immune-modifying drugs for >14 days in total within 6 months prior to Screening. Topical tacrolimus is allowed if not used within 14 days prior to Screening. EXCLUSIONYYAScreening ÂSCREENING 2020-08-04.mRNA-1273-P301IEmRNA-1273-P301-US319-2070US3192070AEXC05 Demonstrated inability to comply with the study procedures. EXCLUSIONYYAScreening ÂSCREENING 2020-08-05.mRNA-1273-P301IEmRNA-1273-P301-US319-2210US3192210AEXC09 Has received or plans to receive a vaccine within 28 days prior to the first dose or plans to receive a non-study vaccine within 28 days prior to or after any dose of IP. EXCLUSIONYYAScreening ÂSCREENING 2020-08-12.mRNA-1273-P301IEmRNA-1273-P301-US319-2265US3192265AEXC14 Has donated >= 450 mL of blood products within 28 days prior to Screening. EXCLUSIONYYAScreening ÂSCREENING 2020-08-15.mRNA-1273-P301IEmRNA-1273-P301-US319-2328US3192328AINC05 Female participants of childbearing potential may be enrolled in the study if the participant fulfills all the criteria listed in the protocol. INCLUSIONNNAScreening ÂSCREENING 2020-08-17.mRNA-1273-P301IEmRNA-1273-P301-US319-2338US3192338AINC03 Able to comply with study procedures based on the assessment of the Investigator. INCLUSIONNNAScreening ÂSCREENING 2020-08-08.mRNA-1273-P301IEmRNA-1273-P301-US319-2343US3192343AEXC09 Has received or plans to receive a vaccine within 28 days prior to the first dose or plans to receive a non-study vaccine within 28 days prior to or after any dose of IP. EXCLUSIONYYAScreening ÂSCREENING 2020-08-18.mRNA-1273-P301IEmRNA-1273-P301-US319-2424US3192424AEXC09AHas received or plans to receive a non-study vaccine within 28 days before/after any dose of IP (except for seasonal influenza vaccine which not permitted within 14 days before/after any dose of IP).EXCLUSIONYYAScreening ÂSCREENING 2020-08-23.mRNA-1273-P301IEmRNA-1273-P301-US319-2547US3192547AEXC09AHas received or plans to receive a non-study vaccine within 28 days before/after any dose of IP (except for seasonal influenza vaccine which not permitted within 14 days before/after any dose of IP).EXCLUSIONYYAScreening ÂSCREENING 2020-08-28.mRNA-1273-P301IEmRNA-1273-P301-US319-2694US3192694AINC05 Female participants of childbearing potential may be enrolled in the study if the participant fulfills all the criteria listed in the protocol. INCLUSIONNNAScreening ÂSCREENING 2020-09-05.mRNA-1273-P301IEmRNA-1273-P301-US319-2741US3192741AEXC05 Demonstrated inability to comply with the study procedures. EXCLUSIONYYAScreening ÂSCREENING 2020-10-05.mRNA-1273-P301IEmRNA-1273-P301-US319-2772US3192760AEXC12 Has received systemic immunosuppressants/immune-modifying drugs for >14 days in total within 6 months prior to Screening. Topical tacrolimus is allowed if not used within 14 days prior to Screening. EXCLUSIONYYAScreening ÂSCREENING 2020-10-08ÁmRNA-1273-P301IEmRNA-1273-P301-US319-2801US3192801AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-10-13.mRNA-1273-P301IEmRNA-1273-P301-US319-2808US3192808AEXC06 An immediate family member or household member of this study's personnel. EXCLUSIONYYAScreening ÂSCREENING 2020-10-14.mRNA-1273-P301IEmRNA-1273-P301-US319-2810US3192810AEXC07AKnown or suspected allergy or history of anaphylaxis, urticaria, or other significant adverse reaction to the vaccine or its excipients. EXCLUSIONYYAScreening ÂSCREENING 2020-10-14.mRNA-1273-P301IEmRNA-1273-P301-US319-2827US3192827AINC01 Adults, >= 18 years of age at time of consent, who are at high risk of SARS-CoV-2 infection. INCLUSIONNNAScreening ÂSCREENING 2020-10-15.mRNA-1273-P301IEmRNA-1273-P301-US320-2044US3202044AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-06.mRNA-1273-P301IEmRNA-1273-P301-US320-2079US3202079AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-08.mRNA-1273-P301IEmRNA-1273-P301-US320-2096US3202096AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-09.mRNA-1273-P301IEmRNA-1273-P301-US320-2238US3202238AEXC11BImmunosuppressive or immunodeficient state, asplenia, recurrent severe infections (HIVpositive participants on stable antiretroviral therapy are not excluded). EXCLUSIONYYAScreening ÂSCREENING 2020-08-18.mRNA-1273-P301IEmRNA-1273-P301-US320-2265US3202265AEXC11BImmunosuppressive or immunodeficient state, asplenia, recurrent severe infections (HIVpositive participants on stable antiretroviral therapy are not excluded). EXCLUSIONYYAScreening ÂSCREENING 2020-08-19.mRNA-1273-P301IEmRNA-1273-P301-US320-2324US3202324AEXC14 Has donated >= 450 mL of blood products within 28 days prior to Screening. EXCLUSIONYYAScreening ÂSCREENING 2020-08-25.mRNA-1273-P301IEmRNA-1273-P301-US320-2330US3202330AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-26.mRNA-1273-P301IEmRNA-1273-P301-US320-2340US3202340AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-26.mRNA-1273-P301IEmRNA-1273-P301-US320-2342US3202342AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-27.mRNA-1273-P301IEmRNA-1273-P301-US320-2365US3202365AEXC05 Demonstrated inability to comply with the study procedures. EXCLUSIONYYAScreening ÂSCREENING 2020-08-31.mRNA-1273-P301IEmRNA-1273-P301-US320-2382US3202382AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-02.mRNA-1273-P301IEmRNA-1273-P301-US321-2032US3212032AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-04.mRNA-1273-P301IEmRNA-1273-P301-US321-2060US3212060AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-05.mRNA-1273-P301IEmRNA-1273-P301-US321-2211US3212211AINC06 INCLUSIONNNAScreening ÂSCREENING 2020-08-17.mRNA-1273-P301IEmRNA-1273-P301-US321-2338US3212338AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-01.mRNA-1273-P301IEmRNA-1273-P301-US322-2107US3222107AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-12.mRNA-1273-P301IEmRNA-1273-P301-US322-2129US3222129AINC03 Able to comply with study procedures based on the assessment of the Investigator. INCLUSIONNNAScreening ÂSCREENING 2020-08-13.mRNA-1273-P301IEmRNA-1273-P301-US322-2208US3222208AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-18.mRNA-1273-P301IEmRNA-1273-P301-US322-2245US3222245AEXC09AHas received or plans to receive a non-study vaccine within 28 days before/after any dose of IP (except for seasonal influenza vaccine which not permitted within 14 days before/after any dose of IP).EXCLUSIONYYAScreening ÂSCREENING 2020-08-20.mRNA-1273-P301IEmRNA-1273-P301-US322-2324US3222324AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-25.mRNA-1273-P301IEmRNA-1273-P301-US322-2352US3222352AINC03 Able to comply with study procedures based on the assessment of the Investigator. INCLUSIONNNAScreening ÂSCREENING 2020-08-27.mRNA-1273-P301IEmRNA-1273-P301-US322-2421US3222421AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-31.mRNA-1273-P301IEmRNA-1273-P301-US322-2470US3222470AEXC03 Known history of SARS-CoV-2 infection. EXCLUSIONYYAScreening ÂSCREENING 2020-09-03.mRNA-1273-P301IEmRNA-1273-P301-US322-2481US3222481AINC03 Able to comply with study procedures based on the assessment of the Investigator. INCLUSIONNNAScreening ÂSCREENING 2020-09-03.mRNA-1273-P301IEmRNA-1273-P301-US322-2529US3222529AEXC03 Known history of SARS-CoV-2 infection. EXCLUSIONYYAScreening ÂSCREENING 2020-09-06.mRNA-1273-P301IEmRNA-1273-P301-US322-2537US3222537AINC03 Able to comply with study procedures based on the assessment of the Investigator. INCLUSIONNNAScreening ÂSCREENING 2020-09-06.mRNA-1273-P301IEmRNA-1273-P301-US323-2032US3232032AEXC03 Known history of SARS-CoV-2 infection. EXCLUSIONYYAScreening ÂSCREENING 2020-08-12.mRNA-1273-P301IEmRNA-1273-P301-US323-2035US3232035AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-12.mRNA-1273-P301IEmRNA-1273-P301-US323-2061US3232061AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-08-17.mRNA-1273-P301IEmRNA-1273-P301-US323-2073US3232027AEXC01 Participants who are acutely ill or febrile 72 hours prior to or at Screening may be rescheduled. Afebrile participants with minor illnesses can be enrolled at the discretion of the investigator. EXCLUSIONYYAScreening ÂSCREENING 2020-08-12Á€mRNA-1273-P301IEmRNA-1273-P301-US323-2076US3232076AEXC05 Demonstrated inability to comply with the study procedures. EXCLUSIONYYAScreening ÂSCREENING 2020-08-20.mRNA-1273-P301IEmRNA-1273-P301-US323-2084US3232084AEXC11BImmunosuppressive or immunodeficient state, asplenia, recurrent severe infections (HIVpositive participants on stable antiretroviral therapy are not excluded). EXCLUSIONYYAScreening ÂSCREENING 2020-08-21.mRNA-1273-P301IEmRNA-1273-P301-US323-2111US3232111AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-27.mRNA-1273-P301IEmRNA-1273-P301-US323-2113US3232113AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-27.mRNA-1273-P301IEmRNA-1273-P301-US323-2129US3232129AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-29.mRNA-1273-P301IEmRNA-1273-P301-US323-2133US3232090AEXC09AHas received or plans to receive a non-study vaccine within 28 days before/after any dose of IP (except for seasonal influenza vaccine which not permitted within 14 days before/after any dose of IP).EXCLUSIONYYAScreening ÂSCREENING 2020-08-21Á mRNA-1273-P301IEmRNA-1273-P301-US323-2168US3232168AEXC12AHas received systemic immunosuppressants or immune-modifying drugs for >14 days in total within 6 months prior to Screening (for corticosteroids = 20 mg/day of prednisone equivalent). EXCLUSIONYYAScreening ÂSCREENING 2020-09-12.mRNA-1273-P301IEmRNA-1273-P301-US323-2186US3232186AINC05 Female participants of childbearing potential may be enrolled in the study if the participant fulfills all the criteria listed in the protocol. INCLUSIONNNAScreening ÂSCREENING 2020-09-29.mRNA-1273-P301IEmRNA-1273-P301-US324-2052US3242052AEXC10 Has participated in an interventional clinical study within 28 days prior to the day of enrollment. EXCLUSIONYYAScreening ÂSCREENING 2020-08-12.mRNA-1273-P301IEmRNA-1273-P301-US324-2058US3242058AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-12.mRNA-1273-P301IEmRNA-1273-P301-US324-2062US3242062AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-12.mRNA-1273-P301IEmRNA-1273-P301-US324-2078US3242078AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-13.mRNA-1273-P301IEmRNA-1273-P301-US324-2144US3242030AEXC09 Has received or plans to receive a vaccine within 28 days prior to the first dose or plans to receive a non-study vaccine within 28 days prior to or after any dose of IP. EXCLUSIONYYAScreening ÂSCREENING 2020-08-07ÁÀmRNA-1273-P301IEmRNA-1273-P301-US324-2155US3242155AEXC11BImmunosuppressive or immunodeficient state, asplenia, recurrent severe infections (HIVpositive participants on stable antiretroviral therapy are not excluded). EXCLUSIONYYAScreening ÂSCREENING 2020-08-19.mRNA-1273-P301IEmRNA-1273-P301-US324-2158US3242158AEXC12 Has received systemic immunosuppressants/immune-modifying drugs for >14 days in total within 6 months prior to Screening. Topical tacrolimus is allowed if not used within 14 days prior to Screening. EXCLUSIONYYAScreening ÂSCREENING 2020-08-20.mRNA-1273-P301IEmRNA-1273-P301-US324-2168US3242168AEXC11BImmunosuppressive or immunodeficient state, asplenia, recurrent severe infections (HIVpositive participants on stable antiretroviral therapy are not excluded). EXCLUSIONYYAScreening ÂSCREENING 2020-08-20.mRNA-1273-P301IEmRNA-1273-P301-US324-2211US3242211AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-25.mRNA-1273-P301IEmRNA-1273-P301-US324-2259US3242259AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-31.mRNA-1273-P301IEmRNA-1273-P301-US324-2316US3242316AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-11.mRNA-1273-P301IEmRNA-1273-P301-US324-2353US3242353AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-21.mRNA-1273-P301IEmRNA-1273-P301-US324-2355US3242355AINC05 Female participants of childbearing potential may be enrolled in the study if the participant fulfills all the criteria listed in the protocol. INCLUSIONNNAScreening ÂSCREENING 2020-09-21.mRNA-1273-P301IEmRNA-1273-P301-US324-2359US3242331AEXC09AHas received or plans to receive a non-study vaccine within 28 days before/after any dose of IP (except for seasonal influenza vaccine which not permitted within 14 days before/after any dose of IP).EXCLUSIONYYAScreening ÂSCREENING 2020-09-15Á`mRNA-1273-P301IEmRNA-1273-P301-US324-2363US3242363AEXC05 Demonstrated inability to comply with the study procedures. EXCLUSIONYYAScreening ÂSCREENING 2020-09-22.mRNA-1273-P301IEmRNA-1273-P301-US324-2363US3242363A INC03 Able to comply with study procedures based on the assessment of the Investigator. INCLUSIONNNAScreening ÂSCREENING 2020-09-22.mRNA-1273-P301IEmRNA-1273-P301-US324-2364US3242364AEXC09AHas received or plans to receive a non-study vaccine within 28 days before/after any dose of IP (except for seasonal influenza vaccine which not permitted within 14 days before/after any dose of IP).EXCLUSIONYYAScreening ÂSCREENING 2020-09-22.mRNA-1273-P301IEmRNA-1273-P301-US324-2369US3242369AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-23.mRNA-1273-P301IEmRNA-1273-P301-US324-2383US3242383AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-25.mRNA-1273-P301IEmRNA-1273-P301-US324-2404US3242404AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-30.mRNA-1273-P301IEmRNA-1273-P301-US324-2405US3242405AEXC09AHas received or plans to receive a non-study vaccine within 28 days before/after any dose of IP (except for seasonal influenza vaccine which not permitted within 14 days before/after any dose of IP).EXCLUSIONYYAScreening ÂSCREENING 2020-09-30.mRNA-1273-P301IEmRNA-1273-P301-US324-2413US3242412AINC01 Adults, >= 18 years of age at time of consent, who are at high risk of SARS-CoV-2 infection. INCLUSIONNNAScreening ÂBLINDED TREATMENT 2020-10-06AmRNA-1273-P301IEmRNA-1273-P301-US325-2023US3252023AEXC07 History of anaphylaxis, urticaria, or other significant adverse reaction requiring medical intervention after receipt of a vaccine. EXCLUSIONYYAScreening ÂSCREENING 2020-08-04.mRNA-1273-P301IEmRNA-1273-P301-US325-2026US3252026AEXC14 Has donated >= 450 mL of blood products within 28 days prior to Screening. EXCLUSIONYYAScreening ÂSCREENING 2020-08-04.mRNA-1273-P301IEmRNA-1273-P301-US325-2028US3252028AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-04.mRNA-1273-P301IEmRNA-1273-P301-US325-2060US3252060AEXC03 Known history of SARS-CoV-2 infection. EXCLUSIONYYAScreening ÂSCREENING 2020-08-06.mRNA-1273-P301IEmRNA-1273-P301-US325-2152US3252152AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-08-13.mRNA-1273-P301IEmRNA-1273-P301-US326-2149US3262149AEXC10 Has participated in an interventional clinical study within 28 days prior to the day of enrollment. EXCLUSIONYYAScreening ÂSCREENING 2020-08-10.mRNA-1273-P301IEmRNA-1273-P301-US326-2218US3262218AEXC09AHas received or plans to receive a non-study vaccine within 28 days before/after any dose of IP (except for seasonal influenza vaccine which not permitted within 14 days before/after any dose of IP).EXCLUSIONYYAScreening ÂSCREENING 2020-08-20.mRNA-1273-P301IEmRNA-1273-P301-US326-2265US3262265AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-03.mRNA-1273-P301IEmRNA-1273-P301-US326-2272US3262272AEXC02 Is pregnant or breastfeeding. EXCLUSIONYYAScreening ÂSCREENING 2020-10-07.mRNA-1273-P301IEmRNA-1273-P301-US327-2008US3272008AINC05 Female participants of childbearing potential may be enrolled in the study if the participant fulfills all the criteria listed in the protocol. INCLUSIONNNAScreening ÂSCREENING 2020-07-29.mRNA-1273-P301IEmRNA-1273-P301-US327-2024US3272024AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-07-31.mRNA-1273-P301IEmRNA-1273-P301-US327-2045US3272045AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-04.mRNA-1273-P301IEmRNA-1273-P301-US327-2053US3272053AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-05.mRNA-1273-P301IEmRNA-1273-P301-US327-2056US3272056AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-05.mRNA-1273-P301IEmRNA-1273-P301-US327-2062US3272062AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-06.mRNA-1273-P301IEmRNA-1273-P301-US327-2072US3272072AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-06.mRNA-1273-P301IEmRNA-1273-P301-US327-2091US3272091AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-10.mRNA-1273-P301IEmRNA-1273-P301-US327-2130US3272130AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-13.mRNA-1273-P301IEmRNA-1273-P301-US327-2131US3272131AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-13.mRNA-1273-P301IEmRNA-1273-P301-US327-2152US3272152AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-14.mRNA-1273-P301IEmRNA-1273-P301-US327-2153US3272153AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-14.mRNA-1273-P301IEmRNA-1273-P301-US327-2155US3272155AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-14.mRNA-1273-P301IEmRNA-1273-P301-US327-2163US3272163AEXC14 Has donated >= 450 mL of blood products within 28 days prior to Screening. EXCLUSIONYYAScreening ÂSCREENING 2020-08-15.mRNA-1273-P301IEmRNA-1273-P301-US327-2222US3272222AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-20.mRNA-1273-P301IEmRNA-1273-P301-US327-2301US3272301AEXC09AHas received or plans to receive a non-study vaccine within 28 days before/after any dose of IP (except for seasonal influenza vaccine which not permitted within 14 days before/after any dose of IP).EXCLUSIONYYAScreening ÂSCREENING 2020-08-23.mRNA-1273-P301IEmRNA-1273-P301-US327-2316US3272316AEXC05 Demonstrated inability to comply with the study procedures. EXCLUSIONYYAScreening ÂSCREENING 2020-08-23.mRNA-1273-P301IEmRNA-1273-P301-US328-2021US3282021AEXC12 Has received systemic immunosuppressants/immune-modifying drugs for >14 days in total within 6 months prior to Screening. Topical tacrolimus is allowed if not used within 14 days prior to Screening. EXCLUSIONYYAScreening ÂSCREENING 2020-08-07.mRNA-1273-P301IEmRNA-1273-P301-US328-2051US3282051AEXC12 Has received systemic immunosuppressants/immune-modifying drugs for >14 days in total within 6 months prior to Screening. Topical tacrolimus is allowed if not used within 14 days prior to Screening. EXCLUSIONYYAScreening ÂSCREENING 2020-08-13.mRNA-1273-P301IEmRNA-1273-P301-US328-2069US3282069AINC01 Adults, >= 18 years of age at time of consent, who are at high risk of SARS-CoV-2 infection. INCLUSIONNNAScreening ÂSCREENING 2020-08-20.mRNA-1273-P301IEmRNA-1273-P301-US328-2093US3282093AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-28.mRNA-1273-P301IEmRNA-1273-P301-US328-2117US3282117AEXC09AHas received or plans to receive a non-study vaccine within 28 days before/after any dose of IP (except for seasonal influenza vaccine which not permitted within 14 days before/after any dose of IP).EXCLUSIONYYAScreening ÂSCREENING 2020-10-22.mRNA-1273-P301IEmRNA-1273-P301-US329-2033US3292033AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-06.mRNA-1273-P301IEmRNA-1273-P301-US329-2046US3292046AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-06.mRNA-1273-P301IEmRNA-1273-P301-US329-2066US3292066AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-08.mRNA-1273-P301IEmRNA-1273-P301-US329-2067US3292067AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-08.mRNA-1273-P301IEmRNA-1273-P301-US329-2071US3292071AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-08.mRNA-1273-P301IEmRNA-1273-P301-US329-2084US3292084AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-08.mRNA-1273-P301IEmRNA-1273-P301-US329-2095US3292095AEXC12 Has received systemic immunosuppressants/immune-modifying drugs for >14 days in total within 6 months prior to Screening. Topical tacrolimus is allowed if not used within 14 days prior to Screening. EXCLUSIONYYAScreening ÂSCREENING 2020-08-08.mRNA-1273-P301IEmRNA-1273-P301-US329-2097US3292097AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-08.mRNA-1273-P301IEmRNA-1273-P301-US329-2111US3292111AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-11.mRNA-1273-P301IEmRNA-1273-P301-US329-2122US3292122AEXC11AImmunosuppressive or immunodeficient state, including HIV infection, asplenia, recurrent severe infections. EXCLUSIONYYAScreening ÂSCREENING 2020-08-11.mRNA-1273-P301IEmRNA-1273-P301-US329-2123US3292123AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-11.mRNA-1273-P301IEmRNA-1273-P301-US329-2136US3292136AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-11.mRNA-1273-P301IEmRNA-1273-P301-US329-2152US3292152AEXC05 Demonstrated inability to comply with the study procedures. EXCLUSIONYYAScreening ÂSCREENING 2020-08-13.mRNA-1273-P301IEmRNA-1273-P301-US329-2153US3292153AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-13.mRNA-1273-P301IEmRNA-1273-P301-US329-2167US3292167AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-04-13.mRNA-1273-P301IEmRNA-1273-P301-US329-2213US3292213AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-18.mRNA-1273-P301IEmRNA-1273-P301-US329-2221US3292221AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-18.mRNA-1273-P301IEmRNA-1273-P301-US329-2246US3292246AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-20.mRNA-1273-P301IEmRNA-1273-P301-US329-2257US3292257AEXC14 Has donated >= 450 mL of blood products within 28 days prior to Screening. EXCLUSIONYYAScreening ÂSCREENING 2020-08-20.mRNA-1273-P301IEmRNA-1273-P301-US329-2269US3292269AEXC05 Demonstrated inability to comply with the study procedures. EXCLUSIONYYAScreening ÂSCREENING 2020-08-21.mRNA-1273-P301IEmRNA-1273-P301-US329-2311US3292311AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-25.mRNA-1273-P301IEmRNA-1273-P301-US329-2315US3292315AEXC14 Has donated >= 450 mL of blood products within 28 days prior to Screening. EXCLUSIONYYAScreening ÂSCREENING 2020-08-25.mRNA-1273-P301IEmRNA-1273-P301-US329-2338US3292338AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-27.mRNA-1273-P301IEmRNA-1273-P301-US329-2347US3292047AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-06ÂmRNA-1273-P301IEmRNA-1273-P301-US329-2373US3292373AINC03 Able to comply with study procedures based on the assessment of the Investigator. INCLUSIONNNAScreening ÂSCREENING 2020-08-29.mRNA-1273-P301IEmRNA-1273-P301-US329-2378US3292378AEXC14 Has donated >= 450 mL of blood products within 28 days prior to Screening. EXCLUSIONYYAScreening ÂSCREENING 2020-08-29.mRNA-1273-P301IEmRNA-1273-P301-US329-2419US3292419AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-24.mRNA-1273-P301IEmRNA-1273-P301-US329-2434US3292434AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-10-01.mRNA-1273-P301IEmRNA-1273-P301-US329-2439US3292439AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-10-20.mRNA-1273-P301IEmRNA-1273-P301-US330-2012US3302012AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-03.mRNA-1273-P301IEmRNA-1273-P301-US330-2028US3302028AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-04.mRNA-1273-P301IEmRNA-1273-P301-US330-2029US3302029AINC03 Able to comply with study procedures based on the assessment of the Investigator. INCLUSIONNNAScreening ÂSCREENING 2020-08-04.mRNA-1273-P301IEmRNA-1273-P301-US330-2037US3302037AEXC05 Demonstrated inability to comply with the study procedures. EXCLUSIONYYAScreening ÂSCREENING 2020-08-04.mRNA-1273-P301IEmRNA-1273-P301-US330-2056US3302056AEXC12 Has received systemic immunosuppressants/immune-modifying drugs for >14 days in total within 6 months prior to Screening. Topical tacrolimus is allowed if not used within 14 days prior to Screening. EXCLUSIONYYAScreening ÂSCREENING 2020-08-05.mRNA-1273-P301IEmRNA-1273-P301-US330-2068US3302068AEXC14 Has donated >= 450 mL of blood products within 28 days prior to Screening. EXCLUSIONYYAScreening ÂSCREENING 2020-08-06.mRNA-1273-P301IEmRNA-1273-P301-US330-2104US3302104AEXC05 Demonstrated inability to comply with the study procedures. EXCLUSIONYYAScreening ÂSCREENING 2020-08-07.mRNA-1273-P301IEmRNA-1273-P301-US330-2134US3302134AEXC14 Has donated >= 450 mL of blood products within 28 days prior to Screening. EXCLUSIONYYAScreening ÂSCREENING 2020-08-10.mRNA-1273-P301IEmRNA-1273-P301-US330-2176US3302176AEXC05 Demonstrated inability to comply with the study procedures. EXCLUSIONYYAScreening ÂSCREENING 2020-08-12.mRNA-1273-P301IEmRNA-1273-P301-US330-2178US3302178AEXC05 Demonstrated inability to comply with the study procedures. EXCLUSIONYYAScreening ÂSCREENING 2020-08-13.mRNA-1273-P301IEmRNA-1273-P301-US330-2224US3302224AEXC05 Demonstrated inability to comply with the study procedures. EXCLUSIONYYAScreening ÂSCREENING 2020-08-17.mRNA-1273-P301IEmRNA-1273-P301-US330-2227US3302227AEXC05 Demonstrated inability to comply with the study procedures. EXCLUSIONYYAScreening ÂSCREENING 2020-08-17.mRNA-1273-P301IEmRNA-1273-P301-US330-2259US3302259AEXC12 Has received systemic immunosuppressants/immune-modifying drugs for >14 days in total within 6 months prior to Screening. Topical tacrolimus is allowed if not used within 14 days prior to Screening. EXCLUSIONYYAScreening ÂSCREENING 2020-08-18.mRNA-1273-P301IEmRNA-1273-P301-US330-2278US3302278AEXC05 Demonstrated inability to comply with the study procedures. EXCLUSIONYYAScreening ÂSCREENING 2020-08-19.mRNA-1273-P301IEmRNA-1273-P301-US330-2309US3302309AEXC05 Demonstrated inability to comply with the study procedures. EXCLUSIONYYAScreening ÂSCREENING 2020-08-20.mRNA-1273-P301IEmRNA-1273-P301-US330-2335US3302335AEXC12AHas received systemic immunosuppressants or immune-modifying drugs for >14 days in total within 6 months prior to Screening (for corticosteroids = 20 mg/day of prednisone equivalent). EXCLUSIONYYAScreening ÂSCREENING 2020-08-24.mRNA-1273-P301IEmRNA-1273-P301-US330-2351US3302351AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-24.mRNA-1273-P301IEmRNA-1273-P301-US330-2389US3302389AEXC05 Demonstrated inability to comply with the study procedures. EXCLUSIONYYAScreening ÂSCREENING 2020-08-26.mRNA-1273-P301IEmRNA-1273-P301-US330-2415US3302415AEXC12AHas received systemic immunosuppressants or immune-modifying drugs for >14 days in total within 6 months prior to Screening (for corticosteroids = 20 mg/day of prednisone equivalent). EXCLUSIONYYAScreening ÂSCREENING 2020-08-27.mRNA-1273-P301IEmRNA-1273-P301-US331-2010US3312010AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-10.mRNA-1273-P301IEmRNA-1273-P301-US331-2011US3312011AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-10.mRNA-1273-P301IEmRNA-1273-P301-US331-2034US3312034AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-11.mRNA-1273-P301IEmRNA-1273-P301-US331-2071US3312071AEXC11BImmunosuppressive or immunodeficient state, asplenia, recurrent severe infections (HIVpositive participants on stable antiretroviral therapy are not excluded). EXCLUSIONYYAScreening ÂSCREENING 2020-08-13.mRNA-1273-P301IEmRNA-1273-P301-US331-2072US3312072AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-13.mRNA-1273-P301IEmRNA-1273-P301-US331-2082US3312082AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-14.mRNA-1273-P301IEmRNA-1273-P301-US331-2088US3312088AEXC02 Is pregnant or breastfeeding. EXCLUSIONYYAScreening ÂSCREENING 2020-08-14.mRNA-1273-P301IEmRNA-1273-P301-US331-2088US3312088A INC05 Female participants of childbearing potential may be enrolled in the study if the participant fulfills all the criteria listed in the protocol. INCLUSIONNNAScreening ÂSCREENING 2020-08-14.mRNA-1273-P301IEmRNA-1273-P301-US331-2094US3312094AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-17.mRNA-1273-P301IEmRNA-1273-P301-US331-2098US3312098AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-17.mRNA-1273-P301IEmRNA-1273-P301-US331-2111US3312111AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-17.mRNA-1273-P301IEmRNA-1273-P301-US331-2114US3312114AINC03 Able to comply with study procedures based on the assessment of the Investigator. INCLUSIONNNAScreening ÂSCREENING 2020-08-17.mRNA-1273-P301IEmRNA-1273-P301-US331-2129US3312129AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-18.mRNA-1273-P301IEmRNA-1273-P301-US331-2134US3312134AEXC07AKnown or suspected allergy or history of anaphylaxis, urticaria, or other significant adverse reaction to the vaccine or its excipients. EXCLUSIONYYAScreening ÂSCREENING 2020-08-18.mRNA-1273-P301IEmRNA-1273-P301-US331-2137US3312137AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-18.mRNA-1273-P301IEmRNA-1273-P301-US331-2150US3312150AINC05 Female participants of childbearing potential may be enrolled in the study if the participant fulfills all the criteria listed in the protocol. INCLUSIONNNAScreening ÂSCREENING 2020-08-19.mRNA-1273-P301IEmRNA-1273-P301-US331-2153US3312153AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-19.mRNA-1273-P301IEmRNA-1273-P301-US331-2162US3312162AEXC05 Demonstrated inability to comply with the study procedures. EXCLUSIONYYAScreening ÂSCREENING 2020-08-19.mRNA-1273-P301IEmRNA-1273-P301-US331-2163US3312163AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-19.mRNA-1273-P301IEmRNA-1273-P301-US331-2166US3312166AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-19.mRNA-1273-P301IEmRNA-1273-P301-US331-2192US3312192AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-20.mRNA-1273-P301IEmRNA-1273-P301-US331-2203US3312203AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-20.mRNA-1273-P301IEmRNA-1273-P301-US331-2220US3312220AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-21.mRNA-1273-P301IEmRNA-1273-P301-US331-2226US3312226AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-24.mRNA-1273-P301IEmRNA-1273-P301-US331-2231US3312231AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-24.mRNA-1273-P301IEmRNA-1273-P301-US331-2241US3312241AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-24.mRNA-1273-P301IEmRNA-1273-P301-US331-2245US3312245AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-24.mRNA-1273-P301IEmRNA-1273-P301-US331-2247US3312247AEXC07AKnown or suspected allergy or history of anaphylaxis, urticaria, or other significant adverse reaction to the vaccine or its excipients. EXCLUSIONYYAScreening ÂSCREENING 2020-08-24.mRNA-1273-P301IEmRNA-1273-P301-US331-2247US3312247A EXC11BImmunosuppressive or immunodeficient state, asplenia, recurrent severe infections (HIVpositive participants on stable antiretroviral therapy are not excluded). EXCLUSIONYYAScreening ÂSCREENING 2020-08-24.mRNA-1273-P301IEmRNA-1273-P301-US331-2257US3312257AINC03 Able to comply with study procedures based on the assessment of the Investigator. INCLUSIONNNAScreening ÂSCREENING 2020-08-25.mRNA-1273-P301IEmRNA-1273-P301-US331-2262US3312262AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-25.mRNA-1273-P301IEmRNA-1273-P301-US331-2265US3312265AEXC08 Bleeding disorder considered a contraindication to intramuscular injection or phlebotomy. EXCLUSIONYYAScreening ÂSCREENING 2020-08-25.mRNA-1273-P301IEmRNA-1273-P301-US331-2267US3312267AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-25.mRNA-1273-P301IEmRNA-1273-P301-US331-2269US3312269AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-25.mRNA-1273-P301IEmRNA-1273-P301-US331-2272US3312272AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-25.mRNA-1273-P301IEmRNA-1273-P301-US331-2278US3312278AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-25.mRNA-1273-P301IEmRNA-1273-P301-US331-2282US3312282AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-25.mRNA-1273-P301IEmRNA-1273-P301-US331-2283US3312283AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-25.mRNA-1273-P301IEmRNA-1273-P301-US331-2286US3312286AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-25.mRNA-1273-P301IEmRNA-1273-P301-US331-2292US3312292AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-26.mRNA-1273-P301IEmRNA-1273-P301-US331-2301US3312301AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-26.mRNA-1273-P301IEmRNA-1273-P301-US331-2303US3312303AEXC09AHas received or plans to receive a non-study vaccine within 28 days before/after any dose of IP (except for seasonal influenza vaccine which not permitted within 14 days before/after any dose of IP).EXCLUSIONYYAScreening ÂSCREENING 2020-08-26.mRNA-1273-P301IEmRNA-1273-P301-US331-2306US3312306AEXC09AHas received or plans to receive a non-study vaccine within 28 days before/after any dose of IP (except for seasonal influenza vaccine which not permitted within 14 days before/after any dose of IP).EXCLUSIONYYAScreening ÂSCREENING 2020-08-26.mRNA-1273-P301IEmRNA-1273-P301-US331-2310US3312310AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-26.mRNA-1273-P301IEmRNA-1273-P301-US331-2315US3312315AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-26.mRNA-1273-P301IEmRNA-1273-P301-US331-2316US3312316AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-26.mRNA-1273-P301IEmRNA-1273-P301-US331-2318US3312318AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-27.mRNA-1273-P301IEmRNA-1273-P301-US331-2322US3312322AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-27.mRNA-1273-P301IEmRNA-1273-P301-US331-2324US3312324AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-27.mRNA-1273-P301IEmRNA-1273-P301-US331-2346US3312346AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-27.mRNA-1273-P301IEmRNA-1273-P301-US331-2359US3312359AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-28.mRNA-1273-P301IEmRNA-1273-P301-US331-2361US3312361AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-28.mRNA-1273-P301IEmRNA-1273-P301-US331-2369US3312369AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-28.mRNA-1273-P301IEmRNA-1273-P301-US331-2371US3312371AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-28.mRNA-1273-P301IEmRNA-1273-P301-US331-2375US3312375AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-28.mRNA-1273-P301IEmRNA-1273-P301-US331-2412US3312412AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-31.mRNA-1273-P301IEmRNA-1273-P301-US331-2425US3312425AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-01.mRNA-1273-P301IEmRNA-1273-P301-US331-2430US3312430AINC03 Able to comply with study procedures based on the assessment of the Investigator. INCLUSIONNNAScreening ÂSCREENING 2020-09-01.mRNA-1273-P301IEmRNA-1273-P301-US331-2443US3312443AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-01.mRNA-1273-P301IEmRNA-1273-P301-US331-2444US3312444AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-01.mRNA-1273-P301IEmRNA-1273-P301-US331-2453US3312453AEXC14 Has donated >= 450 mL of blood products within 28 days prior to Screening. EXCLUSIONYYAScreening ÂSCREENING 2020-09-02.mRNA-1273-P301IEmRNA-1273-P301-US331-2461US3312461AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-02.mRNA-1273-P301IEmRNA-1273-P301-US331-2487US3312487AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-03.mRNA-1273-P301IEmRNA-1273-P301-US331-2488US3312488AINC03 Able to comply with study procedures based on the assessment of the Investigator. INCLUSIONNNAScreening ÂSCREENING 2020-09-03.mRNA-1273-P301IEmRNA-1273-P301-US331-2494US3312494AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-03.mRNA-1273-P301IEmRNA-1273-P301-US331-2499US3312293AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-26Á€mRNA-1273-P301IEmRNA-1273-P301-US331-2508US3312508AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-04.mRNA-1273-P301IEmRNA-1273-P301-US331-2510US3312510AINC03 Able to comply with study procedures based on the assessment of the Investigator. INCLUSIONNNAScreening ÂSCREENING 2020-09-04.mRNA-1273-P301IEmRNA-1273-P301-US331-2521US3312521AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-04.mRNA-1273-P301IEmRNA-1273-P301-US331-2538US3312538AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-08.mRNA-1273-P301IEmRNA-1273-P301-US331-2543US3312543AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-08.mRNA-1273-P301IEmRNA-1273-P301-US331-2544US3312544AINC05 Female participants of childbearing potential may be enrolled in the study if the participant fulfills all the criteria listed in the protocol. INCLUSIONNNAScreening ÂSCREENING 2020-09-08.mRNA-1273-P301IEmRNA-1273-P301-US331-2580US3312580AEXC09AHas received or plans to receive a non-study vaccine within 28 days before/after any dose of IP (except for seasonal influenza vaccine which not permitted within 14 days before/after any dose of IP).EXCLUSIONYYAScreening ÂSCREENING 2020-09-09.mRNA-1273-P301IEmRNA-1273-P301-US331-2591US3312591AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-10.mRNA-1273-P301IEmRNA-1273-P301-US331-2614US3312614AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-09-10.mRNA-1273-P301IEmRNA-1273-P301-US331-2616US3312616AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-09-10.mRNA-1273-P301IEmRNA-1273-P301-US331-2620US3312620AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-09-11.mRNA-1273-P301IEmRNA-1273-P301-US331-2630US3312630AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-09-11.mRNA-1273-P301IEmRNA-1273-P301-US331-2631US3312631AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-11.mRNA-1273-P301IEmRNA-1273-P301-US331-2638US3312638AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-11.mRNA-1273-P301IEmRNA-1273-P301-US332-2044US3322044AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-19.mRNA-1273-P301IEmRNA-1273-P301-US332-2065US3322065AINC03 Able to comply with study procedures based on the assessment of the Investigator. INCLUSIONNNAScreening ÂSCREENING 2020-08-21.mRNA-1273-P301IEmRNA-1273-P301-US332-2099US3322099AEXC01 Participants who are acutely ill or febrile 72 hours prior to or at Screening may be rescheduled. Afebrile participants with minor illnesses can be enrolled at the discretion of the investigator. EXCLUSIONYYAScreening ÂSCREENING 2020-08-25.mRNA-1273-P301IEmRNA-1273-P301-US332-2099US3322099A EXC05 Demonstrated inability to comply with the study procedures. EXCLUSIONYYAScreening ÂSCREENING 2020-08-25.mRNA-1273-P301IEmRNA-1273-P301-US332-2099US3322099A0EXC09AHas received or plans to receive a non-study vaccine within 28 days before/after any dose of IP (except for seasonal influenza vaccine which not permitted within 14 days before/after any dose of IP).EXCLUSIONYYAScreening ÂSCREENING 2020-08-25.mRNA-1273-P301IEmRNA-1273-P301-US332-2099US3322099A@EXC10 Has participated in an interventional clinical study within 28 days prior to the day of enrollment. EXCLUSIONYYAScreening ÂSCREENING 2020-08-25.mRNA-1273-P301IEmRNA-1273-P301-US332-2099US3322099APEXC12AHas received systemic immunosuppressants or immune-modifying drugs for >14 days in total within 6 months prior to Screening (for corticosteroids = 20 mg/day of prednisone equivalent). EXCLUSIONYYAScreening ÂSCREENING 2020-08-25.mRNA-1273-P301IEmRNA-1273-P301-US332-2099US3322099A`EXC13 Has received systemic immunoglobulins or blood products within 3 months prior to the day of screening. EXCLUSIONYYAScreening ÂSCREENING 2020-08-25.mRNA-1273-P301IEmRNA-1273-P301-US332-2099US3322099ApEXC14 Has donated >= 450 mL of blood products within 28 days prior to Screening. EXCLUSIONYYAScreening ÂSCREENING 2020-08-25.mRNA-1273-P301IEmRNA-1273-P301-US332-2099US3322099A€INC03 Able to comply with study procedures based on the assessment of the Investigator. INCLUSIONNNAScreening ÂSCREENING 2020-08-25.mRNA-1273-P301IEmRNA-1273-P301-US332-2099US3322099AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-25.mRNA-1273-P301IEmRNA-1273-P301-US332-2112US3322112AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-26.mRNA-1273-P301IEmRNA-1273-P301-US332-2161US3322161AINC03 Able to comply with study procedures based on the assessment of the Investigator. INCLUSIONNNAScreening ÂSCREENING 2020-09-01.mRNA-1273-P301IEmRNA-1273-P301-US332-2176US3322176AINC01 Adults, >= 18 years of age at time of consent, who are at high risk of SARS-CoV-2 infection. INCLUSIONNNAScreening ÂSCREENING 2020-09-01.mRNA-1273-P301IEmRNA-1273-P301-US332-2186US3322186AEXC11CImmunosuppressive or immunodeficient state, asplenia, recurrent severe infections (HIVpositive participants with CD4 count =350 cells/mm3 and an undetectable HIV viral load within the past year). EXCLUSIONYYAScreening ÂSCREENING 2020-09-02.mRNA-1273-P301IEmRNA-1273-P301-US332-2268US3322268AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-09-08.mRNA-1273-P301IEmRNA-1273-P301-US332-2268US3322268A INC03 Able to comply with study procedures based on the assessment of the Investigator. INCLUSIONNNAScreening ÂSCREENING 2020-09-08.mRNA-1273-P301IEmRNA-1273-P301-US332-2286US3322286AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-09.mRNA-1273-P301IEmRNA-1273-P301-US332-2290US3322290AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-09.mRNA-1273-P301IEmRNA-1273-P301-US332-2326US3322326AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-12.mRNA-1273-P301IEmRNA-1273-P301-US332-2343US3322343AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-12.mRNA-1273-P301IEmRNA-1273-P301-US332-2349US3322349AEXC05 Demonstrated inability to comply with the study procedures. EXCLUSIONYYAScreening ÂSCREENING 2020-09-15.mRNA-1273-P301IEmRNA-1273-P301-US332-2349US3322349A INC03 Able to comply with study procedures based on the assessment of the Investigator. INCLUSIONNNAScreening ÂSCREENING 2020-09-15.mRNA-1273-P301IEmRNA-1273-P301-US332-2349US3322349A0INC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-15.mRNA-1273-P301IEmRNA-1273-P301-US332-2350US3322350AEXC14 Has donated >= 450 mL of blood products within 28 days prior to Screening. EXCLUSIONYYAScreening ÂSCREENING 2020-09-15.mRNA-1273-P301IEmRNA-1273-P301-US332-2350US3322350A INC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-15.mRNA-1273-P301IEmRNA-1273-P301-US332-2363US3322363AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-17.mRNA-1273-P301IEmRNA-1273-P301-US332-2368US3322368AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-17.mRNA-1273-P301IEmRNA-1273-P301-US332-2376US3322376AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-18.mRNA-1273-P301IEmRNA-1273-P301-US332-2383US3322383AEXC05 Demonstrated inability to comply with the study procedures. EXCLUSIONYYAScreening ÂSCREENING 2020-09-18.mRNA-1273-P301IEmRNA-1273-P301-US332-2386US3322386AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-21.mRNA-1273-P301IEmRNA-1273-P301-US332-2399US3322399AEXC05 Demonstrated inability to comply with the study procedures. EXCLUSIONYYAScreening ÂSCREENING 2020-09-29.mRNA-1273-P301IEmRNA-1273-P301-US332-2423US3322423AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-10-12.mRNA-1273-P301IEmRNA-1273-P301-US332-2428US3322428AEXC05 Demonstrated inability to comply with the study procedures. EXCLUSIONYYAScreening ÂSCREENING 2020-10-13.mRNA-1273-P301IEmRNA-1273-P301-US332-2431US3322431AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-10-14.mRNA-1273-P301IEmRNA-1273-P301-US332-2436US3322436AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-10-16.mRNA-1273-P301IEmRNA-1273-P301-US333-2013US3332013AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-06.mRNA-1273-P301IEmRNA-1273-P301-US333-2053US3332053AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-14.mRNA-1273-P301IEmRNA-1273-P301-US333-2070US3332070AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-28.mRNA-1273-P301IEmRNA-1273-P301-US333-2075US3332075AEXC09AHas received or plans to receive a non-study vaccine within 28 days before/after any dose of IP (except for seasonal influenza vaccine which not permitted within 14 days before/after any dose of IP).EXCLUSIONYYAScreening ÂSCREENING 2020-09-02.mRNA-1273-P301IEmRNA-1273-P301-US333-2093US3332093AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-25.mRNA-1273-P301IEmRNA-1273-P301-US334-2075US3342075AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-08-14.mRNA-1273-P301IEmRNA-1273-P301-US334-2108US3342108AEXC11BImmunosuppressive or immunodeficient state, asplenia, recurrent severe infections (HIVpositive participants on stable antiretroviral therapy are not excluded). EXCLUSIONYYAScreening ÂSCREENING 2020-08-18.mRNA-1273-P301IEmRNA-1273-P301-US334-2110US3342110AEXC09AHas received or plans to receive a non-study vaccine within 28 days before/after any dose of IP (except for seasonal influenza vaccine which not permitted within 14 days before/after any dose of IP).EXCLUSIONYYAScreening ÂSCREENING 2020-08-19.mRNA-1273-P301IEmRNA-1273-P301-US334-2149US3342149AEXC11CImmunosuppressive or immunodeficient state, asplenia, recurrent severe infections (HIVpositive participants with CD4 count =350 cells/mm3 and an undetectable HIV viral load within the past year). EXCLUSIONYYAScreening ÂSCREENING 2020-08-28.mRNA-1273-P301IEmRNA-1273-P301-US334-2166US3342166AINC03 Able to comply with study procedures based on the assessment of the Investigator. INCLUSIONNNAScreening ÂSCREENING 2020-09-01.mRNA-1273-P301IEmRNA-1273-P301-US334-2173US3342173AEXC09AHas received or plans to receive a non-study vaccine within 28 days before/after any dose of IP (except for seasonal influenza vaccine which not permitted within 14 days before/after any dose of IP).EXCLUSIONYYAScreening ÂSCREENING 2020-09-02.mRNA-1273-P301IEmRNA-1273-P301-US334-2222US3342222AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-09.mRNA-1273-P301IEmRNA-1273-P301-US334-2266US3342266AEXC07AKnown or suspected allergy or history of anaphylaxis, urticaria, or other significant adverse reaction to the vaccine or its excipients. EXCLUSIONYYAScreening ÂSCREENING 2020-09-15.mRNA-1273-P301IEmRNA-1273-P301-US334-2292US3342292AEXC09AHas received or plans to receive a non-study vaccine within 28 days before/after any dose of IP (except for seasonal influenza vaccine which not permitted within 14 days before/after any dose of IP).EXCLUSIONYYAScreening ÂSCREENING 2020-09-28.mRNA-1273-P301IEmRNA-1273-P301-US334-2307US3342307AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-09-30.mRNA-1273-P301IEmRNA-1273-P301-US334-2315US3342315AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-10-01.mRNA-1273-P301IEmRNA-1273-P301-US334-2318US3342318AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-10-01.mRNA-1273-P301IEmRNA-1273-P301-US334-2319US3342319AEXC09AHas received or plans to receive a non-study vaccine within 28 days before/after any dose of IP (except for seasonal influenza vaccine which not permitted within 14 days before/after any dose of IP).EXCLUSIONYYAScreening ÂSCREENING 2020-10-01.mRNA-1273-P301IEmRNA-1273-P301-US334-2320US3342320AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-10-01.mRNA-1273-P301IEmRNA-1273-P301-US334-2330US3342330AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-10-02.mRNA-1273-P301IEmRNA-1273-P301-US334-2335US3342335AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-10-05.mRNA-1273-P301IEmRNA-1273-P301-US334-2341US3342341AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-10-06.mRNA-1273-P301IEmRNA-1273-P301-US334-2350US3342350AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-10-07.mRNA-1273-P301IEmRNA-1273-P301-US334-2353US3342353AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-10-07.mRNA-1273-P301IEmRNA-1273-P301-US335-2091US3352091AEXC12 Has received systemic immunosuppressants/immune-modifying drugs for >14 days in total within 6 months prior to Screening. Topical tacrolimus is allowed if not used within 14 days prior to Screening. EXCLUSIONYYAScreening ÂSCREENING 2020-08-13.mRNA-1273-P301IEmRNA-1273-P301-US335-2100US3352100AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-18.mRNA-1273-P301IEmRNA-1273-P301-US335-2123US3352123AEXC12 Has received systemic immunosuppressants/immune-modifying drugs for >14 days in total within 6 months prior to Screening. Topical tacrolimus is allowed if not used within 14 days prior to Screening. EXCLUSIONYYAScreening ÂSCREENING 2020-08-18.mRNA-1273-P301IEmRNA-1273-P301-US335-2136US3352136AEXC09AHas received or plans to receive a non-study vaccine within 28 days before/after any dose of IP (except for seasonal influenza vaccine which not permitted within 14 days before/after any dose of IP).EXCLUSIONYYAScreening ÂSCREENING 2020-08-20.mRNA-1273-P301IEmRNA-1273-P301-US335-2138US3352138AEXC03 Known history of SARS-CoV-2 infection. EXCLUSIONYYAScreening ÂSCREENING 2020-08-20.mRNA-1273-P301IEmRNA-1273-P301-US335-2142US3352142AEXC09AHas received or plans to receive a non-study vaccine within 28 days before/after any dose of IP (except for seasonal influenza vaccine which not permitted within 14 days before/after any dose of IP).EXCLUSIONYYAScreening ÂSCREENING 2020-08-20.mRNA-1273-P301IEmRNA-1273-P301-US335-2147US3352147AEXC12 Has received systemic immunosuppressants/immune-modifying drugs for >14 days in total within 6 months prior to Screening. Topical tacrolimus is allowed if not used within 14 days prior to Screening. EXCLUSIONYYAScreening ÂSCREENING 2020-08-20.mRNA-1273-P301IEmRNA-1273-P301-US335-2178US3352178AEXC14 Has donated >= 450 mL of blood products within 28 days prior to Screening. EXCLUSIONYYAScreening ÂSCREENING 2020-08-22.mRNA-1273-P301IEmRNA-1273-P301-US335-2212US3352212AEXC03 Known history of SARS-CoV-2 infection. EXCLUSIONYYAScreening ÂSCREENING 2020-08-22.mRNA-1273-P301IEmRNA-1273-P301-US335-2231US3352231AEXC14 Has donated >= 450 mL of blood products within 28 days prior to Screening. EXCLUSIONYYAScreening ÂSCREENING 2020-08-22.mRNA-1273-P301IEmRNA-1273-P301-US335-2279US3352279AEXC11CImmunosuppressive or immunodeficient state, asplenia, recurrent severe infections (HIVpositive participants with CD4 count =350 cells/mm3 and an undetectable HIV viral load within the past year). EXCLUSIONYYAScreening ÂSCREENING 2020-08-25.mRNA-1273-P301IEmRNA-1273-P301-US335-2305US3352305AEXC12 Has received systemic immunosuppressants/immune-modifying drugs for >14 days in total within 6 months prior to Screening. Topical tacrolimus is allowed if not used within 14 days prior to Screening. EXCLUSIONYYAScreening ÂSCREENING 2020-09-01.mRNA-1273-P301IEmRNA-1273-P301-US335-2352US3352352AEXC07AKnown or suspected allergy or history of anaphylaxis, urticaria, or other significant adverse reaction to the vaccine or its excipients. EXCLUSIONYYAScreening ÂSCREENING 2020-09-10.mRNA-1273-P301IEmRNA-1273-P301-US335-2367US3352367AEXC14 Has donated >= 450 mL of blood products within 28 days prior to Screening. EXCLUSIONYYAScreening ÂSCREENING 2020-09-10.mRNA-1273-P301IEmRNA-1273-P301-US335-2382US3352382AEXC09AHas received or plans to receive a non-study vaccine within 28 days before/after any dose of IP (except for seasonal influenza vaccine which not permitted within 14 days before/after any dose of IP).EXCLUSIONYYAScreening ÂSCREENING 2020-09-19.mRNA-1273-P301IEmRNA-1273-P301-US335-2407US3352407AINC03 Able to comply with study procedures based on the assessment of the Investigator. INCLUSIONNNAScreening ÂSCREENING 2020-09-24.mRNA-1273-P301IEmRNA-1273-P301-US335-2454US3352454AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-29.mRNA-1273-P301IEmRNA-1273-P301-US335-2510US3352510AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-10-08.mRNA-1273-P301IEmRNA-1273-P301-US335-2520US3352520AEXC05 Demonstrated inability to comply with the study procedures. EXCLUSIONYYAScreening ÂSCREENING 2020-10-08.mRNA-1273-P301IEmRNA-1273-P301-US335-2546US3352546AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-10-15.mRNA-1273-P301IEmRNA-1273-P301-US335-2546US3352546A INC03 Able to comply with study procedures based on the assessment of the Investigator. INCLUSIONNNAScreening ÂSCREENING 2020-10-15.mRNA-1273-P301IEmRNA-1273-P301-US335-2578US3352578AEXC03 Known history of SARS-CoV-2 infection. EXCLUSIONYYAScreening ÂSCREENING 2020-10-15.mRNA-1273-P301IEmRNA-1273-P301-US336-2043US3362043AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-05.mRNA-1273-P301IEmRNA-1273-P301-US336-2049US3362049AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-05.mRNA-1273-P301IEmRNA-1273-P301-US336-2050US3362050AINC01 Adults, >= 18 years of age at time of consent, who are at high risk of SARS-CoV-2 infection. INCLUSIONNNAScreening ÂSCREENING 2020-08-05.mRNA-1273-P301IEmRNA-1273-P301-US336-2054US3362054AEXC11AImmunosuppressive or immunodeficient state, including HIV infection, asplenia, recurrent severe infections. EXCLUSIONYYAScreening ÂSCREENING 2020-08-05.mRNA-1273-P301IEmRNA-1273-P301-US336-2174US3362174AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-17.mRNA-1273-P301IEmRNA-1273-P301-US336-2185US3362185AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-18.mRNA-1273-P301IEmRNA-1273-P301-US336-2191US3362191AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-19.mRNA-1273-P301IEmRNA-1273-P301-US336-2224US3362224AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-22.mRNA-1273-P301IEmRNA-1273-P301-US336-2231US3362231AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-22.mRNA-1273-P301IEmRNA-1273-P301-US336-2239US3362239AINC01 Adults, >= 18 years of age at time of consent, who are at high risk of SARS-CoV-2 infection. INCLUSIONNNAScreening ÂSCREENING 2020-08-24.mRNA-1273-P301IEmRNA-1273-P301-US336-2251US3362251AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-08-26.mRNA-1273-P301IEmRNA-1273-P301-US336-2311US3362311AINC01 Adults, >= 18 years of age at time of consent, who are at high risk of SARS-CoV-2 infection. INCLUSIONNNAScreening ÂSCREENING 2020-10-13.mRNA-1273-P301IEmRNA-1273-P301-US337-2010US3372010AINC03 Able to comply with study procedures based on the assessment of the Investigator. INCLUSIONNNAScreening ÂSCREENING 2020-08-03.mRNA-1273-P301IEmRNA-1273-P301-US337-2024US3372024AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-04.mRNA-1273-P301IEmRNA-1273-P301-US337-2029US3372029AEXC12 Has received systemic immunosuppressants/immune-modifying drugs for >14 days in total within 6 months prior to Screening. Topical tacrolimus is allowed if not used within 14 days prior to Screening. EXCLUSIONYYAScreening ÂSCREENING 2020-08-04.mRNA-1273-P301IEmRNA-1273-P301-US337-2054US3372054AEXC11AImmunosuppressive or immunodeficient state, including HIV infection, asplenia, recurrent severe infections. EXCLUSIONYYAScreening ÂSCREENING 2020-08-06.mRNA-1273-P301IEmRNA-1273-P301-US337-2054US3372054A EXC12 Has received systemic immunosuppressants/immune-modifying drugs for >14 days in total within 6 months prior to Screening. Topical tacrolimus is allowed if not used within 14 days prior to Screening. EXCLUSIONYYAScreening ÂSCREENING 2020-08-06.mRNA-1273-P301IEmRNA-1273-P301-US337-2061US3372061AEXC03 Known history of SARS-CoV-2 infection. EXCLUSIONYYAScreening ÂSCREENING 2020-08-07.mRNA-1273-P301IEmRNA-1273-P301-US337-2062US3372062AEXC09 Has received or plans to receive a vaccine within 28 days prior to the first dose or plans to receive a non-study vaccine within 28 days prior to or after any dose of IP. EXCLUSIONYYAScreening ÂSCREENING 2020-08-07.mRNA-1273-P301IEmRNA-1273-P301-US337-2067US3372067AINC06 Male participants that could result in pregnancy of sexual partners must agree to practice adequate contraception and refrain from sperm donation from the 1st dose to 3 months after the second dose. INCLUSIONNNAScreening ÂSCREENING 2020-08-10.mRNA-1273-P301IEmRNA-1273-P301-US337-2071US3372071AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-08-10.mRNA-1273-P301IEmRNA-1273-P301-US337-2091US3372091AINC03 Able to comply with study procedures based on the assessment of the Investigator. INCLUSIONNNAScreening ÂSCREENING 2020-08-11.mRNA-1273-P301IEmRNA-1273-P301-US337-2106US3372106AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-12.mRNA-1273-P301IEmRNA-1273-P301-US337-2118US3372118AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-13.mRNA-1273-P301IEmRNA-1273-P301-US337-2120US3372120AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-08-13.mRNA-1273-P301IEmRNA-1273-P301-US337-2122US3372122AEXC11BImmunosuppressive or immunodeficient state, asplenia, recurrent severe infections (HIVpositive participants on stable antiretroviral therapy are not excluded). EXCLUSIONYYAScreening ÂSCREENING 2020-08-13.mRNA-1273-P301IEmRNA-1273-P301-US337-2160US3372160AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-18.mRNA-1273-P301IEmRNA-1273-P301-US337-2162US3372162AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-18.mRNA-1273-P301IEmRNA-1273-P301-US337-2166US3372166AINC05 Female participants of childbearing potential may be enrolled in the study if the participant fulfills all the criteria listed in the protocol. INCLUSIONNNAScreening ÂSCREENING 2020-08-18.mRNA-1273-P301IEmRNA-1273-P301-US337-2168US3372168AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-18.mRNA-1273-P301IEmRNA-1273-P301-US337-2172US3372172AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-19.mRNA-1273-P301IEmRNA-1273-P301-US337-2173US3372173AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-19.mRNA-1273-P301IEmRNA-1273-P301-US337-2175US3372175AEXC11AImmunosuppressive or immunodeficient state, including HIV infection, asplenia, recurrent severe infections. EXCLUSIONYYAScreening ÂSCREENING 2020-08-19.mRNA-1273-P301IEmRNA-1273-P301-US337-2175US3372175A EXC12 Has received systemic immunosuppressants/immune-modifying drugs for >14 days in total within 6 months prior to Screening. Topical tacrolimus is allowed if not used within 14 days prior to Screening. EXCLUSIONYYAScreening ÂSCREENING 2020-08-19.mRNA-1273-P301IEmRNA-1273-P301-US337-2199US3372199AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-08-20.mRNA-1273-P301IEmRNA-1273-P301-US337-2236US3372236AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-25.mRNA-1273-P301IEmRNA-1273-P301-US337-2244US3372244AEXC05 Demonstrated inability to comply with the study procedures. EXCLUSIONYYAScreening ÂSCREENING 2020-08-25.mRNA-1273-P301IEmRNA-1273-P301-US337-2244US3372244A INC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-08-25.mRNA-1273-P301IEmRNA-1273-P301-US337-2244US3372244A0INC03 Able to comply with study procedures based on the assessment of the Investigator. INCLUSIONNNAScreening ÂSCREENING 2020-08-25.mRNA-1273-P301IEmRNA-1273-P301-US337-2253US3372253AEXC11CImmunosuppressive or immunodeficient state, asplenia, recurrent severe infections (HIVpositive participants with CD4 count =350 cells/mm3 and an undetectable HIV viral load within the past year). EXCLUSIONYYAScreening ÂSCREENING 2020-08-26.mRNA-1273-P301IEmRNA-1273-P301-US337-2259US3372259AEXC10 Has participated in an interventional clinical study within 28 days prior to the day of enrollment. EXCLUSIONYYAScreening ÂSCREENING 2020-08-26.mRNA-1273-P301IEmRNA-1273-P301-US337-2268US3372268AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-27.mRNA-1273-P301IEmRNA-1273-P301-US337-2277US3372277AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-27.mRNA-1273-P301IEmRNA-1273-P301-US337-2279US3372279AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-27.mRNA-1273-P301IEmRNA-1273-P301-US337-2288US3372288AINC03 Able to comply with study procedures based on the assessment of the Investigator. INCLUSIONNNAScreening ÂSCREENING 2020-08-28.mRNA-1273-P301IEmRNA-1273-P301-US337-2305US3372305AEXC10 Has participated in an interventional clinical study within 28 days prior to the day of enrollment. EXCLUSIONYYAScreening ÂSCREENING 2020-09-01.mRNA-1273-P301IEmRNA-1273-P301-US337-2321US3372321AINC06 INCLUSIONNNAScreening ÂSCREENING 2020-09-02.mRNA-1273-P301IEmRNA-1273-P301-US337-2337US3372337AINC06 INCLUSIONNNAScreening ÂSCREENING 2020-09-04.mRNA-1273-P301IEmRNA-1273-P301-US337-2388US3372388AINC03 Able to comply with study procedures based on the assessment of the Investigator. INCLUSIONNNAScreening ÂSCREENING 2020-09-10.mRNA-1273-P301IEmRNA-1273-P301-US337-2401US3372401AEXC11CImmunosuppressive or immunodeficient state, asplenia, recurrent severe infections (HIVpositive participants with CD4 count =350 cells/mm3 and an undetectable HIV viral load within the past year). EXCLUSIONYYAScreening ÂSCREENING 2020-09-13.mRNA-1273-P301IEmRNA-1273-P301-US337-2410US3372410AEXC12AHas received systemic immunosuppressants or immune-modifying drugs for >14 days in total within 6 months prior to Screening (for corticosteroids = 20 mg/day of prednisone equivalent). EXCLUSIONYYAScreening ÂSCREENING 2020-09-13.mRNA-1273-P301IEmRNA-1273-P301-US337-2410US3372410A INC06 INCLUSIONNNAScreening ÂSCREENING 2020-09-13.mRNA-1273-P301IEmRNA-1273-P301-US337-2412US3372412AINC06 INCLUSIONNNAScreening ÂSCREENING 2020-09-13.mRNA-1273-P301IEmRNA-1273-P301-US337-2415US3372415AINC06 INCLUSIONNNAScreening ÂSCREENING 2020-09-13.mRNA-1273-P301IEmRNA-1273-P301-US337-2422US3372422AINC06 INCLUSIONNNAScreening ÂSCREENING 2020-09-15.mRNA-1273-P301IEmRNA-1273-P301-US337-2423US3372423AINC06 INCLUSIONNNAScreening ÂSCREENING 2020-09-15.mRNA-1273-P301IEmRNA-1273-P301-US337-2424US3372424AINC06 INCLUSIONNNAScreening ÂSCREENING 2020-09-15.mRNA-1273-P301IEmRNA-1273-P301-US337-2432US3372432AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-09-17.mRNA-1273-P301IEmRNA-1273-P301-US337-2436US3372436AINC06 INCLUSIONNNAScreening ÂSCREENING 2020-09-17.mRNA-1273-P301IEmRNA-1273-P301-US337-2441US3372441AINC06 INCLUSIONNNAScreening ÂSCREENING 2020-09-21.mRNA-1273-P301IEmRNA-1273-P301-US337-2442US3372442AEXC11CImmunosuppressive or immunodeficient state, asplenia, recurrent severe infections (HIVpositive participants with CD4 count =350 cells/mm3 and an undetectable HIV viral load within the past year). EXCLUSIONYYAScreening ÂSCREENING 2020-09-21.mRNA-1273-P301IEmRNA-1273-P301-US337-2442US3372442A INC06 INCLUSIONNNAScreening ÂSCREENING 2020-09-21.mRNA-1273-P301IEmRNA-1273-P301-US337-2463US3372463AINC06 INCLUSIONNNAScreening ÂSCREENING 2020-10-02.mRNA-1273-P301IEmRNA-1273-P301-US337-2464US3372464AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-10-05.mRNA-1273-P301IEmRNA-1273-P301-US338-2003US3382003AINC01 Adults, >= 18 years of age at time of consent, who are at high risk of SARS-CoV-2 infection. INCLUSIONNNAScreening ÂSCREENING 2020-08-10.mRNA-1273-P301IEmRNA-1273-P301-US338-2023US3382023AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-12.mRNA-1273-P301IEmRNA-1273-P301-US338-2050US3382050AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-17.mRNA-1273-P301IEmRNA-1273-P301-US338-2053US3382053AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-17.mRNA-1273-P301IEmRNA-1273-P301-US338-2074US3382074AEXC07AKnown or suspected allergy or history of anaphylaxis, urticaria, or other significant adverse reaction to the vaccine or its excipients. EXCLUSIONYYAScreening ÂSCREENING 2020-08-19.mRNA-1273-P301IEmRNA-1273-P301-US338-2084US3382084AEXC05 Demonstrated inability to comply with the study procedures. EXCLUSIONYYAScreening ÂSCREENING 2020-08-20.mRNA-1273-P301IEmRNA-1273-P301-US338-2122US3382122AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-27.mRNA-1273-P301IEmRNA-1273-P301-US338-2126US3382126AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-27.mRNA-1273-P301IEmRNA-1273-P301-US338-2130US3382130AEXC14 Has donated >= 450 mL of blood products within 28 days prior to Screening. EXCLUSIONYYAScreening ÂSCREENING 2020-08-27.mRNA-1273-P301IEmRNA-1273-P301-US338-2149US3382149AEXC12AHas received systemic immunosuppressants or immune-modifying drugs for >14 days in total within 6 months prior to Screening (for corticosteroids = 20 mg/day of prednisone equivalent). EXCLUSIONYYAScreening ÂSCREENING 2020-08-31.mRNA-1273-P301IEmRNA-1273-P301-US338-2158US3382158AEXC02 Is pregnant or breastfeeding. EXCLUSIONYYAScreening ÂSCREENING 2020-09-01.mRNA-1273-P301IEmRNA-1273-P301-US338-2158US3382158A INC05 Female participants of childbearing potential may be enrolled in the study if the participant fulfills all the criteria listed in the protocol. INCLUSIONNNAScreening ÂSCREENING 2020-09-01.mRNA-1273-P301IEmRNA-1273-P301-US338-2181US3382181AEXC14 Has donated >= 450 mL of blood products within 28 days prior to Screening. EXCLUSIONYYAScreening ÂSCREENING 2020-09-03.mRNA-1273-P301IEmRNA-1273-P301-US338-2191US3382191AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-03.mRNA-1273-P301IEmRNA-1273-P301-US338-2222US3382222AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-09-08.mRNA-1273-P301IEmRNA-1273-P301-US338-2248US3382248AEXC11CImmunosuppressive or immunodeficient state, asplenia, recurrent severe infections (HIVpositive participants with CD4 count =350 cells/mm3 and an undetectable HIV viral load within the past year). EXCLUSIONYYAScreening ÂSCREENING 2020-09-11.mRNA-1273-P301IEmRNA-1273-P301-US338-2251US3382251AEXC09AHas received or plans to receive a non-study vaccine within 28 days before/after any dose of IP (except for seasonal influenza vaccine which not permitted within 14 days before/after any dose of IP).EXCLUSIONYYAScreening ÂSCREENING 2020-09-11.mRNA-1273-P301IEmRNA-1273-P301-US338-2253US3382253AEXC09AHas received or plans to receive a non-study vaccine within 28 days before/after any dose of IP (except for seasonal influenza vaccine which not permitted within 14 days before/after any dose of IP).EXCLUSIONYYAScreening ÂSCREENING 2020-09-11.mRNA-1273-P301IEmRNA-1273-P301-US339-2051US3392051AEXC11BImmunosuppressive or immunodeficient state, asplenia, recurrent severe infections (HIVpositive participants on stable antiretroviral therapy are not excluded). EXCLUSIONYYAScreening ÂSCREENING 2020-08-19.mRNA-1273-P301IEmRNA-1273-P301-US339-2130US3392130AINC06 INCLUSIONNNAScreening ÂSCREENING 2020-09-01.mRNA-1273-P301IEmRNA-1273-P301-US339-2210US3392210A EXCLUSIONYYAScreening ÂSCREENING 2020-09-10.mRNA-1273-P301IEmRNA-1273-P301-US339-2286US3392286AEXC09AHas received or plans to receive a non-study vaccine within 28 days before/after any dose of IP (except for seasonal influenza vaccine which not permitted within 14 days before/after any dose of IP).EXCLUSIONYYAScreening ÂSCREENING 2020-09-16.mRNA-1273-P301IEmRNA-1273-P301-US339-2292US3392292AEXC09AHas received or plans to receive a non-study vaccine within 28 days before/after any dose of IP (except for seasonal influenza vaccine which not permitted within 14 days before/after any dose of IP).EXCLUSIONYYAScreening ÂSCREENING 2020-09-16.mRNA-1273-P301IEmRNA-1273-P301-US339-2294US3392294AEXC09AHas received or plans to receive a non-study vaccine within 28 days before/after any dose of IP (except for seasonal influenza vaccine which not permitted within 14 days before/after any dose of IP).EXCLUSIONYYAScreening ÂSCREENING 2020-09-16.mRNA-1273-P301IEmRNA-1273-P301-US340-2060US3402060AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-07-28.mRNA-1273-P301IEmRNA-1273-P301-US341-2028US3412028AINC03 Able to comply with study procedures based on the assessment of the Investigator. INCLUSIONNNAScreening ÂSCREENING 2020-07-29.mRNA-1273-P301IEmRNA-1273-P301-US341-2043US3412043AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-07-30.mRNA-1273-P301IEmRNA-1273-P301-US341-2094US3412094AEXC14 Has donated >= 450 mL of blood products within 28 days prior to Screening. EXCLUSIONYYAScreening ÂSCREENING 2020-08-01.mRNA-1273-P301IEmRNA-1273-P301-US341-2142US3412142AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-05.mRNA-1273-P301IEmRNA-1273-P301-US341-2154US3412154AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-06.mRNA-1273-P301IEmRNA-1273-P301-US341-2157US3412157AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-08-06.mRNA-1273-P301IEmRNA-1273-P301-US341-2164US3412164AEXC12 Has received systemic immunosuppressants/immune-modifying drugs for >14 days in total within 6 months prior to Screening. Topical tacrolimus is allowed if not used within 14 days prior to Screening. EXCLUSIONYYAScreening ÂSCREENING 2020-08-07.mRNA-1273-P301IEmRNA-1273-P301-US341-2201US3412201AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-08-11.mRNA-1273-P301IEmRNA-1273-P301-US341-2340US3412340AINC06 INCLUSIONNNAScreening ÂSCREENING 2020-08-31.mRNA-1273-P301IEmRNA-1273-P301-US341-2382US3412140AEXC05 Demonstrated inability to comply with the study procedures. EXCLUSIONYYAScreening ÂSCREENING 2020-08-05ÂMmRNA-1273-P301IEmRNA-1273-P301-US341-2389US3412389AEXC04 Prior administration of an investigational coronavirus (SARS-CoV, MERS-CoV) vaccine or current/planned simultaneous participation in another interventional study to prevent or treat COVID-19. EXCLUSIONYYAScreening ÂSCREENING 2020-10-23.mRNA-1273-P301IEmRNA-1273-P301-US342-2022US3422022AINC01 Adults, >= 18 years of age at time of consent, who are at high risk of SARS-CoV-2 infection. INCLUSIONNNAScreening ÂSCREENING 2020-08-17.mRNA-1273-P301IEmRNA-1273-P301-US342-2044US3422044AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-18.mRNA-1273-P301IEmRNA-1273-P301-US342-2050US3422050AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-19.mRNA-1273-P301IEmRNA-1273-P301-US342-2088US3422088AEXC14 Has donated >= 450 mL of blood products within 28 days prior to Screening. EXCLUSIONYYAScreening ÂSCREENING 2020-08-24.mRNA-1273-P301IEmRNA-1273-P301-US342-2095US3422095AEXC09AHas received or plans to receive a non-study vaccine within 28 days before/after any dose of IP (except for seasonal influenza vaccine which not permitted within 14 days before/after any dose of IP).EXCLUSIONYYAScreening ÂSCREENING 2020-08-24.mRNA-1273-P301IEmRNA-1273-P301-US342-2098US3422098AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-24.mRNA-1273-P301IEmRNA-1273-P301-US342-2100US3422100AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-25.mRNA-1273-P301IEmRNA-1273-P301-US342-2113US3422113AINC06 INCLUSIONNNAScreening ÂSCREENING 2020-08-26.mRNA-1273-P301IEmRNA-1273-P301-US342-2121US3422121AEXC09AHas received or plans to receive a non-study vaccine within 28 days before/after any dose of IP (except for seasonal influenza vaccine which not permitted within 14 days before/after any dose of IP).EXCLUSIONYYAScreening ÂSCREENING 2020-08-26.mRNA-1273-P301IEmRNA-1273-P301-US342-2198US3422198AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-03.mRNA-1273-P301IEmRNA-1273-P301-US342-2214US3422214AEXC14 Has donated >= 450 mL of blood products within 28 days prior to Screening. EXCLUSIONYYAScreening ÂSCREENING 2020-09-04.mRNA-1273-P301IEmRNA-1273-P301-US342-2225US3422225AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-04.mRNA-1273-P301IEmRNA-1273-P301-US342-2227US3422227AEXC11CImmunosuppressive or immunodeficient state, asplenia, recurrent severe infections (HIVpositive participants with CD4 count =350 cells/mm3 and an undetectable HIV viral load within the past year). EXCLUSIONYYAScreening ÂSCREENING 2020-09-08.mRNA-1273-P301IEmRNA-1273-P301-US342-2234US3422234AINC01 Adults, >= 18 years of age at time of consent, who are at high risk of SARS-CoV-2 infection. INCLUSIONNNAScreening ÂSCREENING 2020-09-08.mRNA-1273-P301IEmRNA-1273-P301-US342-2260US3422260AEXC14 Has donated >= 450 mL of blood products within 28 days prior to Screening. EXCLUSIONYYAScreening ÂSCREENING 2020-09-10.mRNA-1273-P301IEmRNA-1273-P301-US342-2266US3422266AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-11.mRNA-1273-P301IEmRNA-1273-P301-US342-2284US3422284AEXC09AHas received or plans to receive a non-study vaccine within 28 days before/after any dose of IP (except for seasonal influenza vaccine which not permitted within 14 days before/after any dose of IP).EXCLUSIONYYAScreening ÂSCREENING 2020-09-15.mRNA-1273-P301IEmRNA-1273-P301-US343-2001US3432001AEXC12 Has received systemic immunosuppressants/immune-modifying drugs for >14 days in total within 6 months prior to Screening. Topical tacrolimus is allowed if not used within 14 days prior to Screening. EXCLUSIONYYAScreening ÂSCREENING 2020-08-03.mRNA-1273-P301IEmRNA-1273-P301-US343-2002US3432002AINC03 Able to comply with study procedures based on the assessment of the Investigator. INCLUSIONNNAScreening ÂSCREENING 2020-08-03.mRNA-1273-P301IEmRNA-1273-P301-US343-2080US3432080AEXC11AImmunosuppressive or immunodeficient state, including HIV infection, asplenia, recurrent severe infections. EXCLUSIONYYAScreening ÂSCREENING 2020-08-10.mRNA-1273-P301IEmRNA-1273-P301-US343-2154US3432154AEXC10 Has participated in an interventional clinical study within 28 days prior to the day of enrollment. EXCLUSIONYYAScreening ÂSCREENING 2020-08-14.mRNA-1273-P301IEmRNA-1273-P301-US343-2154US3432154A EXC11BImmunosuppressive or immunodeficient state, asplenia, recurrent severe infections (HIVpositive participants on stable antiretroviral therapy are not excluded). EXCLUSIONYYAScreening ÂSCREENING 2020-08-14.mRNA-1273-P301IEmRNA-1273-P301-US343-2154US3432154A0EXC12 Has received systemic immunosuppressants/immune-modifying drugs for >14 days in total within 6 months prior to Screening. Topical tacrolimus is allowed if not used within 14 days prior to Screening. EXCLUSIONYYAScreening ÂSCREENING 2020-08-14.mRNA-1273-P301IEmRNA-1273-P301-US343-2205US3432205AEXC09AHas received or plans to receive a non-study vaccine within 28 days before/after any dose of IP (except for seasonal influenza vaccine which not permitted within 14 days before/after any dose of IP).EXCLUSIONYYAScreening ÂSCREENING 2020-08-19.mRNA-1273-P301IEmRNA-1273-P301-US343-2247US3432247AEXC11BImmunosuppressive or immunodeficient state, asplenia, recurrent severe infections (HIVpositive participants on stable antiretroviral therapy are not excluded). EXCLUSIONYYAScreening ÂSCREENING 2020-08-22.mRNA-1273-P301IEmRNA-1273-P301-US343-2276US3432276AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-25.mRNA-1273-P301IEmRNA-1273-P301-US343-2321US3432321AINC06 INCLUSIONNNAScreening ÂSCREENING 2020-08-27.mRNA-1273-P301IEmRNA-1273-P301-US343-2323US3432323AEXC14 Has donated >= 450 mL of blood products within 28 days prior to Screening. EXCLUSIONYYAScreening ÂSCREENING 2020-08-27.mRNA-1273-P301IEmRNA-1273-P301-US343-2331US3432331AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-28.mRNA-1273-P301IEmRNA-1273-P301-US343-2339US3432339AEXC09AHas received or plans to receive a non-study vaccine within 28 days before/after any dose of IP (except for seasonal influenza vaccine which not permitted within 14 days before/after any dose of IP).EXCLUSIONYYAScreening ÂSCREENING 2020-08-28.mRNA-1273-P301IEmRNA-1273-P301-US343-2346US3432346AEXC10 Has participated in an interventional clinical study within 28 days prior to the day of enrollment. EXCLUSIONYYAScreening ÂSCREENING 2020-08-28.mRNA-1273-P301IEmRNA-1273-P301-US343-2371US3432371AEXC07AKnown or suspected allergy or history of anaphylaxis, urticaria, or other significant adverse reaction to the vaccine or its excipients. EXCLUSIONYYAScreening ÂSCREENING 2020-08-31.mRNA-1273-P301IEmRNA-1273-P301-US343-2375US3432375AEXC14 Has donated >= 450 mL of blood products within 28 days prior to Screening. EXCLUSIONYYAScreening ÂSCREENING 2020-08-31.mRNA-1273-P301IEmRNA-1273-P301-US343-2420US3432420AINC06 INCLUSIONNNAScreening ÂSCREENING 2020-09-03.mRNA-1273-P301IEmRNA-1273-P301-US343-2429US3432429AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-09-04.mRNA-1273-P301IEmRNA-1273-P301-US343-2486US3432486AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-11.mRNA-1273-P301IEmRNA-1273-P301-US343-2497US3432324AEXC09AHas received or plans to receive a non-study vaccine within 28 days before/after any dose of IP (except for seasonal influenza vaccine which not permitted within 14 days before/after any dose of IP).EXCLUSIONYYAScreening ÂSCREENING 2020-08-27ÂmRNA-1273-P301IEmRNA-1273-P301-US343-2595US3432595AEXC12AHas received systemic immunosuppressants or immune-modifying drugs for >14 days in total within 6 months prior to Screening (for corticosteroids = 20 mg/day of prednisone equivalent). EXCLUSIONYYAScreening ÂSCREENING 2020-10-07.mRNA-1273-P301IEmRNA-1273-P301-US344-2003US3442003AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-08-13.mRNA-1273-P301IEmRNA-1273-P301-US344-2013US3442013AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-13.mRNA-1273-P301IEmRNA-1273-P301-US344-2025US3442025AEXC07AKnown or suspected allergy or history of anaphylaxis, urticaria, or other significant adverse reaction to the vaccine or its excipients. EXCLUSIONYYAScreening ÂSCREENING 2020-08-18.mRNA-1273-P301IEmRNA-1273-P301-US344-2036US3442036AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-20.mRNA-1273-P301IEmRNA-1273-P301-US344-2045US3442045AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-20.mRNA-1273-P301IEmRNA-1273-P301-US344-2061US3442061AEXC07AKnown or suspected allergy or history of anaphylaxis, urticaria, or other significant adverse reaction to the vaccine or its excipients. EXCLUSIONYYAScreening ÂSCREENING 2020-08-21.mRNA-1273-P301IEmRNA-1273-P301-US344-2091US3442091AEXC09AHas received or plans to receive a non-study vaccine within 28 days before/after any dose of IP (except for seasonal influenza vaccine which not permitted within 14 days before/after any dose of IP).EXCLUSIONYYAScreening ÂSCREENING 2020-08-25.mRNA-1273-P301IEmRNA-1273-P301-US344-2095US3442095AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-27.mRNA-1273-P301IEmRNA-1273-P301-US344-2101US3442054AINC03 Able to comply with study procedures based on the assessment of the Investigator. INCLUSIONNNAScreening ÂSCREENING 2020-08-21.mRNA-1273-P301IEmRNA-1273-P301-US344-2101US3442101A INC03 Able to comply with study procedures based on the assessment of the Investigator. INCLUSIONNNAScreening ÂSCREENING 2020-08-27.mRNA-1273-P301IEmRNA-1273-P301-US344-2117US3442117AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-01.mRNA-1273-P301IEmRNA-1273-P301-US344-2123US3442123AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-03.mRNA-1273-P301IEmRNA-1273-P301-US344-2127US3442090AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-25Á mRNA-1273-P301IEmRNA-1273-P301-US344-2168US3442053AEXC09AHas received or plans to receive a non-study vaccine within 28 days before/after any dose of IP (except for seasonal influenza vaccine which not permitted within 14 days before/after any dose of IP).EXCLUSIONYYAScreening ÂSCREENING 2020-08-21ÂmRNA-1273-P301IEmRNA-1273-P301-US344-2175US3442175AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-16.mRNA-1273-P301IEmRNA-1273-P301-US344-2181US3442181AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-16.mRNA-1273-P301IEmRNA-1273-P301-US344-2201US3442201AINC03 Able to comply with study procedures based on the assessment of the Investigator. INCLUSIONNNAScreening ÂSCREENING 2020-09-22.mRNA-1273-P301IEmRNA-1273-P301-US344-2208US3442208AINC03 Able to comply with study procedures based on the assessment of the Investigator. INCLUSIONNNAScreening ÂSCREENING 2020-10-02.mRNA-1273-P301IEmRNA-1273-P301-US344-2224US3442224AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-10-09.mRNA-1273-P301IEmRNA-1273-P301-US345-2097US3452097AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-08-01.mRNA-1273-P301IEmRNA-1273-P301-US345-2174US3452174AINC06 Male participants that could result in pregnancy of sexual partners must agree to practice adequate contraception and refrain from sperm donation from the 1st dose to 3 months after the second dose. INCLUSIONNNAScreening ÂSCREENING 2020-08-04.mRNA-1273-P301IEmRNA-1273-P301-US345-2197US3452197AEXC03 Known history of SARS-CoV-2 infection. EXCLUSIONYYAScreening ÂSCREENING 2020-08-04.mRNA-1273-P301IEmRNA-1273-P301-US345-2396US3452396AINC03 Able to comply with study procedures based on the assessment of the Investigator. INCLUSIONNNAScreening ÂSCREENING 2020-09-23.mRNA-1273-P301IEmRNA-1273-P301-US346-2330US3462330AEXC02 Is pregnant or breastfeeding. EXCLUSIONYYAScreening ÂSCREENING 2020-08-25.mRNA-1273-P301IEmRNA-1273-P301-US347-2007US3472007AEXC12AHas received systemic immunosuppressants or immune-modifying drugs for >14 days in total within 6 months prior to Screening (for corticosteroids = 20 mg/day of prednisone equivalent). EXCLUSIONYYAScreening ÂSCREENING 2020-09-01.mRNA-1273-P301IEmRNA-1273-P301-US347-2014US3472014AEXC09AHas received or plans to receive a non-study vaccine within 28 days before/after any dose of IP (except for seasonal influenza vaccine which not permitted within 14 days before/after any dose of IP).EXCLUSIONYYAScreening ÂSCREENING 2020-09-03.mRNA-1273-P301IEmRNA-1273-P301-US347-2028US3472028AEXC08 Bleeding disorder considered a contraindication to intramuscular injection or phlebotomy. EXCLUSIONYYAScreening ÂSCREENING 2020-09-10.mRNA-1273-P301IEmRNA-1273-P301-US347-2083US3472083AEXC11CImmunosuppressive or immunodeficient state, asplenia, recurrent severe infections (HIVpositive participants with CD4 count =350 cells/mm3 and an undetectable HIV viral load within the past year). EXCLUSIONYYAScreening ÂSCREENING 2020-09-29.mRNA-1273-P301IEmRNA-1273-P301-US347-2108US3472108AEXC12AHas received systemic immunosuppressants or immune-modifying drugs for >14 days in total within 6 months prior to Screening (for corticosteroids = 20 mg/day of prednisone equivalent). EXCLUSIONYYAScreening ÂSCREENING 2020-10-12.mRNA-1273-P301IEmRNA-1273-P301-US347-2131US3472131AEXC09AHas received or plans to receive a non-study vaccine within 28 days before/after any dose of IP (except for seasonal influenza vaccine which not permitted within 14 days before/after any dose of IP).EXCLUSIONYYAScreening ÂSCREENING 2020-10-23.mRNA-1273-P301IEmRNA-1273-P301-US348-2058US3482058AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-14.mRNA-1273-P301IEmRNA-1273-P301-US348-2059US3482059AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-08-14.mRNA-1273-P301IEmRNA-1273-P301-US348-2074US3482074AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-18.mRNA-1273-P301IEmRNA-1273-P301-US348-2082US3482082AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-19.mRNA-1273-P301IEmRNA-1273-P301-US348-2096US3482096AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-20.mRNA-1273-P301IEmRNA-1273-P301-US348-2115US3482115AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-24.mRNA-1273-P301IEmRNA-1273-P301-US348-2123US3482123AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-24.mRNA-1273-P301IEmRNA-1273-P301-US348-2132US3482132AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-25.mRNA-1273-P301IEmRNA-1273-P301-US348-2146US3482146AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-26.mRNA-1273-P301IEmRNA-1273-P301-US348-2147US3482147AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-26.mRNA-1273-P301IEmRNA-1273-P301-US348-2156US3482156AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-27.mRNA-1273-P301IEmRNA-1273-P301-US348-2169US3482169AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-31.mRNA-1273-P301IEmRNA-1273-P301-US348-2173US3482173AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-31.mRNA-1273-P301IEmRNA-1273-P301-US348-2199US3482199AINC04 Female participants of nonchildbearing potential may be enrolled in the study. Nonchildbearing potential is defined as surgically sterile or postmenopausal. INCLUSIONNNAScreening ÂSCREENING 2020-09-02.mRNA-1273-P301IEmRNA-1273-P301-US348-2199US3482199A INC05 Female participants of childbearing potential may be enrolled in the study if the participant fulfills all the criteria listed in the protocol. INCLUSIONNNAScreening ÂSCREENING 2020-09-02.mRNA-1273-P301IEmRNA-1273-P301-US348-2201US3482201AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-02.mRNA-1273-P301IEmRNA-1273-P301-US348-2203US3482203AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-09-02.mRNA-1273-P301IEmRNA-1273-P301-US348-2212US3482212AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-02.mRNA-1273-P301IEmRNA-1273-P301-US348-2217US3482217AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-03.mRNA-1273-P301IEmRNA-1273-P301-US348-2243US3482243AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-08.mRNA-1273-P301IEmRNA-1273-P301-US348-2258US3482258AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-09-09.mRNA-1273-P301IEmRNA-1273-P301-US348-2259US3482259AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-09.mRNA-1273-P301IEmRNA-1273-P301-US348-2260US3482260AEXC09AHas received or plans to receive a non-study vaccine within 28 days before/after any dose of IP (except for seasonal influenza vaccine which not permitted within 14 days before/after any dose of IP).EXCLUSIONYYAScreening ÂSCREENING 2020-09-09.mRNA-1273-P301IEmRNA-1273-P301-US348-2263US3482263AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-09.mRNA-1273-P301IEmRNA-1273-P301-US348-2264US3482264AEXC07AKnown or suspected allergy or history of anaphylaxis, urticaria, or other significant adverse reaction to the vaccine or its excipients. EXCLUSIONYYAScreening ÂSCREENING 2020-09-09.mRNA-1273-P301IEmRNA-1273-P301-US348-2266US3482266AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-10.mRNA-1273-P301IEmRNA-1273-P301-US348-2273US3482273AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-10.mRNA-1273-P301IEmRNA-1273-P301-US348-2280US3482280AEXC07AKnown or suspected allergy or history of anaphylaxis, urticaria, or other significant adverse reaction to the vaccine or its excipients. EXCLUSIONYYAScreening ÂSCREENING 2020-10-08.mRNA-1273-P301IEmRNA-1273-P301-US348-2290US3482290AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-10-14.mRNA-1273-P301IEmRNA-1273-P301-US348-2293US3482293AINC05 Female participants of childbearing potential may be enrolled in the study if the participant fulfills all the criteria listed in the protocol. INCLUSIONNNAScreening ÂSCREENING 2020-10-15.mRNA-1273-P301IEmRNA-1273-P301-US348-2308US3482308AEXC12AHas received systemic immunosuppressants or immune-modifying drugs for >14 days in total within 6 months prior to Screening (for corticosteroids = 20 mg/day of prednisone equivalent). EXCLUSIONYYAScreening ÂBLINDED TREATMENT 2020-10-20AmRNA-1273-P301IEmRNA-1273-P301-US348-2313US3482313AEXC11CImmunosuppressive or immunodeficient state, asplenia, recurrent severe infections (HIVpositive participants with CD4 count =350 cells/mm3 and an undetectable HIV viral load within the past year). EXCLUSIONYYAScreening ÂSCREENING 2020-10-21.mRNA-1273-P301IEmRNA-1273-P301-US348-2325US3482325AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-10-23.mRNA-1273-P301IEmRNA-1273-P301-US349-2034US3492034AEXC01 Participants who are acutely ill or febrile 72 hours prior to or at Screening may be rescheduled. Afebrile participants with minor illnesses can be enrolled at the discretion of the investigator. EXCLUSIONYYAScreening ÂSCREENING 2020-08-31.mRNA-1273-P301IEmRNA-1273-P301-US349-2034US3492034A EXC11BImmunosuppressive or immunodeficient state, asplenia, recurrent severe infections (HIVpositive participants on stable antiretroviral therapy are not excluded). EXCLUSIONYYAScreening ÂSCREENING 2020-08-31.mRNA-1273-P301IEmRNA-1273-P301-US349-2092US3492092AINC03 Able to comply with study procedures based on the assessment of the Investigator. INCLUSIONNNAScreening ÂSCREENING 2020-09-08.mRNA-1273-P301IEmRNA-1273-P301-US349-2157US3492093AEXC09AHas received or plans to receive a non-study vaccine within 28 days before/after any dose of IP (except for seasonal influenza vaccine which not permitted within 14 days before/after any dose of IP).EXCLUSIONYYAScreening ÂSCREENING 2020-09-08ÁpmRNA-1273-P301IEmRNA-1273-P301-US349-2158US3492147AEXC09AHas received or plans to receive a non-study vaccine within 28 days before/after any dose of IP (except for seasonal influenza vaccine which not permitted within 14 days before/after any dose of IP).EXCLUSIONYYAScreening ÂSCREENING 2020-09-14ÁmRNA-1273-P301IEmRNA-1273-P301-US349-2159US3492159AEXC11CImmunosuppressive or immunodeficient state, asplenia, recurrent severe infections (HIVpositive participants with CD4 count =350 cells/mm3 and an undetectable HIV viral load within the past year). EXCLUSIONYYAScreening ÂSCREENING 2020-09-15.mRNA-1273-P301IEmRNA-1273-P301-US349-2164US3492141AEXC09AHas received or plans to receive a non-study vaccine within 28 days before/after any dose of IP (except for seasonal influenza vaccine which not permitted within 14 days before/after any dose of IP).EXCLUSIONYYAScreening ÂSCREENING 2020-09-12Á0mRNA-1273-P301IEmRNA-1273-P301-US349-2171US3492171AEXC11CImmunosuppressive or immunodeficient state, asplenia, recurrent severe infections (HIVpositive participants with CD4 count =350 cells/mm3 and an undetectable HIV viral load within the past year). EXCLUSIONYYAScreening ÂSCREENING 2020-09-16.mRNA-1273-P301IEmRNA-1273-P301-US349-2181US3492105AEXC09AHas received or plans to receive a non-study vaccine within 28 days before/after any dose of IP (except for seasonal influenza vaccine which not permitted within 14 days before/after any dose of IP).EXCLUSIONYYAScreening ÂSCREENING 2020-09-09Á€mRNA-1273-P301IEmRNA-1273-P301-US349-2182US3492106AEXC09AHas received or plans to receive a non-study vaccine within 28 days before/after any dose of IP (except for seasonal influenza vaccine which not permitted within 14 days before/after any dose of IP).EXCLUSIONYYAScreening ÂSCREENING 2020-09-09Á€mRNA-1273-P301IEmRNA-1273-P301-US349-2203US3492100AEXC09AHas received or plans to receive a non-study vaccine within 28 days before/after any dose of IP (except for seasonal influenza vaccine which not permitted within 14 days before/after any dose of IP).EXCLUSIONYYAScreening ÂSCREENING 2020-09-09ÁmRNA-1273-P301IEmRNA-1273-P301-US349-2232US3492232AEXC12AHas received systemic immunosuppressants or immune-modifying drugs for >14 days in total within 6 months prior to Screening (for corticosteroids = 20 mg/day of prednisone equivalent). EXCLUSIONYYAScreening ÂSCREENING 2020-09-22.mRNA-1273-P301IEmRNA-1273-P301-US349-2268US3492197AEXC09AHas received or plans to receive a non-study vaccine within 28 days before/after any dose of IP (except for seasonal influenza vaccine which not permitted within 14 days before/after any dose of IP).EXCLUSIONYYAScreening ÂSCREENING 2020-09-18Á°mRNA-1273-P301IEmRNA-1273-P301-US350-2141US3502141AEXC09AHas received or plans to receive a non-study vaccine within 28 days before/after any dose of IP (except for seasonal influenza vaccine which not permitted within 14 days before/after any dose of IP).EXCLUSIONYYAScreening ÂSCREENING 2020-09-11.mRNA-1273-P301IEmRNA-1273-P301-US351-2018US3512018AEXC11AImmunosuppressive or immunodeficient state, including HIV infection, asplenia, recurrent severe infections. EXCLUSIONYYAScreening ÂSCREENING 2020-08-06.mRNA-1273-P301IEmRNA-1273-P301-US351-2029US3512029AEXC09 Has received or plans to receive a vaccine within 28 days prior to the first dose or plans to receive a non-study vaccine within 28 days prior to or after any dose of IP. EXCLUSIONYYAScreening ÂSCREENING 2020-08-08.mRNA-1273-P301IEmRNA-1273-P301-US351-2087US3512087AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-08-15.mRNA-1273-P301IEmRNA-1273-P301-US351-2168US3512168AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-27.mRNA-1273-P301IEmRNA-1273-P301-US351-2201US3512201AEXC14 Has donated >= 450 mL of blood products within 28 days prior to Screening. EXCLUSIONYYAScreening ÂSCREENING 2020-09-02.mRNA-1273-P301IEmRNA-1273-P301-US351-2225US3512110AEXC14 Has donated >= 450 mL of blood products within 28 days prior to Screening. EXCLUSIONYYAScreening ÂSCREENING 2020-08-20ÁðmRNA-1273-P301IEmRNA-1273-P301-US351-2243US3512243AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-09-09.mRNA-1273-P301IEmRNA-1273-P301-US351-2245US3512245AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-09-09.mRNA-1273-P301IEmRNA-1273-P301-US351-2249US3512212AEXC14 Has donated >= 450 mL of blood products within 28 days prior to Screening. EXCLUSIONYYAScreening ÂSCREENING 2020-09-03ÁpmRNA-1273-P301IEmRNA-1273-P301-US352-2027US3522027AINC03 Able to comply with study procedures based on the assessment of the Investigator. INCLUSIONNNAScreening ÂSCREENING 2020-08-06.mRNA-1273-P301IEmRNA-1273-P301-US352-2088US3522088AEXC01 Participants who are acutely ill or febrile 72 hours prior to or at Screening may be rescheduled. Afebrile participants with minor illnesses can be enrolled at the discretion of the investigator. EXCLUSIONYYAScreening ÂSCREENING 2020-08-12.mRNA-1273-P301IEmRNA-1273-P301-US352-2278US3522278AEXC09AHas received or plans to receive a non-study vaccine within 28 days before/after any dose of IP (except for seasonal influenza vaccine which not permitted within 14 days before/after any dose of IP).EXCLUSIONYYAScreening ÂSCREENING 2020-08-21.mRNA-1273-P301IEmRNA-1273-P301-US352-2301US3522301AINC03 Able to comply with study procedures based on the assessment of the Investigator. INCLUSIONNN. . .mRNA-1273-P301IEmRNA-1273-P301-US352-2344US3522344AEXC09AHas received or plans to receive a non-study vaccine within 28 days before/after any dose of IP (except for seasonal influenza vaccine which not permitted within 14 days before/after any dose of IP).EXCLUSIONYYAScreening ÂSCREENING 2020-08-25.mRNA-1273-P301IEmRNA-1273-P301-US352-2434US3522434AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNN. . .mRNA-1273-P301IEmRNA-1273-P301-US352-2544US3522544AEXC09AHas received or plans to receive a non-study vaccine within 28 days before/after any dose of IP (except for seasonal influenza vaccine which not permitted within 14 days before/after any dose of IP).EXCLUSIONYYAScreening ÂSCREENING 2020-09-03.mRNA-1273-P301IEmRNA-1273-P301-US352-2651US3522651AEXC09AHas received or plans to receive a non-study vaccine within 28 days before/after any dose of IP (except for seasonal influenza vaccine which not permitted within 14 days before/after any dose of IP).EXCLUSIONYYAScreening ÂSCREENING 2020-09-11.mRNA-1273-P301IEmRNA-1273-P301-US352-2675US3522675AEXC09AHas received or plans to receive a non-study vaccine within 28 days before/after any dose of IP (except for seasonal influenza vaccine which not permitted within 14 days before/after any dose of IP).EXCLUSIONYYAScreening ÂSCREENING 2020-09-14.mRNA-1273-P301IEmRNA-1273-P301-US352-2700US3522700AEXC14 Has donated >= 450 mL of blood products within 28 days prior to Screening. EXCLUSIONYYAScreening ÂSCREENING 2020-09-17.mRNA-1273-P301IEmRNA-1273-P301-US352-2710US3522710AEXC09AHas received or plans to receive a non-study vaccine within 28 days before/after any dose of IP (except for seasonal influenza vaccine which not permitted within 14 days before/after any dose of IP).EXCLUSIONYYAScreening ÂSCREENING 2020-09-18.mRNA-1273-P301IEmRNA-1273-P301-US352-2716US3522716AEXC09AHas received or plans to receive a non-study vaccine within 28 days before/after any dose of IP (except for seasonal influenza vaccine which not permitted within 14 days before/after any dose of IP).EXCLUSIONYYAScreening ÂSCREENING 2020-09-23.mRNA-1273-P301IEmRNA-1273-P301-US353-2026US3532026AEXC11BImmunosuppressive or immunodeficient state, asplenia, recurrent severe infections (HIVpositive participants on stable antiretroviral therapy are not excluded). EXCLUSIONYYAScreening ÂSCREENING 2020-08-13.mRNA-1273-P301IEmRNA-1273-P301-US353-2028US3532028AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-13.mRNA-1273-P301IEmRNA-1273-P301-US353-2038US3532038AEXC11BImmunosuppressive or immunodeficient state, asplenia, recurrent severe infections (HIVpositive participants on stable antiretroviral therapy are not excluded). EXCLUSIONYYAScreening ÂSCREENING 2020-08-17.mRNA-1273-P301IEmRNA-1273-P301-US353-2054US3532054AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-18.mRNA-1273-P301IEmRNA-1273-P301-US353-2061US3532061AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-18.mRNA-1273-P301IEmRNA-1273-P301-US353-2069US3532069AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-19.mRNA-1273-P301IEmRNA-1273-P301-US353-2075US3532075AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-19.mRNA-1273-P301IEmRNA-1273-P301-US353-2101US3532101AEXC12 Has received systemic immunosuppressants/immune-modifying drugs for >14 days in total within 6 months prior to Screening. Topical tacrolimus is allowed if not used within 14 days prior to Screening. EXCLUSIONYYAScreening ÂSCREENING 2020-08-21.mRNA-1273-P301IEmRNA-1273-P301-US353-2102US3532102AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-21.mRNA-1273-P301IEmRNA-1273-P301-US353-2105US3532105AEXC11BImmunosuppressive or immunodeficient state, asplenia, recurrent severe infections (HIVpositive participants on stable antiretroviral therapy are not excluded). EXCLUSIONYYAScreening ÂSCREENING 2020-08-21.mRNA-1273-P301IEmRNA-1273-P301-US353-2110US3532110AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-21.mRNA-1273-P301IEmRNA-1273-P301-US353-2119US3532065AEXC04 Prior administration of an investigational coronavirus (SARS-CoV, MERS-CoV) vaccine or current/planned simultaneous participation in another interventional study to prevent or treat COVID-19. EXCLUSIONYYAScreening ÂSCREENING 2020-08-18Á`mRNA-1273-P301IEmRNA-1273-P301-US353-2130US3532130AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-24.mRNA-1273-P301IEmRNA-1273-P301-US353-2137US3532137AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-25.mRNA-1273-P301IEmRNA-1273-P301-US353-2151US3532151AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-26.mRNA-1273-P301IEmRNA-1273-P301-US353-2157US3532157AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-26.mRNA-1273-P301IEmRNA-1273-P301-US353-2169US3532169AEXC11CImmunosuppressive or immunodeficient state, asplenia, recurrent severe infections (HIVpositive participants with CD4 count =350 cells/mm3 and an undetectable HIV viral load within the past year). EXCLUSIONYYAScreening ÂSCREENING 2020-08-27.mRNA-1273-P301IEmRNA-1273-P301-US353-2178US3532178AEXC12AHas received systemic immunosuppressants or immune-modifying drugs for >14 days in total within 6 months prior to Screening (for corticosteroids = 20 mg/day of prednisone equivalent). EXCLUSIONYYAScreening ÂSCREENING 2020-08-27.mRNA-1273-P301IEmRNA-1273-P301-US353-2183US3532183AEXC04 Prior administration of an investigational coronavirus (SARS-CoV, MERS-CoV) vaccine or current/planned simultaneous participation in another interventional study to prevent or treat COVID-19. EXCLUSIONYYAScreening ÂSCREENING 2020-08-31.mRNA-1273-P301IEmRNA-1273-P301-US353-2185US3532185AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-31.mRNA-1273-P301IEmRNA-1273-P301-US353-2195US3532195AEXC12AHas received systemic immunosuppressants or immune-modifying drugs for >14 days in total within 6 months prior to Screening (for corticosteroids = 20 mg/day of prednisone equivalent). EXCLUSIONYYAScreening ÂSCREENING 2020-08-31.mRNA-1273-P301IEmRNA-1273-P301-US353-2200US3532200AEXC08 Bleeding disorder considered a contraindication to intramuscular injection or phlebotomy. EXCLUSIONYYAScreening ÂSCREENING 2020-09-01.mRNA-1273-P301IEmRNA-1273-P301-US353-2221US3532221AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-09-02.mRNA-1273-P301IEmRNA-1273-P301-US353-2223US3532223AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-02.mRNA-1273-P301IEmRNA-1273-P301-US353-2234US3532234AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-03.mRNA-1273-P301IEmRNA-1273-P301-US353-2249US3532249AINC03 Able to comply with study procedures based on the assessment of the Investigator. INCLUSIONNNAScreening ÂSCREENING 2020-09-08.mRNA-1273-P301IEmRNA-1273-P301-US353-2255US3532255AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-08.mRNA-1273-P301IEmRNA-1273-P301-US353-2263US3532263AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-09.mRNA-1273-P301IEmRNA-1273-P301-US353-2266US3532266AEXC08 Bleeding disorder considered a contraindication to intramuscular injection or phlebotomy. EXCLUSIONYYAScreening ÂSCREENING 2020-09-09.mRNA-1273-P301IEmRNA-1273-P301-US354-2115US3542115AEXC09AHas received or plans to receive a non-study vaccine within 28 days before/after any dose of IP (except for seasonal influenza vaccine which not permitted within 14 days before/after any dose of IP).EXCLUSIONYYAScreening ÂSCREENING 2020-09-01.mRNA-1273-P301IEmRNA-1273-P301-US354-2120US3542084AEXC09AHas received or plans to receive a non-study vaccine within 28 days before/after any dose of IP (except for seasonal influenza vaccine which not permitted within 14 days before/after any dose of IP).EXCLUSIONYYAScreening ÂSCREENING 2020-08-27ÁPmRNA-1273-P301IEmRNA-1273-P301-US354-2145US3542145AEXC09AHas received or plans to receive a non-study vaccine within 28 days before/after any dose of IP (except for seasonal influenza vaccine which not permitted within 14 days before/after any dose of IP).EXCLUSIONYYAScreening ÂSCREENING 2020-09-03.mRNA-1273-P301IEmRNA-1273-P301-US354-2151US3542151AINC06 INCLUSIONNNAScreening ÂSCREENING 2020-09-03.mRNA-1273-P301IEmRNA-1273-P301-US354-2194US3542194AEXC12AHas received systemic immunosuppressants or immune-modifying drugs for >14 days in total within 6 months prior to Screening (for corticosteroids = 20 mg/day of prednisone equivalent). EXCLUSIONYYAScreening ÂSCREENING 2020-09-09.mRNA-1273-P301IEmRNA-1273-P301-US354-2271US3542271AEXC03 Known history of SARS-CoV-2 infection. EXCLUSIONYYAScreening ÂSCREENING 2020-09-21.mRNA-1273-P301IEmRNA-1273-P301-US354-2316US3542316AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-10-05.mRNA-1273-P301IEmRNA-1273-P301-US354-2327US3542327AEXC11CImmunosuppressive or immunodeficient state, asplenia, recurrent severe infections (HIVpositive participants with CD4 count =350 cells/mm3 and an undetectable HIV viral load within the past year). EXCLUSIONYYAScreening ÂSCREENING 2020-10-08.mRNA-1273-P301IEmRNA-1273-P301-US355-2003US3552003AEXC12 Has received systemic immunosuppressants/immune-modifying drugs for >14 days in total within 6 months prior to Screening. Topical tacrolimus is allowed if not used within 14 days prior to Screening. EXCLUSIONYYAScreening ÂSCREENING 2020-08-11.mRNA-1273-P301IEmRNA-1273-P301-US355-2014US3552014AINC06 INCLUSIONNNAScreening ÂSCREENING 2020-08-12.mRNA-1273-P301IEmRNA-1273-P301-US355-2026US3552026AINC06 INCLUSIONNNAScreening ÂSCREENING 2020-08-13.mRNA-1273-P301IEmRNA-1273-P301-US355-2027US3552027AINC06 INCLUSIONNNAScreening ÂSCREENING 2020-08-13.mRNA-1273-P301IEmRNA-1273-P301-US355-2039US3552039AINC06 INCLUSIONNNAScreening ÂSCREENING 2020-08-14.mRNA-1273-P301IEmRNA-1273-P301-US355-2045US3552045AINC06 INCLUSIONNNAScreening ÂSCREENING 2020-08-15.mRNA-1273-P301IEmRNA-1273-P301-US355-2047US3552047AINC06 INCLUSIONNNAScreening ÂSCREENING 2020-08-17.mRNA-1273-P301IEmRNA-1273-P301-US355-2056US3552056AINC06 INCLUSIONNNAScreening ÂSCREENING 2020-08-17.mRNA-1273-P301IEmRNA-1273-P301-US355-2060US3552060AINC06 INCLUSIONNNAScreening ÂSCREENING 2020-08-18.mRNA-1273-P301IEmRNA-1273-P301-US355-2066US3552066AINC06 INCLUSIONNNAScreening ÂSCREENING 2020-08-18.mRNA-1273-P301IEmRNA-1273-P301-US355-2075US3552075AINC06 INCLUSIONNNAScreening ÂSCREENING 2020-08-19.mRNA-1273-P301IEmRNA-1273-P301-US355-2085US3552085AINC06 INCLUSIONNNAScreening ÂSCREENING 2020-08-19.mRNA-1273-P301IEmRNA-1273-P301-US355-2086US3552086AEXC12 Has received systemic immunosuppressants/immune-modifying drugs for >14 days in total within 6 months prior to Screening. Topical tacrolimus is allowed if not used within 14 days prior to Screening. EXCLUSIONYYAScreening ÂSCREENING 2020-08-19.mRNA-1273-P301IEmRNA-1273-P301-US355-2086US3552086A INC06 INCLUSIONNNAScreening ÂSCREENING 2020-08-19.mRNA-1273-P301IEmRNA-1273-P301-US355-2088US3552088AINC06 INCLUSIONNNAScreening ÂSCREENING 2020-08-19.mRNA-1273-P301IEmRNA-1273-P301-US355-2091US3552091AEXC12 Has received systemic immunosuppressants/immune-modifying drugs for >14 days in total within 6 months prior to Screening. Topical tacrolimus is allowed if not used within 14 days prior to Screening. EXCLUSIONYYAScreening ÂSCREENING 2020-08-19.mRNA-1273-P301IEmRNA-1273-P301-US355-2091US3552091A INC06 INCLUSIONNNAScreening ÂSCREENING 2020-08-19.mRNA-1273-P301IEmRNA-1273-P301-US355-2108US3552108AEXC09AHas received or plans to receive a non-study vaccine within 28 days before/after any dose of IP (except for seasonal influenza vaccine which not permitted within 14 days before/after any dose of IP).EXCLUSIONYYAScreening ÂSCREENING 2020-08-20.mRNA-1273-P301IEmRNA-1273-P301-US355-2109US3552109AINC06 INCLUSIONNNAScreening ÂSCREENING 2020-08-20.mRNA-1273-P301IEmRNA-1273-P301-US355-2124US3552124AINC06 INCLUSIONNNAScreening ÂSCREENING 2020-08-21.mRNA-1273-P301IEmRNA-1273-P301-US355-2127US3552127AINC06 INCLUSIONNNAScreening ÂSCREENING 2020-08-21.mRNA-1273-P301IEmRNA-1273-P301-US355-2128US3552128AINC06 INCLUSIONNNAScreening ÂSCREENING 2020-08-21.mRNA-1273-P301IEmRNA-1273-P301-US355-2133US3552133AINC03 Able to comply with study procedures based on the assessment of the Investigator. INCLUSIONNNAScreening ÂSCREENING 2020-08-22.mRNA-1273-P301IEmRNA-1273-P301-US355-2134US3552134AINC06 INCLUSIONNNAScreening ÂSCREENING 2020-08-22.mRNA-1273-P301IEmRNA-1273-P301-US355-2148US3552148AINC05 Female participants of childbearing potential may be enrolled in the study if the participant fulfills all the criteria listed in the protocol. INCLUSIONNNAScreening ÂSCREENING 2020-08-24.mRNA-1273-P301IEmRNA-1273-P301-US355-2152US3552152AINC06 INCLUSIONNNAScreening ÂSCREENING 2020-08-24.mRNA-1273-P301IEmRNA-1273-P301-US355-2154US3552154AINC06 INCLUSIONNNAScreening ÂSCREENING 2020-08-24.mRNA-1273-P301IEmRNA-1273-P301-US355-2157US3552157AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-08-25.mRNA-1273-P301IEmRNA-1273-P301-US355-2176US3552176AEXC14 Has donated >= 450 mL of blood products within 28 days prior to Screening. EXCLUSIONYYAScreening ÂSCREENING 2020-08-26.mRNA-1273-P301IEmRNA-1273-P301-US355-2176US3552176A INC06 INCLUSIONNNAScreening ÂSCREENING 2020-08-26.mRNA-1273-P301IEmRNA-1273-P301-US355-2179US3552179AINC01 Adults, >= 18 years of age at time of consent, who are at high risk of SARS-CoV-2 infection. INCLUSIONNNAScreening ÂSCREENING 2020-08-26.mRNA-1273-P301IEmRNA-1273-P301-US355-2179US3552179A INC06 INCLUSIONNNAScreening ÂSCREENING 2020-08-26.mRNA-1273-P301IEmRNA-1273-P301-US355-2184US3552184AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-08-26.mRNA-1273-P301IEmRNA-1273-P301-US355-2185US3552185AINC06 INCLUSIONNNAScreening ÂSCREENING 2020-08-26.mRNA-1273-P301IEmRNA-1273-P301-US355-2186US3552186AINC06 INCLUSIONNNAScreening ÂSCREENING 2020-08-26.mRNA-1273-P301IEmRNA-1273-P301-US355-2188US3552188AINC06 INCLUSIONNNAScreening ÂSCREENING 2020-08-26.mRNA-1273-P301IEmRNA-1273-P301-US355-2192US3552192AEXC12AHas received systemic immunosuppressants or immune-modifying drugs for >14 days in total within 6 months prior to Screening (for corticosteroids = 20 mg/day of prednisone equivalent). EXCLUSIONYYAScreening ÂSCREENING 2020-08-26.mRNA-1273-P301IEmRNA-1273-P301-US355-2200US3552200AINC06 INCLUSIONNNAScreening ÂSCREENING 2020-08-27.mRNA-1273-P301IEmRNA-1273-P301-US355-2206US3552096AINC06 INCLUSIONNNAScreening ÂSCREENING 2020-08-20ÁpmRNA-1273-P301IEmRNA-1273-P301-US355-2207US3552102AINC06 INCLUSIONNNAScreening ÂSCREENING 2020-08-20ÁpmRNA-1273-P301IEmRNA-1273-P301-US355-2208US3552208AINC06 INCLUSIONNNAScreening ÂSCREENING 2020-08-27.mRNA-1273-P301IEmRNA-1273-P301-US355-2212US3552212AINC06 INCLUSIONNNAScreening ÂSCREENING 2020-08-27.mRNA-1273-P301IEmRNA-1273-P301-US355-2226US3552226AINC06 INCLUSIONNNAScreening ÂSCREENING 2020-08-28.mRNA-1273-P301IEmRNA-1273-P301-US355-2242US3552242AINC06 INCLUSIONNNAScreening ÂSCREENING 2020-08-29.mRNA-1273-P301IEmRNA-1273-P301-US355-2246US3552246AINC06 INCLUSIONNNAScreening ÂSCREENING 2020-08-31.mRNA-1273-P301IEmRNA-1273-P301-US355-2256US3552256AEXC14 Has donated >= 450 mL of blood products within 28 days prior to Screening. EXCLUSIONYYAScreening ÂSCREENING 2020-08-31.mRNA-1273-P301IEmRNA-1273-P301-US355-2264US3552264AEXC05 Demonstrated inability to comply with the study procedures. EXCLUSIONYYAScreening ÂSCREENING 2020-09-01.mRNA-1273-P301IEmRNA-1273-P301-US355-2264US3552264A INC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-09-01.mRNA-1273-P301IEmRNA-1273-P301-US355-2264US3552264A0INC03 Able to comply with study procedures based on the assessment of the Investigator. INCLUSIONNNAScreening ÂSCREENING 2020-09-01.mRNA-1273-P301IEmRNA-1273-P301-US355-2271US3552271AEXC12AHas received systemic immunosuppressants or immune-modifying drugs for >14 days in total within 6 months prior to Screening (for corticosteroids = 20 mg/day of prednisone equivalent). EXCLUSIONYYAScreening ÂSCREENING 2020-09-01.mRNA-1273-P301IEmRNA-1273-P301-US355-2271US3552271A INC06 INCLUSIONNNAScreening ÂSCREENING 2020-09-01.mRNA-1273-P301IEmRNA-1273-P301-US355-2284US3552284AINC06 INCLUSIONNNAScreening ÂSCREENING 2020-09-02.mRNA-1273-P301IEmRNA-1273-P301-US355-2285US3552285AINC06 INCLUSIONNNAScreening ÂSCREENING 2020-09-02.mRNA-1273-P301IEmRNA-1273-P301-US355-2289US3552289AINC06 INCLUSIONNNAScreening ÂSCREENING 2020-09-02.mRNA-1273-P301IEmRNA-1273-P301-US355-2310US3552310AINC06 INCLUSIONNNAScreening ÂSCREENING 2020-09-03.mRNA-1273-P301IEmRNA-1273-P301-US355-2314US3552314AINC06 INCLUSIONNNAScreening ÂSCREENING 2020-09-03.mRNA-1273-P301IEmRNA-1273-P301-US355-2321US3552321AINC03 Able to comply with study procedures based on the assessment of the Investigator. INCLUSIONNNAScreening ÂSCREENING 2020-09-03.mRNA-1273-P301IEmRNA-1273-P301-US355-2329US3552329AEXC12AHas received systemic immunosuppressants or immune-modifying drugs for >14 days in total within 6 months prior to Screening (for corticosteroids = 20 mg/day of prednisone equivalent). EXCLUSIONYYAScreening ÂSCREENING 2020-09-04.mRNA-1273-P301IEmRNA-1273-P301-US355-2332US3552332AINC06 INCLUSIONNNAScreening ÂSCREENING 2020-09-04.mRNA-1273-P301IEmRNA-1273-P301-US355-2338US3552338AINC03 Able to comply with study procedures based on the assessment of the Investigator. INCLUSIONNNAScreening ÂSCREENING 2020-09-04.mRNA-1273-P301IEmRNA-1273-P301-US355-2354US3552354AINC06 INCLUSIONNNAScreening ÂSCREENING 2020-09-08.mRNA-1273-P301IEmRNA-1273-P301-US355-2361US3552098AEXC09AHas received or plans to receive a non-study vaccine within 28 days before/after any dose of IP (except for seasonal influenza vaccine which not permitted within 14 days before/after any dose of IP).EXCLUSIONYYAScreening ÂSCREENING 2020-08-20ÂmRNA-1273-P301IEmRNA-1273-P301-US355-2374US3552374AINC06 INCLUSIONNNAScreening ÂSCREENING 2020-09-09.mRNA-1273-P301IEmRNA-1273-P301-US355-2375US3552375AINC06 INCLUSIONNNAScreening ÂSCREENING 2020-09-09.mRNA-1273-P301IEmRNA-1273-P301-US355-2391US3552231AEXC09AHas received or plans to receive a non-study vaccine within 28 days before/after any dose of IP (except for seasonal influenza vaccine which not permitted within 14 days before/after any dose of IP).EXCLUSIONYYAScreening ÂSCREENING 2020-08-29ÁÀmRNA-1273-P301IEmRNA-1273-P301-US355-2395US3552395AINC06 INCLUSIONNNAScreening ÂSCREENING 2020-09-10.mRNA-1273-P301IEmRNA-1273-P301-US355-2396US3552396AINC06 INCLUSIONNNAScreening ÂSCREENING 2020-09-10.mRNA-1273-P301IEmRNA-1273-P301-US355-2398US3552217AINC06 INCLUSIONNNAScreening ÂSCREENING 2020-08-27ÁàmRNA-1273-P301IEmRNA-1273-P301-US355-2400US3552351AEXC14 Has donated >= 450 mL of blood products within 28 days prior to Screening. EXCLUSIONYYAScreening ÂSCREENING 2020-09-07Á0mRNA-1273-P301IEmRNA-1273-P301-US355-2401US3552401AINC06 INCLUSIONNNAScreening ÂSCREENING 2020-09-10.mRNA-1273-P301IEmRNA-1273-P301-US355-2418US3552418AEXC09AHas received or plans to receive a non-study vaccine within 28 days before/after any dose of IP (except for seasonal influenza vaccine which not permitted within 14 days before/after any dose of IP).EXCLUSIONYYAScreening ÂSCREENING 2020-09-12.mRNA-1273-P301IEmRNA-1273-P301-US355-2419US3552419AINC06 INCLUSIONNNAScreening ÂSCREENING 2020-09-12.mRNA-1273-P301IEmRNA-1273-P301-US355-2421US3552421AEXC11CImmunosuppressive or immunodeficient state, asplenia, recurrent severe infections (HIVpositive participants with CD4 count =350 cells/mm3 and an undetectable HIV viral load within the past year). EXCLUSIONYYAScreening ÂSCREENING 2020-09-12.mRNA-1273-P301IEmRNA-1273-P301-US355-2422US3552422AEXC09AHas received or plans to receive a non-study vaccine within 28 days before/after any dose of IP (except for seasonal influenza vaccine which not permitted within 14 days before/after any dose of IP).EXCLUSIONYYAScreening ÂSCREENING 2020-09-12.mRNA-1273-P301IEmRNA-1273-P301-US355-2428US3552428AINC06 INCLUSIONNNAScreening ÂSCREENING 2020-09-14.mRNA-1273-P301IEmRNA-1273-P301-US355-2431US3552431AINC06 INCLUSIONNNAScreening ÂSCREENING 2020-09-15.mRNA-1273-P301IEmRNA-1273-P301-US355-2433US3552433AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-09-15.mRNA-1273-P301IEmRNA-1273-P301-US355-2434US3552362AINC06 INCLUSIONNNAScreening ÂSCREENING 2020-09-08ÁpmRNA-1273-P301IEmRNA-1273-P301-US355-2438US3552438AINC06 INCLUSIONNNAScreening ÂSCREENING 2020-09-15.mRNA-1273-P301IEmRNA-1273-P301-US355-2440US3552440AINC06 INCLUSIONNNAScreening ÂSCREENING 2020-09-16.mRNA-1273-P301IEmRNA-1273-P301-US355-2442US3552442AEXC09AHas received or plans to receive a non-study vaccine within 28 days before/after any dose of IP (except for seasonal influenza vaccine which not permitted within 14 days before/after any dose of IP).EXCLUSIONYYAScreening ÂSCREENING 2020-09-16.mRNA-1273-P301IEmRNA-1273-P301-US355-2447US3552447AINC06 INCLUSIONNNAScreening ÂSCREENING 2020-09-16.mRNA-1273-P301IEmRNA-1273-P301-US355-2449US3552449AINC06 INCLUSIONNNAScreening ÂSCREENING 2020-09-16.mRNA-1273-P301IEmRNA-1273-P301-US355-2453US3552241AINC06 INCLUSIONNNAScreening ÂSCREENING 2020-08-29ÂmRNA-1273-P301IEmRNA-1273-P301-US355-2466US3552466AEXC14 Has donated >= 450 mL of blood products within 28 days prior to Screening. EXCLUSIONYYAScreening ÂSCREENING 2020-09-18.mRNA-1273-P301IEmRNA-1273-P301-US355-2471US3552471AINC06 INCLUSIONNNAScreening ÂSCREENING 2020-09-18.mRNA-1273-P301IEmRNA-1273-P301-US355-2473US3552381AEXC11CImmunosuppressive or immunodeficient state, asplenia, recurrent severe infections (HIVpositive participants with CD4 count =350 cells/mm3 and an undetectable HIV viral load within the past year). EXCLUSIONYYAScreening ÂSCREENING 2020-09-09Á mRNA-1273-P301IEmRNA-1273-P301-US355-2477US3552245AEXC14 Has donated >= 450 mL of blood products within 28 days prior to Screening. EXCLUSIONYYAScreening ÂSCREENING 2020-08-31ÂmRNA-1273-P301IEmRNA-1273-P301-US355-2477US3552376A INC03 Able to comply with study procedures based on the assessment of the Investigator. INCLUSIONNNAScreening ÂSCREENING 2020-09-09ÁÐmRNA-1273-P301IEmRNA-1273-P301-US355-2480US3552480AINC06 INCLUSIONNNAScreening ÂSCREENING 2020-09-22.mRNA-1273-P301IEmRNA-1273-P301-US355-2481US3552481AINC06 INCLUSIONNNAScreening ÂSCREENING 2020-09-22.mRNA-1273-P301IEmRNA-1273-P301-US355-2483US3552483AEXC12AHas received systemic immunosuppressants or immune-modifying drugs for >14 days in total within 6 months prior to Screening (for corticosteroids = 20 mg/day of prednisone equivalent). EXCLUSIONYYAScreening ÂSCREENING 2020-09-23.mRNA-1273-P301IEmRNA-1273-P301-US355-2485US3552485AINC06 INCLUSIONNNAScreening ÂSCREENING 2020-09-23.mRNA-1273-P301IEmRNA-1273-P301-US355-2493US3552493AINC06 INCLUSIONNNAScreening ÂSCREENING 2020-09-25.mRNA-1273-P301IEmRNA-1273-P301-US355-2510US3552510AEXC14 Has donated >= 450 mL of blood products within 28 days prior to Screening. EXCLUSIONYYAScreening ÂSCREENING 2020-10-03.mRNA-1273-P301IEmRNA-1273-P301-US355-2512US3552512AEXC06 An immediate family member or household member of this study's personnel. EXCLUSIONYYAScreening ÂSCREENING 2020-10-05.mRNA-1273-P301IEmRNA-1273-P301-US355-2513US3552513AINC06 INCLUSIONNNAScreening ÂSCREENING 2020-10-06.mRNA-1273-P301IEmRNA-1273-P301-US355-2515US3552515AINC06 INCLUSIONNNAScreening ÂSCREENING 2020-10-06.mRNA-1273-P301IEmRNA-1273-P301-US355-2516US3552516AINC06 INCLUSIONNNAScreening ÂSCREENING 2020-10-07.mRNA-1273-P301IEmRNA-1273-P301-US355-2520US3552503AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-09-30Á€mRNA-1273-P301IEmRNA-1273-P301-US355-2520US3552503A INC03 Able to comply with study procedures based on the assessment of the Investigator. INCLUSIONNNAScreening ÂSCREENING 2020-09-30Á€mRNA-1273-P301IEmRNA-1273-P301-US355-2523US3552523AINC03 Able to comply with study procedures based on the assessment of the Investigator. INCLUSIONNNAScreening ÂSCREENING 2020-10-09.mRNA-1273-P301IEmRNA-1273-P301-US355-2527US3552527AINC06 INCLUSIONNNAScreening ÂSCREENING 2020-10-12.mRNA-1273-P301IEmRNA-1273-P301-US355-2529US3552529AEXC09AHas received or plans to receive a non-study vaccine within 28 days before/after any dose of IP (except for seasonal influenza vaccine which not permitted within 14 days before/after any dose of IP).EXCLUSIONYYAScreening ÂSCREENING 2020-10-13.mRNA-1273-P301IEmRNA-1273-P301-US355-2537US3552537AINC06 INCLUSIONNNAScreening ÂSCREENING 2020-10-20.mRNA-1273-P301IEmRNA-1273-P301-US356-2012US3562012AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-06.mRNA-1273-P301IEmRNA-1273-P301-US356-2098US3562098AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-31.mRNA-1273-P301IEmRNA-1273-P301-US356-2206US3562206AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-10-01.mRNA-1273-P301IEmRNA-1273-P301-US356-2234US3562234AINC03 Able to comply with study procedures based on the assessment of the Investigator. INCLUSIONNNAScreening ÂSCREENING 2020-10-19.mRNA-1273-P301IEmRNA-1273-P301-US356-2241US3562241AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-10-23.mRNA-1273-P301IEmRNA-1273-P301-US357-2035US3572035AEXC03 Known history of SARS-CoV-2 infection. EXCLUSIONYYAScreening ÂSCREENING 2020-08-20.mRNA-1273-P301IEmRNA-1273-P301-US357-2099US3572099AINC03 Able to comply with study procedures based on the assessment of the Investigator. INCLUSIONNNAScreening ÂSCREENING 2020-08-26.mRNA-1273-P301IEmRNA-1273-P301-US357-2118US3572118AEXC03 Known history of SARS-CoV-2 infection. EXCLUSIONYYAScreening ÂSCREENING 2020-08-27.mRNA-1273-P301IEmRNA-1273-P301-US357-2136US3572136AEXC09AHas received or plans to receive a non-study vaccine within 28 days before/after any dose of IP (except for seasonal influenza vaccine which not permitted within 14 days before/after any dose of IP).EXCLUSIONYYAScreening ÂSCREENING 2020-08-28.mRNA-1273-P301IEmRNA-1273-P301-US357-2144US3572144AEXC05 Demonstrated inability to comply with the study procedures. EXCLUSIONYYAScreening ÂSCREENING 2020-08-31.mRNA-1273-P301IEmRNA-1273-P301-US357-2242US3572242AEXC12AHas received systemic immunosuppressants or immune-modifying drugs for >14 days in total within 6 months prior to Screening (for corticosteroids = 20 mg/day of prednisone equivalent). EXCLUSIONYYAScreening ÂSCREENING 2020-09-09.mRNA-1273-P301IEmRNA-1273-P301-US357-2250US3572250AEXC12AHas received systemic immunosuppressants or immune-modifying drugs for >14 days in total within 6 months prior to Screening (for corticosteroids = 20 mg/day of prednisone equivalent). EXCLUSIONYYAScreening ÂSCREENING 2020-09-10.mRNA-1273-P301IEmRNA-1273-P301-US357-2273US3572273AEXC09AHas received or plans to receive a non-study vaccine within 28 days before/after any dose of IP (except for seasonal influenza vaccine which not permitted within 14 days before/after any dose of IP).EXCLUSIONYYAScreening ÂSCREENING 2020-09-11.mRNA-1273-P301IEmRNA-1273-P301-US357-2276US3572276AEXC05 Demonstrated inability to comply with the study procedures. EXCLUSIONYYAScreening ÂSCREENING 2020-09-11.mRNA-1273-P301IEmRNA-1273-P301-US357-2278US3572278AEXC05 Demonstrated inability to comply with the study procedures. EXCLUSIONYYAScreening ÂSCREENING 2020-09-11.mRNA-1273-P301IEmRNA-1273-P301-US357-2313US3572313AEXC05 Demonstrated inability to comply with the study procedures. EXCLUSIONYYAScreening ÂSCREENING 2020-09-17.mRNA-1273-P301IEmRNA-1273-P301-US357-2314US3572314AEXC05 Demonstrated inability to comply with the study procedures. EXCLUSIONYYAScreening ÂSCREENING 2020-09-17.mRNA-1273-P301IEmRNA-1273-P301-US357-2318US3572318AEXC12AHas received systemic immunosuppressants or immune-modifying drugs for >14 days in total within 6 months prior to Screening (for corticosteroids = 20 mg/day of prednisone equivalent). EXCLUSIONYYAScreening ÂSCREENING 2020-09-17.mRNA-1273-P301IEmRNA-1273-P301-US357-2357US3572357AEXC05 Demonstrated inability to comply with the study procedures. EXCLUSIONYYAScreening ÂSCREENING 2020-09-29.mRNA-1273-P301IEmRNA-1273-P301-US357-2375US3572375AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-10-07.mRNA-1273-P301IEmRNA-1273-P301-US357-2398US3572398AINC04 Female participants of nonchildbearing potential may be enrolled in the study. Nonchildbearing potential is defined as surgically sterile or postmenopausal. INCLUSIONNNAScreening ÂSCREENING 2020-10-14.mRNA-1273-P301IEmRNA-1273-P301-US357-2398US3572398A INC05 Female participants of childbearing potential may be enrolled in the study if the participant fulfills all the criteria listed in the protocol. INCLUSIONNNAScreening ÂSCREENING 2020-10-14.mRNA-1273-P301IEmRNA-1273-P301-US358-2009US3582009AINC03 Able to comply with study procedures based on the assessment of the Investigator. INCLUSIONNNAScreening ÂSCREENING 2020-08-19.mRNA-1273-P301IEmRNA-1273-P301-US358-2061US3582061AINC03 Able to comply with study procedures based on the assessment of the Investigator. INCLUSIONNNAScreening ÂSCREENING 2020-08-27.mRNA-1273-P301IEmRNA-1273-P301-US358-2071US3582071AINC06 INCLUSIONNNAScreening ÂSCREENING 2020-08-28.mRNA-1273-P301IEmRNA-1273-P301-US358-2125US3582125AINC05 Female participants of childbearing potential may be enrolled in the study if the participant fulfills all the criteria listed in the protocol. INCLUSIONNNAScreening ÂSCREENING 2020-09-09.mRNA-1273-P301IEmRNA-1273-P301-US358-2146US3582146AINC03 Able to comply with study procedures based on the assessment of the Investigator. INCLUSIONNNAScreening ÂSCREENING 2020-09-14.mRNA-1273-P301IEmRNA-1273-P301-US358-2152US3582152AINC03 Able to comply with study procedures based on the assessment of the Investigator. INCLUSIONNNAScreening ÂSCREENING 2020-09-17.mRNA-1273-P301IEmRNA-1273-P301-US358-2188US3582188AINC06 INCLUSIONNNAScreening ÂSCREENING 2020-10-19.mRNA-1273-P301IEmRNA-1273-P301-US358-2192US3582192AEXC05 Demonstrated inability to comply with the study procedures. EXCLUSIONYYAScreening ÂSCREENING 2020-10-21.mRNA-1273-P301IEmRNA-1273-P301-US358-2192US3582192A INC03 Able to comply with study procedures based on the assessment of the Investigator. INCLUSIONNNAScreening ÂSCREENING 2020-10-21.mRNA-1273-P301IEmRNA-1273-P301-US359-2017US3592017AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-05.mRNA-1273-P301IEmRNA-1273-P301-US359-2041US3592041AEXC14 Has donated >= 450 mL of blood products within 28 days prior to Screening. EXCLUSIONYYAScreening ÂSCREENING 2020-08-06.mRNA-1273-P301IEmRNA-1273-P301-US359-2074US3592074AEXC14 Has donated >= 450 mL of blood products within 28 days prior to Screening. EXCLUSIONYYAScreening ÂSCREENING 2020-08-08.mRNA-1273-P301IEmRNA-1273-P301-US359-2086US3592086AEXC14 Has donated >= 450 mL of blood products within 28 days prior to Screening. EXCLUSIONYYAScreening ÂSCREENING 2020-08-09.mRNA-1273-P301IEmRNA-1273-P301-US359-2166US3592166AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-14.mRNA-1273-P301IEmRNA-1273-P301-US359-2222US3592222AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-17.mRNA-1273-P301IEmRNA-1273-P301-US360-2018US3602018AEXC07AKnown or suspected allergy or history of anaphylaxis, urticaria, or other significant adverse reaction to the vaccine or its excipients. EXCLUSIONYYAScreening ÂSCREENING 2020-09-08.mRNA-1273-P301IEmRNA-1273-P301-US360-2020US3602020AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-08.mRNA-1273-P301IEmRNA-1273-P301-US360-2087US3602087AEXC12AHas received systemic immunosuppressants or immune-modifying drugs for >14 days in total within 6 months prior to Screening (for corticosteroids = 20 mg/day of prednisone equivalent). EXCLUSIONYYAScreening ÂSCREENING 2020-09-23.mRNA-1273-P301IEmRNA-1273-P301-US360-2138US3602138AEXC14 Has donated >= 450 mL of blood products within 28 days prior to Screening. EXCLUSIONYYAScreening ÂSCREENING 2020-10-08.mRNA-1273-P301IEmRNA-1273-P301-US361-2059US3612001AEXC09AHas received or plans to receive a non-study vaccine within 28 days before/after any dose of IP (except for seasonal influenza vaccine which not permitted within 14 days before/after any dose of IP).EXCLUSIONYYAScreening ÂSCREENING 2020-08-31ÂmRNA-1273-P301IEmRNA-1273-P301-US361-2060US3612002AEXC09AHas received or plans to receive a non-study vaccine within 28 days before/after any dose of IP (except for seasonal influenza vaccine which not permitted within 14 days before/after any dose of IP).EXCLUSIONYYAScreening ÂSCREENING 2020-08-31ÂmRNA-1273-P301IEmRNA-1273-P301-US362-2045US3622045AEXC11BImmunosuppressive or immunodeficient state, asplenia, recurrent severe infections (HIVpositive participants on stable antiretroviral therapy are not excluded). EXCLUSIONYYAScreening ÂSCREENING 2020-08-19.mRNA-1273-P301IEmRNA-1273-P301-US362-2165US3622097AEXC09AHas received or plans to receive a non-study vaccine within 28 days before/after any dose of IP (except for seasonal influenza vaccine which not permitted within 14 days before/after any dose of IP).EXCLUSIONYYAScreening ÂSCREENING 2020-08-28Á°mRNA-1273-P301IEmRNA-1273-P301-US362-2281US3622220AEXC14 Has donated >= 450 mL of blood products within 28 days prior to Screening. EXCLUSIONYYAScreening ÂSCREENING 2020-09-23ÂmRNA-1273-P301IEmRNA-1273-P301-US362-2284US3622284AEXC11CImmunosuppressive or immunodeficient state, asplenia, recurrent severe infections (HIVpositive participants with CD4 count =350 cells/mm3 and an undetectable HIV viral load within the past year). EXCLUSIONYYAScreening ÂSCREENING 2020-10-21.mRNA-1273-P301IEmRNA-1273-P301-US363-2037US3632037AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-02.mRNA-1273-P301IEmRNA-1273-P301-US363-2086US3632086AEXC07AKnown or suspected allergy or history of anaphylaxis, urticaria, or other significant adverse reaction to the vaccine or its excipients. EXCLUSIONYYAScreening ÂSCREENING 2020-09-15.mRNA-1273-P301IEmRNA-1273-P301-US363-2088US3632088AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-16.mRNA-1273-P301IEmRNA-1273-P301-US363-2093US3632093AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-17.mRNA-1273-P301IEmRNA-1273-P301-US363-2103US3632103AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-23.mRNA-1273-P301IEmRNA-1273-P301-US363-2123US3632123AEXC04 Prior administration of an investigational coronavirus (SARS-CoV, MERS-CoV) vaccine or current/planned simultaneous participation in another interventional study to prevent or treat COVID-19. EXCLUSIONYYAScreening ÂSCREENING 2020-10-12.mRNA-1273-P301IEmRNA-1273-P301-US363-2139US3632139AEXC11CImmunosuppressive or immunodeficient state, asplenia, recurrent severe infections (HIVpositive participants with CD4 count =350 cells/mm3 and an undetectable HIV viral load within the past year). EXCLUSIONYYAScreening ÂSCREENING 2020-10-19.mRNA-1273-P301IEmRNA-1273-P301-US363-2159US3632159AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-10-23.mRNA-1273-P301IEmRNA-1273-P301-US363-2161US3632161AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-10-23.mRNA-1273-P301IEmRNA-1273-P301-US364-2002US3642002AEXC12 Has received systemic immunosuppressants/immune-modifying drugs for >14 days in total within 6 months prior to Screening. Topical tacrolimus is allowed if not used within 14 days prior to Screening. EXCLUSIONYYAScreening ÂSCREENING 2020-08-21.mRNA-1273-P301IEmRNA-1273-P301-US364-2049US3642049AEXC11CImmunosuppressive or immunodeficient state, asplenia, recurrent severe infections (HIVpositive participants with CD4 count =350 cells/mm3 and an undetectable HIV viral load within the past year). EXCLUSIONYYAScreening ÂSCREENING 2020-08-29.mRNA-1273-P301IEmRNA-1273-P301-US364-2070US3642070AEXC11CImmunosuppressive or immunodeficient state, asplenia, recurrent severe infections (HIVpositive participants with CD4 count =350 cells/mm3 and an undetectable HIV viral load within the past year). EXCLUSIONYYAScreening ÂSCREENING 2020-09-01.mRNA-1273-P301IEmRNA-1273-P301-US364-2173US3642173AEXC12AHas received systemic immunosuppressants or immune-modifying drugs for >14 days in total within 6 months prior to Screening (for corticosteroids = 20 mg/day of prednisone equivalent). EXCLUSIONYYAScreening ÂSCREENING 2020-09-11.mRNA-1273-P301IEmRNA-1273-P301-US364-2204US3642204AEXC09AHas received or plans to receive a non-study vaccine within 28 days before/after any dose of IP (except for seasonal influenza vaccine which not permitted within 14 days before/after any dose of IP).EXCLUSIONYYAScreening ÂSCREENING 2020-09-14.mRNA-1273-P301IEmRNA-1273-P301-US364-2206US3642206AEXC12AHas received systemic immunosuppressants or immune-modifying drugs for >14 days in total within 6 months prior to Screening (for corticosteroids = 20 mg/day of prednisone equivalent). EXCLUSIONYYAScreening ÂSCREENING 2020-09-14.mRNA-1273-P301IEmRNA-1273-P301-US364-2280US3642280AINC05 Female participants of childbearing potential may be enrolled in the study if the participant fulfills all the criteria listed in the protocol. INCLUSIONNNAScreening ÂSCREENING 2020-09-26.mRNA-1273-P301IEmRNA-1273-P301-US364-2304US3642269AEXC09AHas received or plans to receive a non-study vaccine within 28 days before/after any dose of IP (except for seasonal influenza vaccine which not permitted within 14 days before/after any dose of IP).EXCLUSIONYYAScreening ÂSCREENING 2020-09-22ÂmRNA-1273-P301IEmRNA-1273-P301-US364-2336US3642336AEXC09AHas received or plans to receive a non-study vaccine within 28 days before/after any dose of IP (except for seasonal influenza vaccine which not permitted within 14 days before/after any dose of IP).EXCLUSIONYYAScreening ÂSCREENING 2020-10-22.mRNA-1273-P301IEmRNA-1273-P301-US365-2019US3652019AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-09-04.mRNA-1273-P301IEmRNA-1273-P301-US365-2034US3652034AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-09-21.mRNA-1273-P301IEmRNA-1273-P301-US365-2053US3652053AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-10-13.mRNA-1273-P301IEmRNA-1273-P301-US365-2061US3652061AEXC09AHas received or plans to receive a non-study vaccine within 28 days before/after any dose of IP (except for seasonal influenza vaccine which not permitted within 14 days before/after any dose of IP).EXCLUSIONYYAScreening ÂSCREENING 2020-10-20.mRNA-1273-P301IEmRNA-1273-P301-US366-2012US3662012AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-25.mRNA-1273-P301IEmRNA-1273-P301-US366-2141US3662141AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-09-28.mRNA-1273-P301IEmRNA-1273-P301-US366-2166US3662166AEXC01 Participants who are acutely ill or febrile 72 hours prior to or at Screening may be rescheduled. Afebrile participants with minor illnesses can be enrolled at the discretion of the investigator. EXCLUSIONYYAScreening ÂSCREENING 2020-10-14.mRNA-1273-P301IEmRNA-1273-P301-US367-2037US3672037AEXC05 Demonstrated inability to comply with the study procedures. EXCLUSIONYYAScreening ÂSCREENING 2020-08-10.mRNA-1273-P301IEmRNA-1273-P301-US367-2065US3672065AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-11.mRNA-1273-P301IEmRNA-1273-P301-US367-2136US3672136AINC03 Able to comply with study procedures based on the assessment of the Investigator. INCLUSIONNNAScreening ÂSCREENING 2020-08-17.mRNA-1273-P301IEmRNA-1273-P301-US367-2172US3672172AEXC05 Demonstrated inability to comply with the study procedures. EXCLUSIONYYAScreening ÂSCREENING 2020-08-18.mRNA-1273-P301IEmRNA-1273-P301-US367-2173US3672173AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-18.mRNA-1273-P301IEmRNA-1273-P301-US367-2211US3672211AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-08-19.mRNA-1273-P301IEmRNA-1273-P301-US367-2212US3672212AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-08-20.mRNA-1273-P301IEmRNA-1273-P301-US367-2236US3672236AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-08-20.mRNA-1273-P301IEmRNA-1273-P301-US367-2248US3672248AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-21.mRNA-1273-P301IEmRNA-1273-P301-US368-2051US3682051AEXC14 Has donated >= 450 mL of blood products within 28 days prior to Screening. EXCLUSIONYYAScreening ÂSCREENING 2020-09-03.mRNA-1273-P301IEmRNA-1273-P301-US368-2060US3682060AINC05 Female participants of childbearing potential may be enrolled in the study if the participant fulfills all the criteria listed in the protocol. INCLUSIONNNAScreening ÂSCREENING 2020-09-04.mRNA-1273-P301IEmRNA-1273-P301-US368-2085US3682085AEXC14 Has donated >= 450 mL of blood products within 28 days prior to Screening. EXCLUSIONYYAScreening ÂSCREENING 2020-09-10.mRNA-1273-P301IEmRNA-1273-P301-US368-2129US3682129AEXC09AHas received or plans to receive a non-study vaccine within 28 days before/after any dose of IP (except for seasonal influenza vaccine which not permitted within 14 days before/after any dose of IP).EXCLUSIONYYAScreening ÂSCREENING 2020-09-16.mRNA-1273-P301IEmRNA-1273-P301-US368-2145US3682145AINC05 Female participants of childbearing potential may be enrolled in the study if the participant fulfills all the criteria listed in the protocol. INCLUSIONNNAScreening ÂSCREENING 2020-09-18.mRNA-1273-P301IEmRNA-1273-P301-US368-2152US3682049AEXC14 Has donated >= 450 mL of blood products within 28 days prior to Screening. EXCLUSIONYYAScreening ÂSCREENING 2020-09-02ÂmRNA-1273-P301IEmRNA-1273-P301-US368-2158US3682158AEXC14 Has donated >= 450 mL of blood products within 28 days prior to Screening. EXCLUSIONYYAScreening ÂSCREENING 2020-09-23.mRNA-1273-P301IEmRNA-1273-P301-US368-2163US3682064AEXC09AHas received or plans to receive a non-study vaccine within 28 days before/after any dose of IP (except for seasonal influenza vaccine which not permitted within 14 days before/after any dose of IP).EXCLUSIONYYAScreening ÂSCREENING 2020-09-08ÂmRNA-1273-P301IEmRNA-1273-P301-US368-2168US3682124AEXC09AHas received or plans to receive a non-study vaccine within 28 days before/after any dose of IP (except for seasonal influenza vaccine which not permitted within 14 days before/after any dose of IP).EXCLUSIONYYAScreening ÂSCREENING 2020-09-16ÁmRNA-1273-P301IEmRNA-1273-P301-US368-2182US3682182AINC05 Female participants of childbearing potential may be enrolled in the study if the participant fulfills all the criteria listed in the protocol. INCLUSIONNNAScreening ÂSCREENING 2020-10-02.mRNA-1273-P301IEmRNA-1273-P301-US368-2187US3682187AEXC09AHas received or plans to receive a non-study vaccine within 28 days before/after any dose of IP (except for seasonal influenza vaccine which not permitted within 14 days before/after any dose of IP).EXCLUSIONYYAScreening ÂSCREENING 2020-10-06.mRNA-1273-P301IEmRNA-1273-P301-US368-2195US3682195AEXC09AHas received or plans to receive a non-study vaccine within 28 days before/after any dose of IP (except for seasonal influenza vaccine which not permitted within 14 days before/after any dose of IP).EXCLUSIONYYAScreening ÂSCREENING 2020-10-12.mRNA-1273-P301IEmRNA-1273-P301-US368-2197US3682186AEXC09AHas received or plans to receive a non-study vaccine within 28 days before/after any dose of IP (except for seasonal influenza vaccine which not permitted within 14 days before/after any dose of IP).EXCLUSIONYYAScreening ÂSCREENING 2020-10-06ÁpmRNA-1273-P301IEmRNA-1273-P301-US368-2200US3682200AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-10-14.mRNA-1273-P301IEmRNA-1273-P301-US368-2206US3682206AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-10-16.mRNA-1273-P301IEmRNA-1273-P301-US368-2207US3682201AEXC09AHas received or plans to receive a non-study vaccine within 28 days before/after any dose of IP (except for seasonal influenza vaccine which not permitted within 14 days before/after any dose of IP).EXCLUSIONYYAScreening ÂSCREENING 2020-10-14Á mRNA-1273-P301IEmRNA-1273-P301-US369-2011US3692011AINC01 Adults, >= 18 years of age at time of consent, who are at high risk of SARS-CoV-2 infection. INCLUSIONNNAScreening ÂSCREENING 2020-08-27.mRNA-1273-P301IEmRNA-1273-P301-US369-2012US3692012AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-08-27.mRNA-1273-P301IEmRNA-1273-P301-US369-2017US3692017AINC01 Adults, >= 18 years of age at time of consent, who are at high risk of SARS-CoV-2 infection. INCLUSIONNNAScreening ÂSCREENING 2020-08-28.mRNA-1273-P301IEmRNA-1273-P301-US369-2018US3692018AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-08-28.mRNA-1273-P301IEmRNA-1273-P301-US369-2036US3692036AEXC09AHas received or plans to receive a non-study vaccine within 28 days before/after any dose of IP (except for seasonal influenza vaccine which not permitted within 14 days before/after any dose of IP).EXCLUSIONYYAScreening ÂSCREENING 2020-09-01.mRNA-1273-P301IEmRNA-1273-P301-US369-2039US3692039AEXC05 Demonstrated inability to comply with the study procedures. EXCLUSIONYYAScreening ÂSCREENING 2020-09-01.mRNA-1273-P301IEmRNA-1273-P301-US369-2041US3692041AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-09-02.mRNA-1273-P301IEmRNA-1273-P301-US369-2047US3692047AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-09-03.mRNA-1273-P301IEmRNA-1273-P301-US369-2050US3692050AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-09-02.mRNA-1273-P301IEmRNA-1273-P301-US369-2054US3692054AEXC11CImmunosuppressive or immunodeficient state, asplenia, recurrent severe infections (HIVpositive participants with CD4 count =350 cells/mm3 and an undetectable HIV viral load within the past year). EXCLUSIONYYAScreening ÂSCREENING 2020-09-03.mRNA-1273-P301IEmRNA-1273-P301-US369-2057US3692057AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-09-04.mRNA-1273-P301IEmRNA-1273-P301-US369-2061US3692061AEXC12AHas received systemic immunosuppressants or immune-modifying drugs for >14 days in total within 6 months prior to Screening (for corticosteroids = 20 mg/day of prednisone equivalent). EXCLUSIONYYAScreening ÂSCREENING 2020-09-04.mRNA-1273-P301IEmRNA-1273-P301-US369-2063US3692063AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-09-04.mRNA-1273-P301IEmRNA-1273-P301-US369-2097US3692097AINC01 Adults, >= 18 years of age at time of consent, who are at high risk of SARS-CoV-2 infection. INCLUSIONNNAScreening ÂSCREENING 2020-09-10.mRNA-1273-P301IEmRNA-1273-P301-US369-2109US3692109AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-09-11.mRNA-1273-P301IEmRNA-1273-P301-US369-2116US3692116AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-09-13.mRNA-1273-P301IEmRNA-1273-P301-US369-2126US3692126AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-09-15.mRNA-1273-P301IEmRNA-1273-P301-US369-2127US3692127AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-09-15.mRNA-1273-P301IEmRNA-1273-P301-US369-2132US3692132AINC05 Female participants of childbearing potential may be enrolled in the study if the participant fulfills all the criteria listed in the protocol. INCLUSIONNNAScreening ÂSCREENING 2020-09-16.mRNA-1273-P301IEmRNA-1273-P301-US369-2135US3692135AINC05 Female participants of childbearing potential may be enrolled in the study if the participant fulfills all the criteria listed in the protocol. INCLUSIONNNAScreening ÂSCREENING 2020-09-16.mRNA-1273-P301IEmRNA-1273-P301-US369-2137US3692137AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-09-16.mRNA-1273-P301IEmRNA-1273-P301-US369-2139US3692139AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-17.mRNA-1273-P301IEmRNA-1273-P301-US369-2142US3692142AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-09-18.mRNA-1273-P301IEmRNA-1273-P301-US369-2152US3692152AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-22.mRNA-1273-P301IEmRNA-1273-P301-US369-2158US3692158AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-09-23.mRNA-1273-P301IEmRNA-1273-P301-US369-2162US3692162AEXC01 Participants who are acutely ill or febrile 72 hours prior to or at Screening may be rescheduled. Afebrile participants with minor illnesses can be enrolled at the discretion of the investigator. EXCLUSIONYYAScreening ÂSCREENING 2020-09-24.mRNA-1273-P301IEmRNA-1273-P301-US369-2162US3692162A EXC05 Demonstrated inability to comply with the study procedures. EXCLUSIONYYAScreening ÂSCREENING 2020-09-24.mRNA-1273-P301IEmRNA-1273-P301-US369-2167US3692167AEXC12AHas received systemic immunosuppressants or immune-modifying drugs for >14 days in total within 6 months prior to Screening (for corticosteroids = 20 mg/day of prednisone equivalent). EXCLUSIONYYAScreening ÂSCREENING 2020-09-25.mRNA-1273-P301IEmRNA-1273-P301-US369-2175US3692175AINC03 Able to comply with study procedures based on the assessment of the Investigator. INCLUSIONNNAScreening ÂSCREENING 2020-09-29.mRNA-1273-P301IEmRNA-1273-P301-US369-2178US3692178AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-09-30.mRNA-1273-P301IEmRNA-1273-P301-US369-2187US3692187AINC05 Female participants of childbearing potential may be enrolled in the study if the participant fulfills all the criteria listed in the protocol. INCLUSIONNNAScreening ÂSCREENING 2020-10-08.mRNA-1273-P301IEmRNA-1273-P301-US370-2005US3702005AEXC12 Has received systemic immunosuppressants/immune-modifying drugs for >14 days in total within 6 months prior to Screening. Topical tacrolimus is allowed if not used within 14 days prior to Screening. EXCLUSIONYYAScreening ÂSCREENING 2020-08-27.mRNA-1273-P301IEmRNA-1273-P301-US370-2014US3702014AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-01.mRNA-1273-P301IEmRNA-1273-P301-US370-2033US3702033AEXC05 Demonstrated inability to comply with the study procedures. EXCLUSIONYYAScreening ÂSCREENING 2020-09-15.mRNA-1273-P301IEmRNA-1273-P301-US371-2003US3712003AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-08-24.mRNA-1273-P301IEmRNA-1273-P301-US371-2042US3712042AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-09-08.mRNA-1273-P301IEmRNA-1273-P301-US371-2043US3712043AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-09-08.mRNA-1273-P301IEmRNA-1273-P301-US371-2049US3712049AEXC05 Demonstrated inability to comply with the study procedures. EXCLUSIONYYAScreening ÂSCREENING 2020-09-08.mRNA-1273-P301IEmRNA-1273-P301-US371-2054US3712054AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-09-09.mRNA-1273-P301IEmRNA-1273-P301-US371-2069US3712069AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-09-10.mRNA-1273-P301IEmRNA-1273-P301-US371-2071US3712071AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-09-10.mRNA-1273-P301IEmRNA-1273-P301-US371-2097US3712097AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-14.mRNA-1273-P301IEmRNA-1273-P301-US371-2099US3712099AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-14.mRNA-1273-P301IEmRNA-1273-P301-US371-2132US3712132AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-09-17.mRNA-1273-P301IEmRNA-1273-P301-US371-2135US3712135AEXC02 Is pregnant or breastfeeding. EXCLUSIONYYAScreening ÂSCREENING 2020-09-17.mRNA-1273-P301IEmRNA-1273-P301-US371-2135US3712135A INC05 Female participants of childbearing potential may be enrolled in the study if the participant fulfills all the criteria listed in the protocol. INCLUSIONNNAScreening ÂSCREENING 2020-09-17.mRNA-1273-P301IEmRNA-1273-P301-US371-2137US3712137AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-09-17.mRNA-1273-P301IEmRNA-1273-P301-US371-2148US3712148AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-09-18.mRNA-1273-P301IEmRNA-1273-P301-US371-2149US3712149AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-09-18.mRNA-1273-P301IEmRNA-1273-P301-US371-2159US3712005AEXC14 Has donated >= 450 mL of blood products within 28 days prior to Screening. EXCLUSIONYYAScreening ÂSCREENING 2020-08-24ÂmRNA-1273-P301IEmRNA-1273-P301-US371-2160US3712160AEXC12AHas received systemic immunosuppressants or immune-modifying drugs for >14 days in total within 6 months prior to Screening (for corticosteroids = 20 mg/day of prednisone equivalent). EXCLUSIONYYAScreening ÂSCREENING 2020-09-22.mRNA-1273-P301IEmRNA-1273-P301-US371-2160US3712160A INC05 Female participants of childbearing potential may be enrolled in the study if the participant fulfills all the criteria listed in the protocol. INCLUSIONNNAScreening ÂSCREENING 2020-09-22.mRNA-1273-P301IEmRNA-1273-P301-US371-2162US3712162AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-09-22.mRNA-1273-P301IEmRNA-1273-P301-US371-2163US3712163AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-09-22.mRNA-1273-P301IEmRNA-1273-P301-US371-2166US3712166AEXC02 Is pregnant or breastfeeding. EXCLUSIONYYAScreening ÂSCREENING 2020-09-23.mRNA-1273-P301IEmRNA-1273-P301-US371-2179US3712179AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-10-13.mRNA-1273-P301IEmRNA-1273-P301-US371-2181US3712181AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-10-13.mRNA-1273-P301IEmRNA-1273-P301-US371-2185US3712185AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-10-13.mRNA-1273-P301IEmRNA-1273-P301-US371-2200US3712200AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-10-14.mRNA-1273-P301IEmRNA-1273-P301-US371-2202US3712202AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-10-14.mRNA-1273-P301IEmRNA-1273-P301-US371-2204US3712204AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-10-14.mRNA-1273-P301IEmRNA-1273-P301-US371-2205US3712205AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-10-14.mRNA-1273-P301IEmRNA-1273-P301-US371-2206US3712206AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-10-14.mRNA-1273-P301IEmRNA-1273-P301-US371-2212US3712212AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-10-14.mRNA-1273-P301IEmRNA-1273-P301-US371-2214US3712214AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-10-14.mRNA-1273-P301IEmRNA-1273-P301-US371-2215US3712215AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-10-14.mRNA-1273-P301IEmRNA-1273-P301-US371-2216US3712216AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-10-14.mRNA-1273-P301IEmRNA-1273-P301-US371-2221US3712221AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-10-15.mRNA-1273-P301IEmRNA-1273-P301-US371-2223US3712223AEXC14 Has donated >= 450 mL of blood products within 28 days prior to Screening. EXCLUSIONYYAScreening ÂSCREENING 2020-10-15.mRNA-1273-P301IEmRNA-1273-P301-US371-2227US3712227AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-10-15.mRNA-1273-P301IEmRNA-1273-P301-US371-2232US3712232AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-10-15.mRNA-1273-P301IEmRNA-1273-P301-US371-2238US3712238AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-10-15.mRNA-1273-P301IEmRNA-1273-P301-US371-2239US3712239AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-10-15.mRNA-1273-P301IEmRNA-1273-P301-US371-2243US3712243AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-10-16.mRNA-1273-P301IEmRNA-1273-P301-US371-2257US3712257AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-10-16.mRNA-1273-P301IEmRNA-1273-P301-US371-2259US3712259AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-10-16.mRNA-1273-P301IEmRNA-1273-P301-US371-2266US3712266AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-10-16.mRNA-1273-P301IEmRNA-1273-P301-US371-2267US3712267AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-10-16.mRNA-1273-P301IEmRNA-1273-P301-US371-2268US3712268AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-10-16.mRNA-1273-P301IEmRNA-1273-P301-US371-2270US3712270AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-10-20.mRNA-1273-P301IEmRNA-1273-P301-US371-2272US3712272AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-10-20.mRNA-1273-P301IEmRNA-1273-P301-US371-2273US3712273AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-10-20.mRNA-1273-P301IEmRNA-1273-P301-US371-2274US3712274AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-10-20.mRNA-1273-P301IEmRNA-1273-P301-US371-2275US3712275AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-10-20.mRNA-1273-P301IEmRNA-1273-P301-US371-2277US3712277AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-10-20.mRNA-1273-P301IEmRNA-1273-P301-US371-2279US3712279AEXC10 Has participated in an interventional clinical study within 28 days prior to the day of enrollment. EXCLUSIONYYAScreening ÂSCREENING 2020-10-20.mRNA-1273-P301IEmRNA-1273-P301-US371-2280US3712280AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-10-20.mRNA-1273-P301IEmRNA-1273-P301-US371-2282US3712282AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-10-21.mRNA-1273-P301IEmRNA-1273-P301-US371-2283US3712283AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-10-21.mRNA-1273-P301IEmRNA-1273-P301-US371-2284US3712284AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-10-21.mRNA-1273-P301IEmRNA-1273-P301-US371-2287US3712287AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-10-21.mRNA-1273-P301IEmRNA-1273-P301-US371-2288US3712288AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-10-21.mRNA-1273-P301IEmRNA-1273-P301-US371-2290US3712290AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-10-21.mRNA-1273-P301IEmRNA-1273-P301-US371-2292US3712292AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-10-21.mRNA-1273-P301IEmRNA-1273-P301-US371-2293US3712293AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-10-21.mRNA-1273-P301IEmRNA-1273-P301-US371-2295US3712295AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-10-21.mRNA-1273-P301IEmRNA-1273-P301-US371-2305US3712305AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-10-23.mRNA-1273-P301IEmRNA-1273-P301-US372-2024US3722024AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-08-01.mRNA-1273-P301IEmRNA-1273-P301-US372-2103US3722103AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-05.mRNA-1273-P301IEmRNA-1273-P301-US372-2189US3722189AEXC02 Is pregnant or breastfeeding. EXCLUSIONYYAScreening ÂSCREENING 2020-08-11.mRNA-1273-P301IEmRNA-1273-P301-US372-2366US3722366AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-08-24.mRNA-1273-P301IEmRNA-1273-P301-US372-2386US3722386AEXC09AHas received or plans to receive a non-study vaccine within 28 days before/after any dose of IP (except for seasonal influenza vaccine which not permitted within 14 days before/after any dose of IP).EXCLUSIONYYAScreening ÂSCREENING 2020-08-25.mRNA-1273-P301IEmRNA-1273-P301-US372-2418US3722418AEXC12AHas received systemic immunosuppressants or immune-modifying drugs for >14 days in total within 6 months prior to Screening (for corticosteroids = 20 mg/day of prednisone equivalent). EXCLUSIONYYAScreening ÂBLINDED TREATMENT 2020-09-12AmRNA-1273-P301IEmRNA-1273-P301-US372-2430US3722430AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-30.mRNA-1273-P301IEmRNA-1273-P301-US373-2053US3732053AEXC12 Has received systemic immunosuppressants/immune-modifying drugs for >14 days in total within 6 months prior to Screening. Topical tacrolimus is allowed if not used within 14 days prior to Screening. EXCLUSIONYYAScreening ÂSCREENING 2020-08-12.mRNA-1273-P301IEmRNA-1273-P301-US373-2068US3732068AEXC08 Bleeding disorder considered a contraindication to intramuscular injection or phlebotomy. EXCLUSIONYYAScreening ÂSCREENING 2020-08-14.mRNA-1273-P301IEmRNA-1273-P301-US373-2068US3732068A INC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-14.mRNA-1273-P301IEmRNA-1273-P301-US373-2080US3732080AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-08-17.mRNA-1273-P301IEmRNA-1273-P301-US373-2082US3732082AEXC12 Has received systemic immunosuppressants/immune-modifying drugs for >14 days in total within 6 months prior to Screening. Topical tacrolimus is allowed if not used within 14 days prior to Screening. EXCLUSIONYYAScreening ÂSCREENING 2020-08-17.mRNA-1273-P301IEmRNA-1273-P301-US373-2104US3732104AEXC06 An immediate family member or household member of this study's personnel. EXCLUSIONYYAScreening ÂSCREENING 2020-08-19.mRNA-1273-P301IEmRNA-1273-P301-US373-2197US3732197AEXC12AHas received systemic immunosuppressants or immune-modifying drugs for >14 days in total within 6 months prior to Screening (for corticosteroids = 20 mg/day of prednisone equivalent). EXCLUSIONYYAScreening ÂSCREENING 2020-08-27.mRNA-1273-P301IEmRNA-1273-P301-US373-2215US3732215AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-28.mRNA-1273-P301IEmRNA-1273-P301-US373-2271US3732271AINC03 Able to comply with study procedures based on the assessment of the Investigator. INCLUSIONNNAScreening ÂSCREENING 2020-09-03.mRNA-1273-P301IEmRNA-1273-P301-US373-2405US3732405AEXC09AHas received or plans to receive a non-study vaccine within 28 days before/after any dose of IP (except for seasonal influenza vaccine which not permitted within 14 days before/after any dose of IP).EXCLUSIONYYAScreening ÂSCREENING 2020-10-22.mRNA-1273-P301IEmRNA-1273-P301-US373-2405US3732405A INC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-10-22.mRNA-1273-P301IEmRNA-1273-P301-US374-2006US3742006AEXC09AHas received or plans to receive a non-study vaccine within 28 days before/after any dose of IP (except for seasonal influenza vaccine which not permitted within 14 days before/after any dose of IP).EXCLUSIONYYAScreening ÂSCREENING 2020-08-17.mRNA-1273-P301IEmRNA-1273-P301-US374-2012US3742012AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-18.mRNA-1273-P301IEmRNA-1273-P301-US374-2055US3742055AINC01 Adults, >= 18 years of age at time of consent, who are at high risk of SARS-CoV-2 infection. INCLUSIONNNAScreening ÂSCREENING 2020-08-24.mRNA-1273-P301IEmRNA-1273-P301-US374-2069US3742069AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-08-24.mRNA-1273-P301IEmRNA-1273-P301-US374-2084US3742084AEXC11CImmunosuppressive or immunodeficient state, asplenia, recurrent severe infections (HIVpositive participants with CD4 count =350 cells/mm3 and an undetectable HIV viral load within the past year). EXCLUSIONYYAScreening ÂSCREENING 2020-08-25.mRNA-1273-P301IEmRNA-1273-P301-US374-2157US3742157AINC01 Adults, >= 18 years of age at time of consent, who are at high risk of SARS-CoV-2 infection. INCLUSIONNNAScreening ÂSCREENING 2020-08-29.mRNA-1273-P301IEmRNA-1273-P301-US374-2183US3742183AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-08-31.mRNA-1273-P301IEmRNA-1273-P301-US374-2188US3742188AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-08-31.mRNA-1273-P301IEmRNA-1273-P301-US374-2198US3742198AEXC01 Participants who are acutely ill or febrile 72 hours prior to or at Screening may be rescheduled. Afebrile participants with minor illnesses can be enrolled at the discretion of the investigator. EXCLUSIONYYAScreening ÂSCREENING 2020-09-01.mRNA-1273-P301IEmRNA-1273-P301-US374-2199US3742199AINC01 Adults, >= 18 years of age at time of consent, who are at high risk of SARS-CoV-2 infection. INCLUSIONNNAScreening ÂSCREENING 2020-09-01.mRNA-1273-P301IEmRNA-1273-P301-US374-2200US3742200AINC05 Female participants of childbearing potential may be enrolled in the study if the participant fulfills all the criteria listed in the protocol. INCLUSIONNNAScreening ÂSCREENING 2020-09-01.mRNA-1273-P301IEmRNA-1273-P301-US374-2210US3742210AINC01 Adults, >= 18 years of age at time of consent, who are at high risk of SARS-CoV-2 infection. INCLUSIONNNAScreening ÂSCREENING 2020-09-02.mRNA-1273-P301IEmRNA-1273-P301-US374-2239US3742239AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-09-03.mRNA-1273-P301IEmRNA-1273-P301-US374-2240US3742240AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-09-03.mRNA-1273-P301IEmRNA-1273-P301-US374-2241US3742241AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-09-03.mRNA-1273-P301IEmRNA-1273-P301-US374-2246US3742246AINC05 Female participants of childbearing potential may be enrolled in the study if the participant fulfills all the criteria listed in the protocol. INCLUSIONNNAScreening ÂSCREENING 2020-09-03.mRNA-1273-P301IEmRNA-1273-P301-US374-2252US3742252AINC01 Adults, >= 18 years of age at time of consent, who are at high risk of SARS-CoV-2 infection. INCLUSIONNNAScreening ÂSCREENING 2020-09-04.mRNA-1273-P301IEmRNA-1273-P301-US374-2256US3742256AEXC11CImmunosuppressive or immunodeficient state, asplenia, recurrent severe infections (HIVpositive participants with CD4 count =350 cells/mm3 and an undetectable HIV viral load within the past year). EXCLUSIONYYAScreening ÂSCREENING 2020-09-04.mRNA-1273-P301IEmRNA-1273-P301-US374-2281US3742281AINC01 Adults, >= 18 years of age at time of consent, who are at high risk of SARS-CoV-2 infection. INCLUSIONNNAScreening ÂSCREENING 2020-09-08.mRNA-1273-P301IEmRNA-1273-P301-US374-2282US3742282AINC01 Adults, >= 18 years of age at time of consent, who are at high risk of SARS-CoV-2 infection. INCLUSIONNNAScreening ÂSCREENING 2020-09-08.mRNA-1273-P301IEmRNA-1273-P301-US374-2292US3742292AEXC12AHas received systemic immunosuppressants or immune-modifying drugs for >14 days in total within 6 months prior to Screening (for corticosteroids = 20 mg/day of prednisone equivalent). EXCLUSIONYYAScreening ÂSCREENING 2020-09-09.mRNA-1273-P301IEmRNA-1273-P301-US374-2306US3742306AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-10.mRNA-1273-P301IEmRNA-1273-P301-US374-2317US3742317AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-10.mRNA-1273-P301IEmRNA-1273-P301-US374-2319US3742319AINC01 Adults, >= 18 years of age at time of consent, who are at high risk of SARS-CoV-2 infection. INCLUSIONNNAScreening ÂSCREENING 2020-09-10.mRNA-1273-P301IEmRNA-1273-P301-US374-2331US3742331AINC01 Adults, >= 18 years of age at time of consent, who are at high risk of SARS-CoV-2 infection. INCLUSIONNNAScreening ÂSCREENING 2020-09-11.mRNA-1273-P301IEmRNA-1273-P301-US374-2340US3742340AINC01 Adults, >= 18 years of age at time of consent, who are at high risk of SARS-CoV-2 infection. INCLUSIONNNAScreening ÂSCREENING 2020-09-11.mRNA-1273-P301IEmRNA-1273-P301-US374-2345US3742345AINC01 Adults, >= 18 years of age at time of consent, who are at high risk of SARS-CoV-2 infection. INCLUSIONNNAScreening ÂSCREENING 2020-09-11.mRNA-1273-P301IEmRNA-1273-P301-US374-2362US3742362AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-09-14.mRNA-1273-P301IEmRNA-1273-P301-US374-2365US3742365AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-09-14.mRNA-1273-P301IEmRNA-1273-P301-US374-2366US3742366AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-09-14.mRNA-1273-P301IEmRNA-1273-P301-US374-2369US3742369AEXC09AHas received or plans to receive a non-study vaccine within 28 days before/after any dose of IP (except for seasonal influenza vaccine which not permitted within 14 days before/after any dose of IP).EXCLUSIONYYAScreening ÂSCREENING 2020-09-14.mRNA-1273-P301IEmRNA-1273-P301-US374-2370US3742370AEXC09AHas received or plans to receive a non-study vaccine within 28 days before/after any dose of IP (except for seasonal influenza vaccine which not permitted within 14 days before/after any dose of IP).EXCLUSIONYYAScreening ÂSCREENING 2020-09-15.mRNA-1273-P301IEmRNA-1273-P301-US374-2378US3742378AINC03 Able to comply with study procedures based on the assessment of the Investigator. INCLUSIONNNAScreening ÂSCREENING 2020-09-14.mRNA-1273-P301IEmRNA-1273-P301-US374-2400US3742400AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-09-17.mRNA-1273-P301IEmRNA-1273-P301-US374-2402US3742402AINC01 Adults, >= 18 years of age at time of consent, who are at high risk of SARS-CoV-2 infection. INCLUSIONNNAScreening ÂSCREENING 2020-09-17.mRNA-1273-P301IEmRNA-1273-P301-US374-2403US3742403AINC01 Adults, >= 18 years of age at time of consent, who are at high risk of SARS-CoV-2 infection. INCLUSIONNNAScreening ÂSCREENING 2020-09-17.mRNA-1273-P301IEmRNA-1273-P301-US374-2405US3742405AINC03 Able to comply with study procedures based on the assessment of the Investigator. INCLUSIONNNAScreening ÂSCREENING 2020-09-17.mRNA-1273-P301IEmRNA-1273-P301-US374-2407US3742407AINC03 Able to comply with study procedures based on the assessment of the Investigator. INCLUSIONNNAScreening ÂSCREENING 2020-09-17.mRNA-1273-P301IEmRNA-1273-P301-US374-2410US3742410AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-09-17.mRNA-1273-P301IEmRNA-1273-P301-US374-2419US3742419AEXC05 Demonstrated inability to comply with the study procedures. EXCLUSIONYYAScreening ÂSCREENING 2020-09-18.mRNA-1273-P301IEmRNA-1273-P301-US374-2446US3742446AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-09-21.mRNA-1273-P301IEmRNA-1273-P301-US374-2447US3742447AINC01 Adults, >= 18 years of age at time of consent, who are at high risk of SARS-CoV-2 infection. INCLUSIONNNAScreening ÂSCREENING 2020-09-21.mRNA-1273-P301IEmRNA-1273-P301-US374-2448US3742448AINC05 Female participants of childbearing potential may be enrolled in the study if the participant fulfills all the criteria listed in the protocol. INCLUSIONNNAScreening ÂSCREENING 2020-09-21.mRNA-1273-P301IEmRNA-1273-P301-US374-2474US3742474AINC01 Adults, >= 18 years of age at time of consent, who are at high risk of SARS-CoV-2 infection. INCLUSIONNNAScreening ÂSCREENING 2020-09-24.mRNA-1273-P301IEmRNA-1273-P301-US374-2476US3742406AINC05 Female participants of childbearing potential may be enrolled in the study if the participant fulfills all the criteria listed in the protocol. INCLUSIONNNAScreening ÂSCREENING 2020-09-17Á°mRNA-1273-P301IEmRNA-1273-P301-US374-2481US3742481AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-28.mRNA-1273-P301IEmRNA-1273-P301-US374-2484US3742484AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-09-28.mRNA-1273-P301IEmRNA-1273-P301-US375-2016US3752016AEXC11AImmunosuppressive or immunodeficient state, including HIV infection, asplenia, recurrent severe infections. EXCLUSIONYYAScreening ÂSCREENING 2020-08-07.mRNA-1273-P301IEmRNA-1273-P301-US375-2018US3752018AEXC11AImmunosuppressive or immunodeficient state, including HIV infection, asplenia, recurrent severe infections. EXCLUSIONYYAScreening ÂSCREENING 2020-08-10.mRNA-1273-P301IEmRNA-1273-P301-US375-2019US3752019AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-10.mRNA-1273-P301IEmRNA-1273-P301-US375-2057US3752057AINC06 INCLUSIONNNAScreening ÂSCREENING 2020-08-12.mRNA-1273-P301IEmRNA-1273-P301-US375-2067US3752067AINC06 INCLUSIONNNAScreening ÂSCREENING 2020-08-12.mRNA-1273-P301IEmRNA-1273-P301-US375-2076US3752076AINC01 Adults, >= 18 years of age at time of consent, who are at high risk of SARS-CoV-2 infection. INCLUSIONNNAScreening ÂSCREENING 2020-08-13.mRNA-1273-P301IEmRNA-1273-P301-US375-2104US3752104AEXC08 Bleeding disorder considered a contraindication to intramuscular injection or phlebotomy. EXCLUSIONYYAScreening ÂSCREENING 2020-08-14.mRNA-1273-P301IEmRNA-1273-P301-US375-2106US3752106AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-17.mRNA-1273-P301IEmRNA-1273-P301-US375-2112US3752112AEXC12 Has received systemic immunosuppressants/immune-modifying drugs for >14 days in total within 6 months prior to Screening. Topical tacrolimus is allowed if not used within 14 days prior to Screening. EXCLUSIONYYAScreening ÂSCREENING 2020-08-17.mRNA-1273-P301IEmRNA-1273-P301-US375-2113US3752113AINC01 Adults, >= 18 years of age at time of consent, who are at high risk of SARS-CoV-2 infection. INCLUSIONNNAScreening ÂSCREENING 2020-08-17.mRNA-1273-P301IEmRNA-1273-P301-US375-2136US3752136AEXC09AHas received or plans to receive a non-study vaccine within 28 days before/after any dose of IP (except for seasonal influenza vaccine which not permitted within 14 days before/after any dose of IP).EXCLUSIONYYAScreening ÂSCREENING 2020-08-18.mRNA-1273-P301IEmRNA-1273-P301-US375-2144US3752144AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-19.mRNA-1273-P301IEmRNA-1273-P301-US375-2146US3752146AEXC09AHas received or plans to receive a non-study vaccine within 28 days before/after any dose of IP (except for seasonal influenza vaccine which not permitted within 14 days before/after any dose of IP).EXCLUSIONYYAScreening ÂSCREENING 2020-08-19.mRNA-1273-P301IEmRNA-1273-P301-US375-2171US3752171AINC06 INCLUSIONNNAScreening ÂSCREENING 2020-08-20.mRNA-1273-P301IEmRNA-1273-P301-US375-2201US3752201AEXC12 Has received systemic immunosuppressants/immune-modifying drugs for >14 days in total within 6 months prior to Screening. Topical tacrolimus is allowed if not used within 14 days prior to Screening. EXCLUSIONYYAScreening ÂSCREENING 2020-08-21.mRNA-1273-P301IEmRNA-1273-P301-US375-2218US3752218AEXC14 Has donated >= 450 mL of blood products within 28 days prior to Screening. EXCLUSIONYYAScreening ÂSCREENING 2020-08-24.mRNA-1273-P301IEmRNA-1273-P301-US375-2220US3752220AINC06 INCLUSIONNNAScreening ÂSCREENING 2020-08-24.mRNA-1273-P301IEmRNA-1273-P301-US375-2246US3752246AEXC09AHas received or plans to receive a non-study vaccine within 28 days before/after any dose of IP (except for seasonal influenza vaccine which not permitted within 14 days before/after any dose of IP).EXCLUSIONYYAScreening ÂSCREENING 2020-08-25.mRNA-1273-P301IEmRNA-1273-P301-US375-2276US3752276AEXC14 Has donated >= 450 mL of blood products within 28 days prior to Screening. EXCLUSIONYYAScreening ÂSCREENING 2020-08-27.mRNA-1273-P301IEmRNA-1273-P301-US375-2310US3752310AINC06 INCLUSIONNNAScreening ÂSCREENING 2020-08-31.mRNA-1273-P301IEmRNA-1273-P301-US375-2311US3752311AINC06 INCLUSIONNNAScreening ÂSCREENING 2020-08-31.mRNA-1273-P301IEmRNA-1273-P301-US375-2375US3752375AINC06 INCLUSIONNNAScreening ÂSCREENING 2020-09-03.mRNA-1273-P301IEmRNA-1273-P301-US376-2002US3762002AEXC09AHas received or plans to receive a non-study vaccine within 28 days before/after any dose of IP (except for seasonal influenza vaccine which not permitted within 14 days before/after any dose of IP).EXCLUSIONYYAScreening ÂBLINDED TREATMENT 2020-08-20AmRNA-1273-P301IEmRNA-1273-P301-US376-2016US3762016AEXC12 Has received systemic immunosuppressants/immune-modifying drugs for >14 days in total within 6 months prior to Screening. Topical tacrolimus is allowed if not used within 14 days prior to Screening. EXCLUSIONYYAScreening ÂBLINDED TREATMENT 2020-08-21AmRNA-1273-P301IEmRNA-1273-P301-US376-2025US3762025AINC01 Adults, >= 18 years of age at time of consent, who are at high risk of SARS-CoV-2 infection. INCLUSIONNNAScreening ÂSCREENING 2020-08-21.mRNA-1273-P301IEmRNA-1273-P301-US376-2043US3762043AEXC12 Has received systemic immunosuppressants/immune-modifying drugs for >14 days in total within 6 months prior to Screening. Topical tacrolimus is allowed if not used within 14 days prior to Screening. EXCLUSIONYYAScreening ÂSCREENING 2020-08-08.mRNA-1273-P301IEmRNA-1273-P301-US376-2059US3762059AINC01 Adults, >= 18 years of age at time of consent, who are at high risk of SARS-CoV-2 infection. INCLUSIONNNAScreening ÂSCREENING 2020-08-25.mRNA-1273-P301IEmRNA-1273-P301-US376-2069US3762069AINC01 Adults, >= 18 years of age at time of consent, who are at high risk of SARS-CoV-2 infection. INCLUSIONNNAScreening ÂSCREENING 2020-08-26.mRNA-1273-P301IEmRNA-1273-P301-US376-2073US3762073AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-08-27.mRNA-1273-P301IEmRNA-1273-P301-US376-2103US3762103AEXC12 Has received systemic immunosuppressants/immune-modifying drugs for >14 days in total within 6 months prior to Screening. Topical tacrolimus is allowed if not used within 14 days prior to Screening. EXCLUSIONYYAScreening ÂSCREENING 2020-08-28.mRNA-1273-P301IEmRNA-1273-P301-US376-2108US3762108AINC01 Adults, >= 18 years of age at time of consent, who are at high risk of SARS-CoV-2 infection. INCLUSIONNNAScreening ÂSCREENING 2020-08-31.mRNA-1273-P301IEmRNA-1273-P301-US376-2151US3762151AINC01 Adults, >= 18 years of age at time of consent, who are at high risk of SARS-CoV-2 infection. INCLUSIONNNAScreening ÂSCREENING 2020-09-02.mRNA-1273-P301IEmRNA-1273-P301-US376-2176US3762176AEXC12AHas received systemic immunosuppressants or immune-modifying drugs for >14 days in total within 6 months prior to Screening (for corticosteroids = 20 mg/day of prednisone equivalent). EXCLUSIONYYAScreening ÂSCREENING 2020-09-03.mRNA-1273-P301IEmRNA-1273-P301-US376-2246US3762246AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-09-10.mRNA-1273-P301IEmRNA-1273-P301-US376-2269US3762269AEXC11CImmunosuppressive or immunodeficient state, asplenia, recurrent severe infections (HIVpositive participants with CD4 count =350 cells/mm3 and an undetectable HIV viral load within the past year). EXCLUSIONYYAScreening ÂSCREENING 2020-09-14.mRNA-1273-P301IEmRNA-1273-P301-US376-2284US3762284AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-09-16.mRNA-1273-P301IEmRNA-1273-P301-US376-2293US3762293AEXC10 Has participated in an interventional clinical study within 28 days prior to the day of enrollment. EXCLUSIONYYAScreening ÂSCREENING 2020-09-30.mRNA-1273-P301IEmRNA-1273-P301-US376-2304US3762304AINC01 Adults, >= 18 years of age at time of consent, who are at high risk of SARS-CoV-2 infection. INCLUSIONNNAScreening ÂSCREENING 2020-10-16.mRNA-1273-P301IEmRNA-1273-P301-US376-2305US3762305AEXC10 Has participated in an interventional clinical study within 28 days prior to the day of enrollment. EXCLUSIONYYAScreening ÂSCREENING 2020-10-21.mRNA-1273-P301IEmRNA-1273-P301-US377-2085US3772085AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNN. . .mRNA-1273-P301IEmRNA-1273-P301-US377-2088US3772088AINC03 Able to comply with study procedures based on the assessment of the Investigator. INCLUSIONNNAScreening ÂSCREENING 2020-08-18.mRNA-1273-P301IEmRNA-1273-P301-US377-2108US3772108AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-20.mRNA-1273-P301IEmRNA-1273-P301-US377-2112US3772112AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-08-21.mRNA-1273-P301IEmRNA-1273-P301-US377-2114US3772114AEXC11BImmunosuppressive or immunodeficient state, asplenia, recurrent severe infections (HIVpositive participants on stable antiretroviral therapy are not excluded). EXCLUSIONYYAScreening ÂSCREENING 2020-08-21.mRNA-1273-P301IEmRNA-1273-P301-US377-2114US3772114A EXC12 Has received systemic immunosuppressants/immune-modifying drugs for >14 days in total within 6 months prior to Screening. Topical tacrolimus is allowed if not used within 14 days prior to Screening. EXCLUSIONYYAScreening ÂSCREENING 2020-08-21.mRNA-1273-P301IEmRNA-1273-P301-US377-2136US3772136AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-08-24.mRNA-1273-P301IEmRNA-1273-P301-US377-2185US3772185AEXC03 Known history of SARS-CoV-2 infection. EXCLUSIONYYAScreening ÂSCREENING 2020-08-31.mRNA-1273-P301IEmRNA-1273-P301-US377-2206US3772206AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-09-02.mRNA-1273-P301IEmRNA-1273-P301-US377-2221US3772221AEXC11CImmunosuppressive or immunodeficient state, asplenia, recurrent severe infections (HIVpositive participants with CD4 count =350 cells/mm3 and an undetectable HIV viral load within the past year). EXCLUSIONYYAScreening ÂSCREENING 2020-09-03.mRNA-1273-P301IEmRNA-1273-P301-US377-2228US3772228AEXC09AHas received or plans to receive a non-study vaccine within 28 days before/after any dose of IP (except for seasonal influenza vaccine which not permitted within 14 days before/after any dose of IP).EXCLUSIONYYAScreening ÂSCREENING 2020-09-05.mRNA-1273-P301IEmRNA-1273-P301-US377-2243US3772243AINC03 Able to comply with study procedures based on the assessment of the Investigator. INCLUSIONNNAScreening ÂSCREENING 2020-09-10.mRNA-1273-P301IEmRNA-1273-P301-US377-2245US3772245AINC03 Able to comply with study procedures based on the assessment of the Investigator. INCLUSIONNNAScreening ÂSCREENING 2020-09-10.mRNA-1273-P301IEmRNA-1273-P301-US377-2272US3772231AEXC09AHas received or plans to receive a non-study vaccine within 28 days before/after any dose of IP (except for seasonal influenza vaccine which not permitted within 14 days before/after any dose of IP).EXCLUSIONYYAScreening ÂSCREENING 2020-09-05ÁÐmRNA-1273-P301IEmRNA-1273-P301-US377-2274US3772274AEXC09AHas received or plans to receive a non-study vaccine within 28 days before/after any dose of IP (except for seasonal influenza vaccine which not permitted within 14 days before/after any dose of IP).EXCLUSIONYYAScreening ÂSCREENING 2020-09-18.mRNA-1273-P301IEmRNA-1273-P301-US377-2276US3772276AEXC09AHas received or plans to receive a non-study vaccine within 28 days before/after any dose of IP (except for seasonal influenza vaccine which not permitted within 14 days before/after any dose of IP).EXCLUSIONYYAScreening ÂSCREENING 2020-09-18.mRNA-1273-P301IEmRNA-1273-P301-US378-2013US3782013AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-13.mRNA-1273-P301IEmRNA-1273-P301-US378-2046US3782046AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-18.mRNA-1273-P301IEmRNA-1273-P301-US378-2079US3782079AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-24.mRNA-1273-P301IEmRNA-1273-P301-US378-2085US3782085AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-25.mRNA-1273-P301IEmRNA-1273-P301-US378-2106US3782106AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-28.mRNA-1273-P301IEmRNA-1273-P301-US378-2121US3782121AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-31.mRNA-1273-P301IEmRNA-1273-P301-US378-2133US3782133AEXC09AHas received or plans to receive a non-study vaccine within 28 days before/after any dose of IP (except for seasonal influenza vaccine which not permitted within 14 days before/after any dose of IP).EXCLUSIONYYAScreening ÂSCREENING 2020-09-02.mRNA-1273-P301IEmRNA-1273-P301-US378-2134US3782134AEXC09AHas received or plans to receive a non-study vaccine within 28 days before/after any dose of IP (except for seasonal influenza vaccine which not permitted within 14 days before/after any dose of IP).EXCLUSIONYYAScreening ÂSCREENING 2020-09-02.mRNA-1273-P301IEmRNA-1273-P301-US378-2135US3782135AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-02.mRNA-1273-P301IEmRNA-1273-P301-US378-2137US3782137AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-02.mRNA-1273-P301IEmRNA-1273-P301-US378-2150US3782099AEXC14 Has donated >= 450 mL of blood products within 28 days prior to Screening. EXCLUSIONYYAScreening ÂSCREENING 2020-08-27Á€mRNA-1273-P301IEmRNA-1273-P301-US378-2151US3782029AINC06 INCLUSIONNNAScreening ÂSCREENING 2020-08-17ÂmRNA-1273-P301IEmRNA-1273-P301-US378-2173US3782173AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-22.mRNA-1273-P301IEmRNA-1273-P301-US378-2175US3782175AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-10-05.mRNA-1273-P301IEmRNA-1273-P301-US378-2178US3782178AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-10-08.mRNA-1273-P301IEmRNA-1273-P301-US379-2030US3792030AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-08-21.mRNA-1273-P301IEmRNA-1273-P301-US379-2041US3792041AEXC12AHas received systemic immunosuppressants or immune-modifying drugs for >14 days in total within 6 months prior to Screening (for corticosteroids = 20 mg/day of prednisone equivalent). EXCLUSIONYYAScreening ÂBLINDED TREATMENT 2020-09-09AmRNA-1273-P301IEmRNA-1273-P301-US379-2042US3792042AEXC11CImmunosuppressive or immunodeficient state, asplenia, recurrent severe infections (HIVpositive participants with CD4 count =350 cells/mm3 and an undetectable HIV viral load within the past year). EXCLUSIONYYAScreening ÂSCREENING 2020-09-10.mRNA-1273-P301IEmRNA-1273-P301-US379-2049US3792049A INCLUSIONNNAScreening ÂSCREENING 2020-09-14.mRNA-1273-P301IEmRNA-1273-P301-US380-2020US3802020AEXC13 Has received systemic immunoglobulins or blood products within 3 months prior to the day of screening. EXCLUSIONYYAScreening ÂSCREENING 2020-08-21.mRNA-1273-P301IEmRNA-1273-P301-US380-2061US3802061AINC06 INCLUSIONNNAScreening ÂSCREENING 2020-08-28.mRNA-1273-P301IEmRNA-1273-P301-US380-2070US3802070AEXC14 Has donated >= 450 mL of blood products within 28 days prior to Screening. EXCLUSIONYYAScreening ÂSCREENING 2020-08-28.mRNA-1273-P301IEmRNA-1273-P301-US380-2084US3802022AEXC09AHas received or plans to receive a non-study vaccine within 28 days before/after any dose of IP (except for seasonal influenza vaccine which not permitted within 14 days before/after any dose of IP).EXCLUSIONYYAScreening ÂSCREENING 2020-08-24ÁpmRNA-1273-P301IEmRNA-1273-P301-US380-2086US3802086AINC06 INCLUSIONNNAScreening ÂSCREENING 2020-09-01.mRNA-1273-P301IEmRNA-1273-P301-US380-2101US3802101AEXC12AHas received systemic immunosuppressants or immune-modifying drugs for >14 days in total within 6 months prior to Screening (for corticosteroids = 20 mg/day of prednisone equivalent). EXCLUSIONYYAScreening ÂSCREENING 2020-09-02.mRNA-1273-P301IEmRNA-1273-P301-US380-2161US3802161AEXC09AHas received or plans to receive a non-study vaccine within 28 days before/after any dose of IP (except for seasonal influenza vaccine which not permitted within 14 days before/after any dose of IP).EXCLUSIONYYAScreening ÂSCREENING 2020-09-08.mRNA-1273-P301IEmRNA-1273-P301-US380-2174US3802174AEXC05 Demonstrated inability to comply with the study procedures. EXCLUSIONYYAScreening ÂSCREENING 2020-09-08.mRNA-1273-P301IEmRNA-1273-P301-US380-2176US3802176AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-09-08.mRNA-1273-P301IEmRNA-1273-P301-US380-2182US3802182AEXC05 Demonstrated inability to comply with the study procedures. EXCLUSIONYYAScreening ÂSCREENING 2020-09-09.mRNA-1273-P301IEmRNA-1273-P301-US380-2214US3802214AINC06 INCLUSIONNNAScreening ÂSCREENING 2020-09-11.mRNA-1273-P301IEmRNA-1273-P301-US380-2222US3802222AINC03 Able to comply with study procedures based on the assessment of the Investigator. INCLUSIONNNAScreening ÂSCREENING 2020-09-11.mRNA-1273-P301IEmRNA-1273-P301-US381-2016US3812016AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-03.mRNA-1273-P301IEmRNA-1273-P301-US381-2030US3812030AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-04.mRNA-1273-P301IEmRNA-1273-P301-US381-2034US3812034AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-04.mRNA-1273-P301IEmRNA-1273-P301-US381-2040US3812040AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-05.mRNA-1273-P301IEmRNA-1273-P301-US381-2042US3812042AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-05.mRNA-1273-P301IEmRNA-1273-P301-US381-2063US3812063AEXC11AImmunosuppressive or immunodeficient state, including HIV infection, asplenia, recurrent severe infections. EXCLUSIONYYAScreening ÂSCREENING 2020-08-06.mRNA-1273-P301IEmRNA-1273-P301-US381-2069US3812069AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-07.mRNA-1273-P301IEmRNA-1273-P301-US381-2070US3812070AEXC05 Demonstrated inability to comply with the study procedures. EXCLUSIONYYAScreening ÂSCREENING 2020-08-07.mRNA-1273-P301IEmRNA-1273-P301-US381-2070US3812070A INC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-07.mRNA-1273-P301IEmRNA-1273-P301-US381-2074US3812074AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-07.mRNA-1273-P301IEmRNA-1273-P301-US381-2082US3812082AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-07.mRNA-1273-P301IEmRNA-1273-P301-US381-2088US3812088AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-08.mRNA-1273-P301IEmRNA-1273-P301-US381-2115US3812115AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-10.mRNA-1273-P301IEmRNA-1273-P301-US381-2123US3812123AEXC03 Known history of SARS-CoV-2 infection. EXCLUSIONYYAScreening ÂSCREENING 2020-08-11.mRNA-1273-P301IEmRNA-1273-P301-US381-2126US3812126AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-11.mRNA-1273-P301IEmRNA-1273-P301-US381-2144US3812144AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-12.mRNA-1273-P301IEmRNA-1273-P301-US381-2163US3812163AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-13.mRNA-1273-P301IEmRNA-1273-P301-US381-2171US3812171AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-14.mRNA-1273-P301IEmRNA-1273-P301-US381-2177US3812177AEXC05 Demonstrated inability to comply with the study procedures. EXCLUSIONYYAScreening ÂSCREENING 2020-08-14.mRNA-1273-P301IEmRNA-1273-P301-US381-2177US3812177A INC03 Able to comply with study procedures based on the assessment of the Investigator. INCLUSIONNNAScreening ÂSCREENING 2020-08-14.mRNA-1273-P301IEmRNA-1273-P301-US381-2181US3812181AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-15.mRNA-1273-P301IEmRNA-1273-P301-US381-2206US3812206AINC03 Able to comply with study procedures based on the assessment of the Investigator. INCLUSIONNNAScreening ÂSCREENING 2020-08-19.mRNA-1273-P301IEmRNA-1273-P301-US381-2206US3812206A INC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-19.mRNA-1273-P301IEmRNA-1273-P301-US381-2238US3812238AEXC10 Has participated in an interventional clinical study within 28 days prior to the day of enrollment. EXCLUSIONYYAScreening ÂSCREENING 2020-08-21.mRNA-1273-P301IEmRNA-1273-P301-US381-2252US3812252AEXC10 Has participated in an interventional clinical study within 28 days prior to the day of enrollment. EXCLUSIONYYAScreening ÂSCREENING 2020-08-24.mRNA-1273-P301IEmRNA-1273-P301-US381-2259US3812259AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-25.mRNA-1273-P301IEmRNA-1273-P301-US381-2262US3812262AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-25.mRNA-1273-P301IEmRNA-1273-P301-US381-2273US3812273AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-26.mRNA-1273-P301IEmRNA-1273-P301-US381-2284US3812284AEXC11BImmunosuppressive or immunodeficient state, asplenia, recurrent severe infections (HIVpositive participants on stable antiretroviral therapy are not excluded). EXCLUSIONYYAScreening ÂSCREENING 2020-08-28.mRNA-1273-P301IEmRNA-1273-P301-US381-2311US3812311AEXC03 Known history of SARS-CoV-2 infection. EXCLUSIONYYAScreening ÂSCREENING 2020-09-03.mRNA-1273-P301IEmRNA-1273-P301-US381-2327US3812327AEXC01 Participants who are acutely ill or febrile 72 hours prior to or at Screening may be rescheduled. Afebrile participants with minor illnesses can be enrolled at the discretion of the investigator. EXCLUSIONYYAScreening ÂSCREENING 2020-09-17.mRNA-1273-P301IEmRNA-1273-P301-US381-2327US3812327A INC03 Able to comply with study procedures based on the assessment of the Investigator. INCLUSIONNNAScreening ÂSCREENING 2020-09-17.mRNA-1273-P301IEmRNA-1273-P301-US381-2327US3812327A0INC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-17.mRNA-1273-P301IEmRNA-1273-P301-US382-2042US3822042AEXC12 Has received systemic immunosuppressants/immune-modifying drugs for >14 days in total within 6 months prior to Screening. Topical tacrolimus is allowed if not used within 14 days prior to Screening. EXCLUSIONYYAScreening ÂSCREENING 2020-08-07.mRNA-1273-P301IEmRNA-1273-P301-US382-2070US3822070AEXC03 Known history of SARS-CoV-2 infection. EXCLUSIONYYAScreening ÂSCREENING 2020-08-11.mRNA-1273-P301IEmRNA-1273-P301-US382-2124US3822124AEXC03 Known history of SARS-CoV-2 infection. EXCLUSIONYYAScreening ÂSCREENING 2020-08-13.mRNA-1273-P301IEmRNA-1273-P301-US382-2321US3822321AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-31.mRNA-1273-P301IEmRNA-1273-P301-US382-2370US3822370AEXC11CImmunosuppressive or immunodeficient state, asplenia, recurrent severe infections (HIVpositive participants with CD4 count =350 cells/mm3 and an undetectable HIV viral load within the past year). EXCLUSIONYYAScreening ÂSCREENING 2020-09-04.mRNA-1273-P301IEmRNA-1273-P301-US382-2384US3822384AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-09-10.mRNA-1273-P301IEmRNA-1273-P301-US382-2398US3822398AEXC09AHas received or plans to receive a non-study vaccine within 28 days before/after any dose of IP (except for seasonal influenza vaccine which not permitted within 14 days before/after any dose of IP).EXCLUSIONYYAScreening ÂSCREENING 2020-09-15.mRNA-1273-P301IEmRNA-1273-P301-US382-2444US3822444AEXC11CImmunosuppressive or immunodeficient state, asplenia, recurrent severe infections (HIVpositive participants with CD4 count =350 cells/mm3 and an undetectable HIV viral load within the past year). EXCLUSIONYYAScreening ÂSCREENING 2020-09-29.mRNA-1273-P301IEmRNA-1273-P301-US383-2023US3832023AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-07-31.mRNA-1273-P301IEmRNA-1273-P301-US383-2027US3832027AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-07-31.mRNA-1273-P301IEmRNA-1273-P301-US383-2230US3832230AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-19.mRNA-1273-P301IEmRNA-1273-P301-US383-2234US3832234AEXC11BImmunosuppressive or immunodeficient state, asplenia, recurrent severe infections (HIVpositive participants on stable antiretroviral therapy are not excluded). EXCLUSIONYYAScreening ÂSCREENING 2020-08-20.mRNA-1273-P301IEmRNA-1273-P301-US383-2241US3832241AEXC09AHas received or plans to receive a non-study vaccine within 28 days before/after any dose of IP (except for seasonal influenza vaccine which not permitted within 14 days before/after any dose of IP).EXCLUSIONYYAScreening ÂSCREENING 2020-08-21.mRNA-1273-P301IEmRNA-1273-P301-US383-2255US3832255AEXC12AHas received systemic immunosuppressants or immune-modifying drugs for >14 days in total within 6 months prior to Screening (for corticosteroids = 20 mg/day of prednisone equivalent). EXCLUSIONYYAScreening ÂSCREENING 2020-08-26.mRNA-1273-P301IEmRNA-1273-P301-US383-2275US3832275AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-10-14.mRNA-1273-P301IEmRNA-1273-P301-US383-2276US3832276AINC06 INCLUSIONNNAScreening ÂSCREENING 2020-10-15.mRNA-1273-P301IEmRNA-1273-P301-US384-2001US3842001AEXC10 Has participated in an interventional clinical study within 28 days prior to the day of enrollment. EXCLUSIONYYAScreening ÂSCREENING 2020-08-27.mRNA-1273-P301IEmRNA-1273-P301-US384-2002US3842002AEXC05 Demonstrated inability to comply with the study procedures. EXCLUSIONYYAScreening ÂSCREENING 2020-08-27.mRNA-1273-P301IEmRNA-1273-P301-US384-2004US3842004AEXC09AHas received or plans to receive a non-study vaccine within 28 days before/after any dose of IP (except for seasonal influenza vaccine which not permitted within 14 days before/after any dose of IP).EXCLUSIONYYAScreening ÂSCREENING 2020-08-28.mRNA-1273-P301IEmRNA-1273-P301-US384-2011US3842011AEXC05 Demonstrated inability to comply with the study procedures. EXCLUSIONYYAScreening ÂSCREENING 2020-09-01.mRNA-1273-P301IEmRNA-1273-P301-US384-2018US3842018AEXC12AHas received systemic immunosuppressants or immune-modifying drugs for >14 days in total within 6 months prior to Screening (for corticosteroids = 20 mg/day of prednisone equivalent). EXCLUSIONYYAScreening ÂSCREENING 2020-09-04.mRNA-1273-P301IEmRNA-1273-P301-US385-2038US3852038AEXC09AHas received or plans to receive a non-study vaccine within 28 days before/after any dose of IP (except for seasonal influenza vaccine which not permitted within 14 days before/after any dose of IP).EXCLUSIONYYAScreening ÂSCREENING 2020-08-26.mRNA-1273-P301IEmRNA-1273-P301-US385-2062US3852062AINC03 Able to comply with study procedures based on the assessment of the Investigator. INCLUSIONNNAScreening ÂSCREENING 2020-08-28.mRNA-1273-P301IEmRNA-1273-P301-US385-2104US3852104AEXC14 Has donated >= 450 mL of blood products within 28 days prior to Screening. EXCLUSIONYYAScreening ÂSCREENING 2020-09-03.mRNA-1273-P301IEmRNA-1273-P301-US385-2112US3852112AEXC14 Has donated >= 450 mL of blood products within 28 days prior to Screening. EXCLUSIONYYAScreening ÂSCREENING 2020-09-04.mRNA-1273-P301IEmRNA-1273-P301-US385-2140US3852013AEXC09AHas received or plans to receive a non-study vaccine within 28 days before/after any dose of IP (except for seasonal influenza vaccine which not permitted within 14 days before/after any dose of IP).EXCLUSIONYYAScreening ÂSCREENING 2020-08-24ÂmRNA-1273-P301IEmRNA-1273-P301-US385-2154US3852154AEXC02 Is pregnant or breastfeeding. EXCLUSIONYYAScreening ÂSCREENING 2020-09-10.mRNA-1273-P301IEmRNA-1273-P301-US386-2009US3862009AEXC12 Has received systemic immunosuppressants/immune-modifying drugs for >14 days in total within 6 months prior to Screening. Topical tacrolimus is allowed if not used within 14 days prior to Screening. EXCLUSIONYYAScreening ÂSCREENING 2020-08-13.mRNA-1273-P301IEmRNA-1273-P301-US386-2029US3862029AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-18.mRNA-1273-P301IEmRNA-1273-P301-US386-2031US3862031AEXC05 Demonstrated inability to comply with the study procedures. EXCLUSIONYYAScreening ÂSCREENING 2020-08-19.mRNA-1273-P301IEmRNA-1273-P301-US386-2078US3862078AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-28.mRNA-1273-P301IEmRNA-1273-P301-US386-2093US3862093AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-31.mRNA-1273-P301IEmRNA-1273-P301-US386-2107US3862107AEXC11CImmunosuppressive or immunodeficient state, asplenia, recurrent severe infections (HIVpositive participants with CD4 count =350 cells/mm3 and an undetectable HIV viral load within the past year). EXCLUSIONYYAScreening ÂSCREENING 2020-09-01.mRNA-1273-P301IEmRNA-1273-P301-US386-2122US3862122AEXC11CImmunosuppressive or immunodeficient state, asplenia, recurrent severe infections (HIVpositive participants with CD4 count =350 cells/mm3 and an undetectable HIV viral load within the past year). EXCLUSIONYYAScreening ÂSCREENING 2020-09-03.mRNA-1273-P301IEmRNA-1273-P301-US386-2126US3862126AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-03.mRNA-1273-P301IEmRNA-1273-P301-US386-2133US3862133AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-04.mRNA-1273-P301IEmRNA-1273-P301-US386-2150US3862150AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-08.mRNA-1273-P301IEmRNA-1273-P301-US386-2165US3862165AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-10.mRNA-1273-P301IEmRNA-1273-P301-US386-2176US3862176AINC05 Female participants of childbearing potential may be enrolled in the study if the participant fulfills all the criteria listed in the protocol. INCLUSIONNNAScreening ÂSCREENING 2020-09-11.mRNA-1273-P301IEmRNA-1273-P301-US386-2180US3862180AINC01 Adults, >= 18 years of age at time of consent, who are at high risk of SARS-CoV-2 infection. INCLUSIONNNAScreening ÂSCREENING 2020-09-14.mRNA-1273-P301IEmRNA-1273-P301-US386-2183US3862183AEXC12AHas received systemic immunosuppressants or immune-modifying drugs for >14 days in total within 6 months prior to Screening (for corticosteroids = 20 mg/day of prednisone equivalent). EXCLUSIONYYAScreening ÂSCREENING 2020-09-14.mRNA-1273-P301IEmRNA-1273-P301-US386-2194US3862194AEXC12AHas received systemic immunosuppressants or immune-modifying drugs for >14 days in total within 6 months prior to Screening (for corticosteroids = 20 mg/day of prednisone equivalent). EXCLUSIONYYAScreening ÂSCREENING 2020-09-15.mRNA-1273-P301IEmRNA-1273-P301-US386-2195US3862195AEXC12AHas received systemic immunosuppressants or immune-modifying drugs for >14 days in total within 6 months prior to Screening (for corticosteroids = 20 mg/day of prednisone equivalent). EXCLUSIONYYAScreening ÂSCREENING 2020-09-16.mRNA-1273-P301IEmRNA-1273-P301-US386-2199US3862199AEXC05 Demonstrated inability to comply with the study procedures. EXCLUSIONYYAScreening ÂSCREENING 2020-09-16.mRNA-1273-P301IEmRNA-1273-P301-US386-2212US3862212AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-17.mRNA-1273-P301IEmRNA-1273-P301-US386-2214US3862214AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-18.mRNA-1273-P301IEmRNA-1273-P301-US386-2226US3862226AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-21.mRNA-1273-P301IEmRNA-1273-P301-US386-2234US3862234AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-23.mRNA-1273-P301IEmRNA-1273-P301-US386-2236US3862236AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-23.mRNA-1273-P301IEmRNA-1273-P301-US386-2240US3862240AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-24.mRNA-1273-P301IEmRNA-1273-P301-US386-2244US3862244AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-25.mRNA-1273-P301IEmRNA-1273-P301-US386-2287US3862220AINC05 Female participants of childbearing potential may be enrolled in the study if the participant fulfills all the criteria listed in the protocol. INCLUSIONNNAScreening ÂSCREENING 2020-09-21ÂmRNA-1273-P301IEmRNA-1273-P301-US387-2034US3872034AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-04.mRNA-1273-P301IEmRNA-1273-P301-US387-2047US3872047AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-04.mRNA-1273-P301IEmRNA-1273-P301-US387-2093US3872093AEXC11AImmunosuppressive or immunodeficient state, including HIV infection, asplenia, recurrent severe infections. EXCLUSIONYYAScreening ÂSCREENING 2020-08-07.mRNA-1273-P301IEmRNA-1273-P301-US387-2111US3872111AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-10.mRNA-1273-P301IEmRNA-1273-P301-US387-2123US3872123AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-10.mRNA-1273-P301IEmRNA-1273-P301-US387-2133US3872133AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-11.mRNA-1273-P301IEmRNA-1273-P301-US387-2137US3872137AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-11.mRNA-1273-P301IEmRNA-1273-P301-US387-2151US3872151AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-12.mRNA-1273-P301IEmRNA-1273-P301-US387-2166US3872166AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-13.mRNA-1273-P301IEmRNA-1273-P301-US387-2183US3872183AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-08-07.mRNA-1273-P301IEmRNA-1273-P301-US387-2204US3872204AEXC09AHas received or plans to receive a non-study vaccine within 28 days before/after any dose of IP (except for seasonal influenza vaccine which not permitted within 14 days before/after any dose of IP).EXCLUSIONYYAScreening ÂSCREENING 2020-08-14.mRNA-1273-P301IEmRNA-1273-P301-US387-2222US3872222AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-17.mRNA-1273-P301IEmRNA-1273-P301-US387-2311US3872311AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-26.mRNA-1273-P301IEmRNA-1273-P301-US387-2362US3872362AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-29.mRNA-1273-P301IEmRNA-1273-P301-US387-2390US3872390AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-31.mRNA-1273-P301IEmRNA-1273-P301-US387-2454US3872454AEXC09AHas received or plans to receive a non-study vaccine within 28 days before/after any dose of IP (except for seasonal influenza vaccine which not permitted within 14 days before/after any dose of IP).EXCLUSIONYYAScreening ÂSCREENING 2020-09-04.mRNA-1273-P301IEmRNA-1273-P301-US387-2458US3872458AEXC09AHas received or plans to receive a non-study vaccine within 28 days before/after any dose of IP (except for seasonal influenza vaccine which not permitted within 14 days before/after any dose of IP).EXCLUSIONYYAScreening ÂSCREENING 2020-09-04.mRNA-1273-P301IEmRNA-1273-P301-US387-2473US3872473AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-08.mRNA-1273-P301IEmRNA-1273-P301-US387-2515US3872515AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-10.mRNA-1273-P301IEmRNA-1273-P301-US388-2007US3882007AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-09-01.mRNA-1273-P301IEmRNA-1273-P301-US388-2013US3882013AINC03 Able to comply with study procedures based on the assessment of the Investigator. INCLUSIONNNAScreening ÂSCREENING 2020-09-02.mRNA-1273-P301IEmRNA-1273-P301-US388-2017US3882017AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-09-03.mRNA-1273-P301IEmRNA-1273-P301-US388-2022US3882022AEXC05 Demonstrated inability to comply with the study procedures. EXCLUSIONYYAScreening ÂSCREENING 2020-09-04.mRNA-1273-P301IEmRNA-1273-P301-US388-2025US3882025AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-09-10.mRNA-1273-P301IEmRNA-1273-P301-US388-2030US3882030AINC03 Able to comply with study procedures based on the assessment of the Investigator. INCLUSIONNNAScreening ÂSCREENING 2020-09-16.mRNA-1273-P301IEmRNA-1273-P301-US388-2046US3882046AEXC05 Demonstrated inability to comply with the study procedures. EXCLUSIONYYAScreening ÂSCREENING 2020-10-16.mRNA-1273-P301IEmRNA-1273-P301-US388-2052US3882052AEXC05 Demonstrated inability to comply with the study procedures. EXCLUSIONYYAScreening ÂSCREENING 2020-10-20.mRNA-1273-P301IEmRNA-1273-P301-US388-2055US3882055AEXC05 Demonstrated inability to comply with the study procedures. EXCLUSIONYYAScreening ÂSCREENING 2020-10-20.mRNA-1273-P301IEmRNA-1273-P301-US388-2056US3882056AEXC05 Demonstrated inability to comply with the study procedures. EXCLUSIONYYAScreening ÂSCREENING 2020-10-21.mRNA-1273-P301IEmRNA-1273-P301-US388-2062US3882062AEXC05 Demonstrated inability to comply with the study procedures. EXCLUSIONYYAScreening ÂSCREENING 2020-10-21.mRNA-1273-P301IEmRNA-1273-P301-US388-2065US3882065AEXC05 Demonstrated inability to comply with the study procedures. EXCLUSIONYYAScreening ÂSCREENING 2020-10-22.mRNA-1273-P301IEmRNA-1273-P301-US388-2072US3882072AEXC05 Demonstrated inability to comply with the study procedures. EXCLUSIONYYAScreening ÂSCREENING 2020-10-23.mRNA-1273-P301IEmRNA-1273-P301-US389-2007US3892007AINC01 Adults, >= 18 years of age at time of consent, who are at high risk of SARS-CoV-2 infection. INCLUSIONNNAScreening ÂSCREENING 2020-08-24.mRNA-1273-P301IEmRNA-1273-P301-US389-2007US3892007A INC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-24.mRNA-1273-P301IEmRNA-1273-P301-US389-2012US3892012AEXC14 Has donated >= 450 mL of blood products within 28 days prior to Screening. EXCLUSIONYYAScreening ÂSCREENING 2020-08-26.mRNA-1273-P301IEmRNA-1273-P301-US389-2048US3892048AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-09-02.mRNA-1273-P301IEmRNA-1273-P301-US389-2051US3892051AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-04.mRNA-1273-P301IEmRNA-1273-P301-US389-2053US3892053AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-04.mRNA-1273-P301IEmRNA-1273-P301-US389-2068US3892068AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-09.mRNA-1273-P301IEmRNA-1273-P301-US389-2075US3892031AEXC14 Has donated >= 450 mL of blood products within 28 days prior to Screening. EXCLUSIONYYAScreening ÂSCREENING 2020-08-31Á°mRNA-1273-P301IEmRNA-1273-P301-US389-2082US3892082AEXC07AKnown or suspected allergy or history of anaphylaxis, urticaria, or other significant adverse reaction to the vaccine or its excipients. EXCLUSIONYYAScreening ÂSCREENING 2020-09-15.mRNA-1273-P301IEmRNA-1273-P301-US389-2085US3892085AINC03 Able to comply with study procedures based on the assessment of the Investigator. INCLUSIONNNAScreening ÂSCREENING 2020-09-21.mRNA-1273-P301IEmRNA-1273-P301-US390-2004US3902004AEXC12AHas received systemic immunosuppressants or immune-modifying drugs for >14 days in total within 6 months prior to Screening (for corticosteroids = 20 mg/day of prednisone equivalent). EXCLUSIONYYAScreening ÂSCREENING 2020-08-31.mRNA-1273-P301IEmRNA-1273-P301-US390-2013US3902013AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-01.mRNA-1273-P301IEmRNA-1273-P301-US390-2025US3902025AINC03 Able to comply with study procedures based on the assessment of the Investigator. INCLUSIONNNAScreening ÂSCREENING 2020-09-03.mRNA-1273-P301IEmRNA-1273-P301-US390-2040US3902040AEXC12AHas received systemic immunosuppressants or immune-modifying drugs for >14 days in total within 6 months prior to Screening (for corticosteroids = 20 mg/day of prednisone equivalent). EXCLUSIONYYAScreening ÂSCREENING 2020-09-04.mRNA-1273-P301IEmRNA-1273-P301-US390-2046US3902046AEXC14 Has donated >= 450 mL of blood products within 28 days prior to Screening. EXCLUSIONYYAScreening ÂSCREENING 2020-09-08.mRNA-1273-P301IEmRNA-1273-P301-US390-2047US3902047AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-08.mRNA-1273-P301IEmRNA-1273-P301-US390-2065US3902065AEXC10 Has participated in an interventional clinical study within 28 days prior to the day of enrollment. EXCLUSIONYYAScreening ÂSCREENING 2020-09-10.mRNA-1273-P301IEmRNA-1273-P301-US390-2113US3902113AINC03 Able to comply with study procedures based on the assessment of the Investigator. INCLUSIONNNAScreening ÂSCREENING 2020-09-25.mRNA-1273-P301IEmRNA-1273-P301-US390-2114US3902114AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-09-25.mRNA-1273-P301IEmRNA-1273-P301-US390-2131US3902131AINC03 Able to comply with study procedures based on the assessment of the Investigator. INCLUSIONNNAScreening ÂSCREENING 2020-10-16.mRNA-1273-P301IEmRNA-1273-P301-US390-2134US3902134AEXC09AHas received or plans to receive a non-study vaccine within 28 days before/after any dose of IP (except for seasonal influenza vaccine which not permitted within 14 days before/after any dose of IP).EXCLUSIONYYAScreening ÂSCREENING 2020-10-20.mRNA-1273-P301IEmRNA-1273-P301-US390-2137US3902137AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-10-21.mRNA-1273-P301IEmRNA-1273-P301-US390-2138US3902138AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-10-21.mRNA-1273-P301IEmRNA-1273-P301-US391-2008US3912008AINC01 Adults, >= 18 years of age at time of consent, who are at high risk of SARS-CoV-2 infection. INCLUSIONNNAScreening ÂSCREENING 2020-08-26.mRNA-1273-P301IEmRNA-1273-P301-US391-2009US3912009AINC01 Adults, >= 18 years of age at time of consent, who are at high risk of SARS-CoV-2 infection. INCLUSIONNNAScreening ÂSCREENING 2020-08-26.mRNA-1273-P301IEmRNA-1273-P301-US391-2010US3912010AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-08-26.mRNA-1273-P301IEmRNA-1273-P301-US391-2015US3912015AINC01 Adults, >= 18 years of age at time of consent, who are at high risk of SARS-CoV-2 infection. INCLUSIONNNAScreening ÂSCREENING 2020-08-27.mRNA-1273-P301IEmRNA-1273-P301-US391-2016US3912016AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-27.mRNA-1273-P301IEmRNA-1273-P301-US391-2018US3912018AINC01 Adults, >= 18 years of age at time of consent, who are at high risk of SARS-CoV-2 infection. INCLUSIONNNAScreening ÂSCREENING 2020-08-28.mRNA-1273-P301IEmRNA-1273-P301-US391-2023US3912023AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-28.mRNA-1273-P301IEmRNA-1273-P301-US391-2027US3912027AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-28.mRNA-1273-P301IEmRNA-1273-P301-US391-2035US3912035AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-29.mRNA-1273-P301IEmRNA-1273-P301-US391-2038US3912038AINC03 Able to comply with study procedures based on the assessment of the Investigator. INCLUSIONNNAScreening ÂSCREENING 2020-08-29.mRNA-1273-P301IEmRNA-1273-P301-US391-2038US3912038A INC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-29.mRNA-1273-P301IEmRNA-1273-P301-US391-2043US3912043AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-31.mRNA-1273-P301IEmRNA-1273-P301-US391-2049US3912049AEXC11CImmunosuppressive or immunodeficient state, asplenia, recurrent severe infections (HIVpositive participants with CD4 count =350 cells/mm3 and an undetectable HIV viral load within the past year). EXCLUSIONYYAScreening ÂSCREENING 2020-08-31.mRNA-1273-P301IEmRNA-1273-P301-US391-2050US3912050AEXC12AHas received systemic immunosuppressants or immune-modifying drugs for >14 days in total within 6 months prior to Screening (for corticosteroids = 20 mg/day of prednisone equivalent). EXCLUSIONYYAScreening ÂSCREENING 2020-08-31.mRNA-1273-P301IEmRNA-1273-P301-US391-2062US3912062AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-01.mRNA-1273-P301IEmRNA-1273-P301-US391-2064US3912064AEXC09AHas received or plans to receive a non-study vaccine within 28 days before/after any dose of IP (except for seasonal influenza vaccine which not permitted within 14 days before/after any dose of IP).EXCLUSIONYYAScreening ÂSCREENING 2020-09-01.mRNA-1273-P301IEmRNA-1273-P301-US391-2064US3912064A INC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-01.mRNA-1273-P301IEmRNA-1273-P301-US391-2069US3912069AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-01.mRNA-1273-P301IEmRNA-1273-P301-US391-2072US3912072AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-01.mRNA-1273-P301IEmRNA-1273-P301-US391-2080US3912080AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-02.mRNA-1273-P301IEmRNA-1273-P301-US391-2082US3912082AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-02.mRNA-1273-P301IEmRNA-1273-P301-US391-2085US3912085AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-02.mRNA-1273-P301IEmRNA-1273-P301-US391-2092US3912092AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-03.mRNA-1273-P301IEmRNA-1273-P301-US391-2095US3912095AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-03.mRNA-1273-P301IEmRNA-1273-P301-US391-2096US3912096AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-09-03.mRNA-1273-P301IEmRNA-1273-P301-US391-2100US3912100AEXC13 Has received systemic immunoglobulins or blood products within 3 months prior to the day of screening. EXCLUSIONYYAScreening ÂSCREENING 2020-09-03.mRNA-1273-P301IEmRNA-1273-P301-US391-2104US3912104AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-04.mRNA-1273-P301IEmRNA-1273-P301-US391-2106US3912106AEXC12AHas received systemic immunosuppressants or immune-modifying drugs for >14 days in total within 6 months prior to Screening (for corticosteroids = 20 mg/day of prednisone equivalent). EXCLUSIONYYAScreening ÂSCREENING 2020-09-04.mRNA-1273-P301IEmRNA-1273-P301-US391-2109US3912109AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-04.mRNA-1273-P301IEmRNA-1273-P301-US391-2112US3912112AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-04.mRNA-1273-P301IEmRNA-1273-P301-US391-2123US3912123AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-08.mRNA-1273-P301IEmRNA-1273-P301-US391-2127US3912127AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-08.mRNA-1273-P301IEmRNA-1273-P301-US391-2142US3912142AEXC14 Has donated >= 450 mL of blood products within 28 days prior to Screening. EXCLUSIONYYAScreening ÂSCREENING 2020-09-09.mRNA-1273-P301IEmRNA-1273-P301-US391-2146US3912146AEXC09AHas received or plans to receive a non-study vaccine within 28 days before/after any dose of IP (except for seasonal influenza vaccine which not permitted within 14 days before/after any dose of IP).EXCLUSIONYYAScreening ÂSCREENING 2020-09-11.mRNA-1273-P301IEmRNA-1273-P301-US391-2147US3912147AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-11.mRNA-1273-P301IEmRNA-1273-P301-US391-2150US3912150AEXC12AHas received systemic immunosuppressants or immune-modifying drugs for >14 days in total within 6 months prior to Screening (for corticosteroids = 20 mg/day of prednisone equivalent). EXCLUSIONYYAScreening ÂSCREENING 2020-09-11.mRNA-1273-P301IEmRNA-1273-P301-US391-2155US3912155AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-11.mRNA-1273-P301IEmRNA-1273-P301-US391-2157US3912157AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-11.mRNA-1273-P301IEmRNA-1273-P301-US391-2162US3912162AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-15.mRNA-1273-P301IEmRNA-1273-P301-US391-2175US3912175AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-16.mRNA-1273-P301IEmRNA-1273-P301-US391-2180US3912180AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-17.mRNA-1273-P301IEmRNA-1273-P301-US391-2181US3912181AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-17.mRNA-1273-P301IEmRNA-1273-P301-US391-2183US3912183AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-17.mRNA-1273-P301IEmRNA-1273-P301-US391-2189US3912189AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-18.mRNA-1273-P301IEmRNA-1273-P301-US391-2199US3912199AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-22.mRNA-1273-P301IEmRNA-1273-P301-US391-2210US3912210AEXC14 Has donated >= 450 mL of blood products within 28 days prior to Screening. EXCLUSIONYYAScreening ÂSCREENING 2020-09-23.mRNA-1273-P301IEmRNA-1273-P301-US391-2213US3912213AEXC11CImmunosuppressive or immunodeficient state, asplenia, recurrent severe infections (HIVpositive participants with CD4 count =350 cells/mm3 and an undetectable HIV viral load within the past year). EXCLUSIONYYAScreening ÂSCREENING 2020-09-24.mRNA-1273-P301IEmRNA-1273-P301-US391-2214US3912214AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-24.mRNA-1273-P301IEmRNA-1273-P301-US391-2227US3912227AINC03 Able to comply with study procedures based on the assessment of the Investigator. INCLUSIONNNAScreening ÂSCREENING 2020-09-30.mRNA-1273-P301IEmRNA-1273-P301-US391-2237US3912237AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-10-09.mRNA-1273-P301IEmRNA-1273-P301-US391-2238US3912238AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-10-09.mRNA-1273-P301IEmRNA-1273-P301-US392-2012US3922012AINC03 Able to comply with study procedures based on the assessment of the Investigator. INCLUSIONNNAScreening ÂSCREENING 2020-08-20.mRNA-1273-P301IEmRNA-1273-P301-US392-2019US3922019AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-22.mRNA-1273-P301IEmRNA-1273-P301-US392-2021US3922021AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-22.mRNA-1273-P301IEmRNA-1273-P301-US392-2024US3922024AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-24.mRNA-1273-P301IEmRNA-1273-P301-US392-2026US3922026AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-24.mRNA-1273-P301IEmRNA-1273-P301-US392-2027US3922027AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-24.mRNA-1273-P301IEmRNA-1273-P301-US392-2028US3922028AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-24.mRNA-1273-P301IEmRNA-1273-P301-US392-2030US3922030AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-25.mRNA-1273-P301IEmRNA-1273-P301-US392-2039US3922039AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-26.mRNA-1273-P301IEmRNA-1273-P301-US392-2048US3922048AEXC11CImmunosuppressive or immunodeficient state, asplenia, recurrent severe infections (HIVpositive participants with CD4 count =350 cells/mm3 and an undetectable HIV viral load within the past year). EXCLUSIONYYAScreening ÂSCREENING 2020-08-28.mRNA-1273-P301IEmRNA-1273-P301-US392-2048US3922048A EXC12AHas received systemic immunosuppressants or immune-modifying drugs for >14 days in total within 6 months prior to Screening (for corticosteroids = 20 mg/day of prednisone equivalent). EXCLUSIONYYAScreening ÂSCREENING 2020-08-28.mRNA-1273-P301IEmRNA-1273-P301-US392-2049US3922049AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-08-29.mRNA-1273-P301IEmRNA-1273-P301-US392-2055US3922055AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-31.mRNA-1273-P301IEmRNA-1273-P301-US392-2058US3922058AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-31.mRNA-1273-P301IEmRNA-1273-P301-US392-2062US3922062AINC03 Able to comply with study procedures based on the assessment of the Investigator. INCLUSIONNNAScreening ÂSCREENING 2020-08-31.mRNA-1273-P301IEmRNA-1273-P301-US392-2073US3922073AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-02.mRNA-1273-P301IEmRNA-1273-P301-US392-2077US3922077AINC01 Adults, >= 18 years of age at time of consent, who are at high risk of SARS-CoV-2 infection. INCLUSIONNNAScreening ÂSCREENING 2020-09-02.mRNA-1273-P301IEmRNA-1273-P301-US392-2083US3922083AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-03.mRNA-1273-P301IEmRNA-1273-P301-US392-2097US3922097AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-09.mRNA-1273-P301IEmRNA-1273-P301-US392-2107US3922002AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-17ÂmRNA-1273-P301IEmRNA-1273-P301-US392-2120US3922120AEXC11CImmunosuppressive or immunodeficient state, asplenia, recurrent severe infections (HIVpositive participants with CD4 count =350 cells/mm3 and an undetectable HIV viral load within the past year). EXCLUSIONYYAScreening ÂSCREENING 2020-09-16.mRNA-1273-P301IEmRNA-1273-P301-US392-2122US3922122AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-18.mRNA-1273-P301IEmRNA-1273-P301-US392-2123US3922123AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-09-18.mRNA-1273-P301IEmRNA-1273-P301-US392-2125US3922125AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-18.mRNA-1273-P301IEmRNA-1273-P301-US392-2126US3922126AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-18.mRNA-1273-P301IEmRNA-1273-P301-US392-2128US3922128AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-22.mRNA-1273-P301IEmRNA-1273-P301-US392-2130US3922130AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-22.mRNA-1273-P301IEmRNA-1273-P301-US392-2134US3922134AEXC11CImmunosuppressive or immunodeficient state, asplenia, recurrent severe infections (HIVpositive participants with CD4 count =350 cells/mm3 and an undetectable HIV viral load within the past year). EXCLUSIONYYAScreening ÂSCREENING 2020-09-23.mRNA-1273-P301IEmRNA-1273-P301-US392-2134US3922134A EXC12AHas received systemic immunosuppressants or immune-modifying drugs for >14 days in total within 6 months prior to Screening (for corticosteroids = 20 mg/day of prednisone equivalent). EXCLUSIONYYAScreening ÂSCREENING 2020-09-23.mRNA-1273-P301IEmRNA-1273-P301-US392-2135US3922135AEXC05 Demonstrated inability to comply with the study procedures. EXCLUSIONYYAScreening ÂSCREENING 2020-09-24.mRNA-1273-P301IEmRNA-1273-P301-US392-2135US3922135A INC03 Able to comply with study procedures based on the assessment of the Investigator. INCLUSIONNNAScreening ÂSCREENING 2020-09-24.mRNA-1273-P301IEmRNA-1273-P301-US392-2138US3922111AEXC09AHas received or plans to receive a non-study vaccine within 28 days before/after any dose of IP (except for seasonal influenza vaccine which not permitted within 14 days before/after any dose of IP).EXCLUSIONYYAScreening ÂSCREENING 2020-09-15ÂmRNA-1273-P301IEmRNA-1273-P301-US392-2148US3922148AEXC01 Participants who are acutely ill or febrile 72 hours prior to or at Screening may be rescheduled. Afebrile participants with minor illnesses can be enrolled at the discretion of the investigator. EXCLUSIONYYAScreening ÂSCREENING 2020-10-13.mRNA-1273-P301IEmRNA-1273-P301-US392-2169US3922169AEXC08 Bleeding disorder considered a contraindication to intramuscular injection or phlebotomy. EXCLUSIONYYAScreening ÂSCREENING 2020-10-21.mRNA-1273-P301IEmRNA-1273-P301-US392-2169US3922169A INC03 Able to comply with study procedures based on the assessment of the Investigator. INCLUSIONNNAScreening ÂSCREENING 2020-10-21.mRNA-1273-P301IEmRNA-1273-P301-US392-2173US3922173AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-10-21.mRNA-1273-P301IEmRNA-1273-P301-US392-2178US3922178AEXC08 Bleeding disorder considered a contraindication to intramuscular injection or phlebotomy. EXCLUSIONYYAScreening ÂSCREENING 2020-10-22.mRNA-1273-P301IEmRNA-1273-P301-US393-2006US3932006AEXC12 Has received systemic immunosuppressants/immune-modifying drugs for >14 days in total within 6 months prior to Screening. Topical tacrolimus is allowed if not used within 14 days prior to Screening. EXCLUSIONYYAScreening ÂSCREENING 2020-08-26.mRNA-1273-P301IEmRNA-1273-P301-US393-2010US3932010AEXC07AKnown or suspected allergy or history of anaphylaxis, urticaria, or other significant adverse reaction to the vaccine or its excipients. EXCLUSIONYYAScreening ÂSCREENING 2020-08-27.mRNA-1273-P301IEmRNA-1273-P301-US393-2013US3932013AINC01 Adults, >= 18 years of age at time of consent, who are at high risk of SARS-CoV-2 infection. INCLUSIONNNAScreening ÂSCREENING 2020-08-27.mRNA-1273-P301IEmRNA-1273-P301-US393-2014US3932014AINC01 Adults, >= 18 years of age at time of consent, who are at high risk of SARS-CoV-2 infection. INCLUSIONNNAScreening ÂSCREENING 2020-08-27.mRNA-1273-P301IEmRNA-1273-P301-US393-2022US3932022AINC03 Able to comply with study procedures based on the assessment of the Investigator. INCLUSIONNNAScreening ÂSCREENING 2020-08-28.mRNA-1273-P301IEmRNA-1273-P301-US393-2023US3932023AEXC10 Has participated in an interventional clinical study within 28 days prior to the day of enrollment. EXCLUSIONYYAScreening ÂSCREENING 2020-08-28.mRNA-1273-P301IEmRNA-1273-P301-US393-2034US3932034AINC03 Able to comply with study procedures based on the assessment of the Investigator. INCLUSIONNNAScreening ÂSCREENING 2020-08-31.mRNA-1273-P301IEmRNA-1273-P301-US393-2038US3932038AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-31.mRNA-1273-P301IEmRNA-1273-P301-US393-2045US3932045AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-09-01.mRNA-1273-P301IEmRNA-1273-P301-US393-2059US3932059AEXC13 Has received systemic immunoglobulins or blood products within 3 months prior to the day of screening. EXCLUSIONYYAScreening ÂSCREENING 2020-09-02.mRNA-1273-P301IEmRNA-1273-P301-US393-2060US3932060AEXC11CImmunosuppressive or immunodeficient state, asplenia, recurrent severe infections (HIVpositive participants with CD4 count =350 cells/mm3 and an undetectable HIV viral load within the past year). EXCLUSIONYYAScreening ÂSCREENING 2020-09-02.mRNA-1273-P301IEmRNA-1273-P301-US393-2060US3932060A EXC12AHas received systemic immunosuppressants or immune-modifying drugs for >14 days in total within 6 months prior to Screening (for corticosteroids = 20 mg/day of prednisone equivalent). EXCLUSIONYYAScreening ÂSCREENING 2020-09-02.mRNA-1273-P301IEmRNA-1273-P301-US393-2060US3932060A0EXC14 Has donated >= 450 mL of blood products within 28 days prior to Screening. EXCLUSIONYYAScreening ÂSCREENING 2020-09-02.mRNA-1273-P301IEmRNA-1273-P301-US393-2075US3932075AEXC10 Has participated in an interventional clinical study within 28 days prior to the day of enrollment. EXCLUSIONYYAScreening ÂSCREENING 2020-09-04.mRNA-1273-P301IEmRNA-1273-P301-US393-2076US3932076AEXC12AHas received systemic immunosuppressants or immune-modifying drugs for >14 days in total within 6 months prior to Screening (for corticosteroids = 20 mg/day of prednisone equivalent). EXCLUSIONYYAScreening ÂSCREENING 2020-09-04.mRNA-1273-P301IEmRNA-1273-P301-US393-2079US3932079AINC03 Able to comply with study procedures based on the assessment of the Investigator. INCLUSIONNNAScreening ÂSCREENING 2020-09-04.mRNA-1273-P301IEmRNA-1273-P301-US393-2084US3932084AEXC07AKnown or suspected allergy or history of anaphylaxis, urticaria, or other significant adverse reaction to the vaccine or its excipients. EXCLUSIONYYAScreening ÂSCREENING 2020-09-08.mRNA-1273-P301IEmRNA-1273-P301-US393-2084US3932084A INC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-08.mRNA-1273-P301IEmRNA-1273-P301-US393-2106US3932106AEXC14 Has donated >= 450 mL of blood products within 28 days prior to Screening. EXCLUSIONYYAScreening ÂSCREENING 2020-09-11.mRNA-1273-P301IEmRNA-1273-P301-US393-2107US3932107AEXC14 Has donated >= 450 mL of blood products within 28 days prior to Screening. EXCLUSIONYYAScreening ÂSCREENING 2020-09-11.mRNA-1273-P301IEmRNA-1273-P301-US393-2132US3932132AEXC10 Has participated in an interventional clinical study within 28 days prior to the day of enrollment. EXCLUSIONYYAScreening ÂSCREENING 2020-09-15.mRNA-1273-P301IEmRNA-1273-P301-US393-2137US3932137AEXC14 Has donated >= 450 mL of blood products within 28 days prior to Screening. EXCLUSIONYYAScreening ÂSCREENING 2020-09-15.mRNA-1273-P301IEmRNA-1273-P301-US393-2152US3932152AEXC10 Has participated in an interventional clinical study within 28 days prior to the day of enrollment. EXCLUSIONYYAScreening ÂSCREENING 2020-09-16.mRNA-1273-P301IEmRNA-1273-P301-US393-2162US3932162AINC03 Able to comply with study procedures based on the assessment of the Investigator. INCLUSIONNNAScreening ÂSCREENING 2020-09-21.mRNA-1273-P301IEmRNA-1273-P301-US393-2166US3932166AEXC12AHas received systemic immunosuppressants or immune-modifying drugs for >14 days in total within 6 months prior to Screening (for corticosteroids = 20 mg/day of prednisone equivalent). EXCLUSIONYYAScreening ÂSCREENING 2020-09-21.mRNA-1273-P301IEmRNA-1273-P301-US393-2170US3932170AEXC03 Known history of SARS-CoV-2 infection. EXCLUSIONYYAScreening ÂSCREENING 2020-09-22.mRNA-1273-P301IEmRNA-1273-P301-US393-2198US3932198AEXC14 Has donated >= 450 mL of blood products within 28 days prior to Screening. EXCLUSIONYYAScreening ÂSCREENING 2020-09-26.mRNA-1273-P301IEmRNA-1273-P301-US393-2199US3932199AINC03 Able to comply with study procedures based on the assessment of the Investigator. INCLUSIONNNAScreening ÂSCREENING 2020-09-26.mRNA-1273-P301IEmRNA-1273-P301-US393-2210US3932210AINC03 Able to comply with study procedures based on the assessment of the Investigator. INCLUSIONNNAScreening ÂSCREENING 2020-09-29.mRNA-1273-P301IEmRNA-1273-P301-US393-2241US3932241AEXC09AHas received or plans to receive a non-study vaccine within 28 days before/after any dose of IP (except for seasonal influenza vaccine which not permitted within 14 days before/after any dose of IP).EXCLUSIONYYAScreening ÂSCREENING 2020-10-13.mRNA-1273-P301IEmRNA-1273-P301-US393-2245US3932245AEXC09AHas received or plans to receive a non-study vaccine within 28 days before/after any dose of IP (except for seasonal influenza vaccine which not permitted within 14 days before/after any dose of IP).EXCLUSIONYYAScreening ÂSCREENING 2020-10-13.mRNA-1273-P301IEmRNA-1273-P301-US393-2251US3932251AINC03 Able to comply with study procedures based on the assessment of the Investigator. INCLUSIONNNAScreening ÂSCREENING 2020-10-14.mRNA-1273-P301IEmRNA-1273-P301-US393-2252US3932252AEXC14 Has donated >= 450 mL of blood products within 28 days prior to Screening. EXCLUSIONYYAScreening ÂSCREENING 2020-10-14.mRNA-1273-P301IEmRNA-1273-P301-US393-2254US3932254AEXC14 Has donated >= 450 mL of blood products within 28 days prior to Screening. EXCLUSIONYYAScreening ÂSCREENING 2020-10-14.mRNA-1273-P301IEmRNA-1273-P301-US393-2258US3932258AEXC11CImmunosuppressive or immunodeficient state, asplenia, recurrent severe infections (HIVpositive participants with CD4 count =350 cells/mm3 and an undetectable HIV viral load within the past year). EXCLUSIONYYAScreening ÂSCREENING 2020-10-14.mRNA-1273-P301IEmRNA-1273-P301-US393-2264US3932264AINC03 Able to comply with study procedures based on the assessment of the Investigator. INCLUSIONNNAScreening ÂSCREENING 2020-10-15.mRNA-1273-P301IEmRNA-1273-P301-US393-2265US3932265AINC03 Able to comply with study procedures based on the assessment of the Investigator. INCLUSIONNNAScreening ÂSCREENING 2020-10-15.mRNA-1273-P301IEmRNA-1273-P301-US393-2269US3932269AEXC14 Has donated >= 450 mL of blood products within 28 days prior to Screening. EXCLUSIONYYAScreening ÂSCREENING 2020-10-15.mRNA-1273-P301IEmRNA-1273-P301-US393-2282US3932282AINC05 Female participants of childbearing potential may be enrolled in the study if the participant fulfills all the criteria listed in the protocol. INCLUSIONNNAScreening ÂSCREENING 2020-10-16.mRNA-1273-P301IEmRNA-1273-P301-US393-2287US3932287AEXC11CImmunosuppressive or immunodeficient state, asplenia, recurrent severe infections (HIVpositive participants with CD4 count =350 cells/mm3 and an undetectable HIV viral load within the past year). EXCLUSIONYYAScreening ÂSCREENING 2020-10-17.mRNA-1273-P301IEmRNA-1273-P301-US393-2294US3932294AEXC03 Known history of SARS-CoV-2 infection. EXCLUSIONYYAScreening ÂSCREENING 2020-10-19.mRNA-1273-P301IEmRNA-1273-P301-US393-2299US3932299AINC03 Able to comply with study procedures based on the assessment of the Investigator. INCLUSIONNNAScreening ÂSCREENING 2020-10-20.mRNA-1273-P301IEmRNA-1273-P301-US393-2300US3932300AINC03 Able to comply with study procedures based on the assessment of the Investigator. INCLUSIONNNAScreening ÂSCREENING 2020-10-20.mRNA-1273-P301IEmRNA-1273-P301-US393-2301US3932301AINC03 Able to comply with study procedures based on the assessment of the Investigator. INCLUSIONNNAScreening ÂSCREENING 2020-10-20.mRNA-1273-P301IEmRNA-1273-P301-US393-2302US3932302AINC03 Able to comply with study procedures based on the assessment of the Investigator. INCLUSIONNNAScreening ÂSCREENING 2020-10-20.mRNA-1273-P301IEmRNA-1273-P301-US393-2303US3932303AEXC14 Has donated >= 450 mL of blood products within 28 days prior to Screening. EXCLUSIONYYAScreening ÂSCREENING 2020-10-20.mRNA-1273-P301IEmRNA-1273-P301-US393-2306US3932306AINC03 Able to comply with study procedures based on the assessment of the Investigator. INCLUSIONNNAScreening ÂSCREENING 2020-09-23.mRNA-1273-P301IEmRNA-1273-P301-US394-2026US3942026AINC05 Female participants of childbearing potential may be enrolled in the study if the participant fulfills all the criteria listed in the protocol. INCLUSIONNNAScreening ÂSCREENING 2020-08-28.mRNA-1273-P301IEmRNA-1273-P301-US394-2040US3942040AEXC11CImmunosuppressive or immunodeficient state, asplenia, recurrent severe infections (HIVpositive participants with CD4 count =350 cells/mm3 and an undetectable HIV viral load within the past year). EXCLUSIONYYAScreening ÂSCREENING 2020-09-01.mRNA-1273-P301IEmRNA-1273-P301-US394-2040US3942040A EXC12AHas received systemic immunosuppressants or immune-modifying drugs for >14 days in total within 6 months prior to Screening (for corticosteroids = 20 mg/day of prednisone equivalent). EXCLUSIONYYAScreening ÂSCREENING 2020-09-01.mRNA-1273-P301IEmRNA-1273-P301-US394-2046US3942046AEXC11CImmunosuppressive or immunodeficient state, asplenia, recurrent severe infections (HIVpositive participants with CD4 count =350 cells/mm3 and an undetectable HIV viral load within the past year). EXCLUSIONYYAScreening ÂSCREENING 2020-09-02.mRNA-1273-P301IEmRNA-1273-P301-US394-2050US3942050AEXC05 Demonstrated inability to comply with the study procedures. EXCLUSIONYYAScreening ÂSCREENING 2020-09-02.mRNA-1273-P301IEmRNA-1273-P301-US394-2053US3942053AEXC11CImmunosuppressive or immunodeficient state, asplenia, recurrent severe infections (HIVpositive participants with CD4 count =350 cells/mm3 and an undetectable HIV viral load within the past year). EXCLUSIONYYAScreening ÂSCREENING 2020-09-03.mRNA-1273-P301IEmRNA-1273-P301-US394-2060US3942060AEXC11CImmunosuppressive or immunodeficient state, asplenia, recurrent severe infections (HIVpositive participants with CD4 count =350 cells/mm3 and an undetectable HIV viral load within the past year). EXCLUSIONYYAScreening ÂSCREENING 2020-09-03.mRNA-1273-P301IEmRNA-1273-P301-US394-2060US3942060A EXC12AHas received systemic immunosuppressants or immune-modifying drugs for >14 days in total within 6 months prior to Screening (for corticosteroids = 20 mg/day of prednisone equivalent). EXCLUSIONYYAScreening ÂSCREENING 2020-09-03.mRNA-1273-P301IEmRNA-1273-P301-US394-2065US3942065AEXC02 Is pregnant or breastfeeding. EXCLUSIONYYAScreening ÂSCREENING 2020-09-04.mRNA-1273-P301IEmRNA-1273-P301-US394-2095US3942095AEXC10 Has participated in an interventional clinical study within 28 days prior to the day of enrollment. EXCLUSIONYYAScreening ÂSCREENING 2020-09-10.mRNA-1273-P301IEmRNA-1273-P301-US394-2103US3942103AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-15.mRNA-1273-P301IEmRNA-1273-P301-US394-2106US3942106AEXC05 Demonstrated inability to comply with the study procedures. EXCLUSIONYYAScreening ÂSCREENING 2020-09-15.mRNA-1273-P301IEmRNA-1273-P301-US394-2107US3942107AEXC05 Demonstrated inability to comply with the study procedures. EXCLUSIONYYAScreening ÂSCREENING 2020-09-15.mRNA-1273-P301IEmRNA-1273-P301-US394-2140US3942140AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-10-05.mRNA-1273-P301IEmRNA-1273-P301-US394-2143US3942143AEXC14 Has donated >= 450 mL of blood products within 28 days prior to Screening. EXCLUSIONYYAScreening ÂSCREENING 2020-10-07.mRNA-1273-P301IEmRNA-1273-P301-US395-2008US3952008AEXC09AHas received or plans to receive a non-study vaccine within 28 days before/after any dose of IP (except for seasonal influenza vaccine which not permitted within 14 days before/after any dose of IP).EXCLUSIONYYAScreening ÂSCREENING 2020-08-28.mRNA-1273-P301IEmRNA-1273-P301-US395-2011US3952011AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-28.mRNA-1273-P301IEmRNA-1273-P301-US395-2013US3952013AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-31.mRNA-1273-P301IEmRNA-1273-P301-US395-2029US3952029AEXC14 Has donated >= 450 mL of blood products within 28 days prior to Screening. EXCLUSIONYYAScreening ÂSCREENING 2020-09-02.mRNA-1273-P301IEmRNA-1273-P301-US395-2038US3952038AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-03.mRNA-1273-P301IEmRNA-1273-P301-US395-2042US3952042AEXC11BImmunosuppressive or immunodeficient state, asplenia, recurrent severe infections (HIVpositive participants on stable antiretroviral therapy are not excluded). EXCLUSIONYYAScreening ÂSCREENING 2020-09-03.mRNA-1273-P301IEmRNA-1273-P301-US395-2042US3952042A EXC12 Has received systemic immunosuppressants/immune-modifying drugs for >14 days in total within 6 months prior to Screening. Topical tacrolimus is allowed if not used within 14 days prior to Screening. EXCLUSIONYYAScreening ÂSCREENING 2020-09-03.mRNA-1273-P301IEmRNA-1273-P301-US395-2050US3952050AINC03 Able to comply with study procedures based on the assessment of the Investigator. INCLUSIONNNAScreening ÂSCREENING 2020-09-04.mRNA-1273-P301IEmRNA-1273-P301-US395-2077US3952077AINC05 Female participants of childbearing potential may be enrolled in the study if the participant fulfills all the criteria listed in the protocol. INCLUSIONNNAScreening ÂSCREENING 2020-09-11.mRNA-1273-P301IEmRNA-1273-P301-US395-2078US3952054AEXC09AHas received or plans to receive a non-study vaccine within 28 days before/after any dose of IP (except for seasonal influenza vaccine which not permitted within 14 days before/after any dose of IP).EXCLUSIONYYAScreening ÂSCREENING 2020-09-08.mRNA-1273-P301IEmRNA-1273-P301-US395-2078US3952078A INC03 Able to comply with study procedures based on the assessment of the Investigator. INCLUSIONNNAScreening ÂSCREENING 2020-09-11.mRNA-1273-P301IEmRNA-1273-P301-US395-2081US3952081AINC03 Able to comply with study procedures based on the assessment of the Investigator. INCLUSIONNNAScreening ÂSCREENING 2020-09-11.mRNA-1273-P301IEmRNA-1273-P301-US395-2087US3952087AINC05 Female participants of childbearing potential may be enrolled in the study if the participant fulfills all the criteria listed in the protocol. INCLUSIONNNAScreening ÂSCREENING 2020-09-14.mRNA-1273-P301IEmRNA-1273-P301-US395-2088US3952088AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-14.mRNA-1273-P301IEmRNA-1273-P301-US395-2089US3952089AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-14.mRNA-1273-P301IEmRNA-1273-P301-US395-2111US3952111AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-18.mRNA-1273-P301IEmRNA-1273-P301-US395-2119US3952119AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-21.mRNA-1273-P301IEmRNA-1273-P301-US395-2120US3952120AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-21.mRNA-1273-P301IEmRNA-1273-P301-US395-2123US3952123AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-21.mRNA-1273-P301IEmRNA-1273-P301-US395-2124US3952124AINC03 Able to comply with study procedures based on the assessment of the Investigator. INCLUSIONNNAScreening ÂSCREENING 2020-09-21.mRNA-1273-P301IEmRNA-1273-P301-US395-2124US3952124A INC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-21.mRNA-1273-P301IEmRNA-1273-P301-US395-2125US3952125AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-21.mRNA-1273-P301IEmRNA-1273-P301-US395-2126US3952126AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-21.mRNA-1273-P301IEmRNA-1273-P301-US395-2131US3952131AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-22.mRNA-1273-P301IEmRNA-1273-P301-US395-2138US3952138AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-23.mRNA-1273-P301IEmRNA-1273-P301-US395-2139US3952139AINC03 Able to comply with study procedures based on the assessment of the Investigator. INCLUSIONNNAScreening ÂSCREENING 2020-09-23.mRNA-1273-P301IEmRNA-1273-P301-US395-2139US3952139A INC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-23.mRNA-1273-P301IEmRNA-1273-P301-US395-2143US3952143AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-23.mRNA-1273-P301IEmRNA-1273-P301-US395-2144US3952144AINC03 Able to comply with study procedures based on the assessment of the Investigator. INCLUSIONNNAScreening ÂSCREENING 2020-09-23.mRNA-1273-P301IEmRNA-1273-P301-US395-2144US3952144A INC05 Female participants of childbearing potential may be enrolled in the study if the participant fulfills all the criteria listed in the protocol. INCLUSIONNNAScreening ÂSCREENING 2020-09-23.mRNA-1273-P301IEmRNA-1273-P301-US395-2144US3952144A0INC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-23.mRNA-1273-P301IEmRNA-1273-P301-US395-2146US3952146AINC05 Female participants of childbearing potential may be enrolled in the study if the participant fulfills all the criteria listed in the protocol. INCLUSIONNNAScreening ÂSCREENING 2020-09-24.mRNA-1273-P301IEmRNA-1273-P301-US395-2151US3952069AEXC09 Has received or plans to receive a vaccine within 28 days prior to the first dose or plans to receive a non-study vaccine within 28 days prior to or after any dose of IP. EXCLUSIONYYAScreening ÂSCREENING 2020-09-10ÁàmRNA-1273-P301IEmRNA-1273-P301-US395-2153US3952153AEXC09AHas received or plans to receive a non-study vaccine within 28 days before/after any dose of IP (except for seasonal influenza vaccine which not permitted within 14 days before/after any dose of IP).EXCLUSIONYYAScreening ÂSCREENING 2020-09-24.mRNA-1273-P301IEmRNA-1273-P301-US395-2162US3952162AINC03 Able to comply with study procedures based on the assessment of the Investigator. INCLUSIONNNAScreening ÂSCREENING 2020-09-28.mRNA-1273-P301IEmRNA-1273-P301-US395-2163US3952163AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-28.mRNA-1273-P301IEmRNA-1273-P301-US395-2165US3952165AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-28.mRNA-1273-P301IEmRNA-1273-P301-US395-2176US3952176AEXC11CImmunosuppressive or immunodeficient state, asplenia, recurrent severe infections (HIVpositive participants with CD4 count =350 cells/mm3 and an undetectable HIV viral load within the past year). EXCLUSIONYYAScreening ÂSCREENING 2020-09-29.mRNA-1273-P301IEmRNA-1273-P301-US395-2178US3952178AINC05 Female participants of childbearing potential may be enrolled in the study if the participant fulfills all the criteria listed in the protocol. INCLUSIONNNAScreening ÂSCREENING 2020-09-30.mRNA-1273-P301IEmRNA-1273-P301-US395-2183US3952183AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-30.mRNA-1273-P301IEmRNA-1273-P301-US395-2192US3952192AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-10-05.mRNA-1273-P301IEmRNA-1273-P301-US395-2198US3952198AEXC09AHas received or plans to receive a non-study vaccine within 28 days before/after any dose of IP (except for seasonal influenza vaccine which not permitted within 14 days before/after any dose of IP).EXCLUSIONYYAScreening ÂSCREENING 2020-10-06.mRNA-1273-P301IEmRNA-1273-P301-US395-2200US3952200AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-10-06.mRNA-1273-P301IEmRNA-1273-P301-US395-2203US3952203AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-10-07.mRNA-1273-P301IEmRNA-1273-P301-US395-2204US3952204AINC03 Able to comply with study procedures based on the assessment of the Investigator. INCLUSIONNNAScreening ÂSCREENING 2020-10-07.mRNA-1273-P301IEmRNA-1273-P301-US395-2213US3952213AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-10-08.mRNA-1273-P301IEmRNA-1273-P301-US396-2013US3962013AEXC07AKnown or suspected allergy or history of anaphylaxis, urticaria, or other significant adverse reaction to the vaccine or its excipients. EXCLUSIONYYAScreening ÂSCREENING 2020-08-21.mRNA-1273-P301IEmRNA-1273-P301-US396-2024US3962024AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-25.mRNA-1273-P301IEmRNA-1273-P301-US396-2025US3962025AEXC09AHas received or plans to receive a non-study vaccine within 28 days before/after any dose of IP (except for seasonal influenza vaccine which not permitted within 14 days before/after any dose of IP).EXCLUSIONYYAScreening ÂSCREENING 2020-08-25.mRNA-1273-P301IEmRNA-1273-P301-US396-2030US3962030AEXC05 Demonstrated inability to comply with the study procedures. EXCLUSIONYYAScreening ÂSCREENING 2020-08-28.mRNA-1273-P301IEmRNA-1273-P301-US396-2046US3962046AEXC14 Has donated >= 450 mL of blood products within 28 days prior to Screening. EXCLUSIONYYAScreening ÂSCREENING 2020-09-01.mRNA-1273-P301IEmRNA-1273-P301-US396-2049US3962049AINC01 Adults, >= 18 years of age at time of consent, who are at high risk of SARS-CoV-2 infection. INCLUSIONNNAScreening ÂSCREENING 2020-09-01.mRNA-1273-P301IEmRNA-1273-P301-US396-2051US3962051AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-09-01.mRNA-1273-P301IEmRNA-1273-P301-US396-2051US3962051A INC03 Able to comply with study procedures based on the assessment of the Investigator. INCLUSIONNNAScreening ÂSCREENING 2020-09-01.mRNA-1273-P301IEmRNA-1273-P301-US396-2052US3962052AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-02.mRNA-1273-P301IEmRNA-1273-P301-US396-2054US3962054AINC01 Adults, >= 18 years of age at time of consent, who are at high risk of SARS-CoV-2 infection. INCLUSIONNNAScreening ÂSCREENING 2020-09-02.mRNA-1273-P301IEmRNA-1273-P301-US396-2059US3962059AINC01 Adults, >= 18 years of age at time of consent, who are at high risk of SARS-CoV-2 infection. INCLUSIONNNAScreening ÂSCREENING 2020-09-02.mRNA-1273-P301IEmRNA-1273-P301-US396-2062US3962062AINC01 Adults, >= 18 years of age at time of consent, who are at high risk of SARS-CoV-2 infection. INCLUSIONNNAScreening ÂSCREENING 2020-09-02.mRNA-1273-P301IEmRNA-1273-P301-US396-2069US3962069AINC01 Adults, >= 18 years of age at time of consent, who are at high risk of SARS-CoV-2 infection. INCLUSIONNNAScreening ÂSCREENING 2020-09-04.mRNA-1273-P301IEmRNA-1273-P301-US396-2070US3962070AINC01 Adults, >= 18 years of age at time of consent, who are at high risk of SARS-CoV-2 infection. INCLUSIONNNAScreening ÂSCREENING 2020-09-04.mRNA-1273-P301IEmRNA-1273-P301-US396-2077US3962077AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-08.mRNA-1273-P301IEmRNA-1273-P301-US396-2087US3962087AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-09.mRNA-1273-P301IEmRNA-1273-P301-US396-2090US3962090AEXC14 Has donated >= 450 mL of blood products within 28 days prior to Screening. EXCLUSIONYYAScreening ÂSCREENING 2020-09-09.mRNA-1273-P301IEmRNA-1273-P301-US396-2098US3962098AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-11.mRNA-1273-P301IEmRNA-1273-P301-US396-2103US3962103AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-24.mRNA-1273-P301IEmRNA-1273-P301-US396-2107US3962048AEXC14 Has donated >= 450 mL of blood products within 28 days prior to Screening. EXCLUSIONYYAScreening ÂSCREENING 2020-09-01Â+mRNA-1273-P301IEmRNA-1273-P301-US396-2115US3962115AINC03 Able to comply with study procedures based on the assessment of the Investigator. INCLUSIONNNAScreening ÂSCREENING 2020-10-20.mRNA-1273-P301IEmRNA-1273-P301-US396-2116US3962116AEXC09AHas received or plans to receive a non-study vaccine within 28 days before/after any dose of IP (except for seasonal influenza vaccine which not permitted within 14 days before/after any dose of IP).EXCLUSIONYYAScreening ÂSCREENING 2020-10-20.mRNA-1273-P301IEmRNA-1273-P301-US397-2009US3972009AEXC09AHas received or plans to receive a non-study vaccine within 28 days before/after any dose of IP (except for seasonal influenza vaccine which not permitted within 14 days before/after any dose of IP).EXCLUSIONYYAScreening ÂSCREENING 2020-08-24.mRNA-1273-P301IEmRNA-1273-P301-US397-2012US3972012AEXC14 Has donated >= 450 mL of blood products within 28 days prior to Screening. EXCLUSIONYYAScreening ÂSCREENING 2020-08-24.mRNA-1273-P301IEmRNA-1273-P301-US397-2056US3972056AEXC12AHas received systemic immunosuppressants or immune-modifying drugs for >14 days in total within 6 months prior to Screening (for corticosteroids = 20 mg/day of prednisone equivalent). EXCLUSIONYYAScreening ÂSCREENING 2020-08-28.mRNA-1273-P301IEmRNA-1273-P301-US397-2061US3972061AEXC13 Has received systemic immunoglobulins or blood products within 3 months prior to the day of screening. EXCLUSIONYYAScreening ÂSCREENING 2020-08-31.mRNA-1273-P301IEmRNA-1273-P301-US397-2063US3972063AEXC09AHas received or plans to receive a non-study vaccine within 28 days before/after any dose of IP (except for seasonal influenza vaccine which not permitted within 14 days before/after any dose of IP).EXCLUSIONYYAScreening ÂSCREENING 2020-08-31.mRNA-1273-P301IEmRNA-1273-P301-US397-2066US3972066AEXC10 Has participated in an interventional clinical study within 28 days prior to the day of enrollment. EXCLUSIONYYAScreening ÂSCREENING 2020-08-31.mRNA-1273-P301IEmRNA-1273-P301-US397-2074US3972074AEXC14 Has donated >= 450 mL of blood products within 28 days prior to Screening. EXCLUSIONYYAScreening ÂSCREENING 2020-08-31.mRNA-1273-P301IEmRNA-1273-P301-US397-2075US3972075AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-08-31.mRNA-1273-P301IEmRNA-1273-P301-US397-2078US3972078AEXC12AHas received systemic immunosuppressants or immune-modifying drugs for >14 days in total within 6 months prior to Screening (for corticosteroids = 20 mg/day of prednisone equivalent). EXCLUSIONYYAScreening ÂSCREENING 2020-09-01.mRNA-1273-P301IEmRNA-1273-P301-US397-2085US3972085AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-01.mRNA-1273-P301IEmRNA-1273-P301-US397-2094US3972094AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-02.mRNA-1273-P301IEmRNA-1273-P301-US397-2105US3972105AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-03.mRNA-1273-P301IEmRNA-1273-P301-US397-2110US3972110AEXC12AHas received systemic immunosuppressants or immune-modifying drugs for >14 days in total within 6 months prior to Screening (for corticosteroids = 20 mg/day of prednisone equivalent). EXCLUSIONYYAScreening ÂSCREENING 2020-09-04.mRNA-1273-P301IEmRNA-1273-P301-US397-2125US3972125AEXC12AHas received systemic immunosuppressants or immune-modifying drugs for >14 days in total within 6 months prior to Screening (for corticosteroids = 20 mg/day of prednisone equivalent). EXCLUSIONYYAScreening ÂSCREENING 2020-09-08.mRNA-1273-P301IEmRNA-1273-P301-US397-2125US3972125A INC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-08.mRNA-1273-P301IEmRNA-1273-P301-US397-2130US3972130AEXC12AHas received systemic immunosuppressants or immune-modifying drugs for >14 days in total within 6 months prior to Screening (for corticosteroids = 20 mg/day of prednisone equivalent). EXCLUSIONYYAScreening ÂSCREENING 2020-09-08.mRNA-1273-P301IEmRNA-1273-P301-US397-2130US3972130A INC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-08.mRNA-1273-P301IEmRNA-1273-P301-US397-2133US3972133AEXC14 Has donated >= 450 mL of blood products within 28 days prior to Screening. EXCLUSIONYYAScreening ÂSCREENING 2020-09-09.mRNA-1273-P301IEmRNA-1273-P301-US397-2137US3972102AEXC09AHas received or plans to receive a non-study vaccine within 28 days before/after any dose of IP (except for seasonal influenza vaccine which not permitted within 14 days before/after any dose of IP).EXCLUSIONYYAScreening ÂSCREENING 2020-09-03ÁpmRNA-1273-P301IEmRNA-1273-P301-US397-2153US3972153AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-14.mRNA-1273-P301IEmRNA-1273-P301-US397-2160US3972160AEXC05 Demonstrated inability to comply with the study procedures. EXCLUSIONYYAScreening ÂSCREENING 2020-09-15.mRNA-1273-P301IEmRNA-1273-P301-US397-2168US3972168AEXC09AHas received or plans to receive a non-study vaccine within 28 days before/after any dose of IP (except for seasonal influenza vaccine which not permitted within 14 days before/after any dose of IP).EXCLUSIONYYAScreening ÂSCREENING 2020-09-15.mRNA-1273-P301IEmRNA-1273-P301-US397-2174US3972174AEXC14 Has donated >= 450 mL of blood products within 28 days prior to Screening. EXCLUSIONYYAScreening ÂSCREENING 2020-09-16.mRNA-1273-P301IEmRNA-1273-P301-US397-2175US3972175AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-16.mRNA-1273-P301IEmRNA-1273-P301-US397-2185US3972185AEXC05 Demonstrated inability to comply with the study procedures. EXCLUSIONYYAScreening ÂSCREENING 2020-09-17.mRNA-1273-P301IEmRNA-1273-P301-US397-2185US3972185A INC03 Able to comply with study procedures based on the assessment of the Investigator. INCLUSIONNNAScreening ÂSCREENING 2020-09-17.mRNA-1273-P301IEmRNA-1273-P301-US397-2188US3972188AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-09-17.mRNA-1273-P301IEmRNA-1273-P301-US397-2198US3972198AEXC12AHas received systemic immunosuppressants or immune-modifying drugs for >14 days in total within 6 months prior to Screening (for corticosteroids = 20 mg/day of prednisone equivalent). EXCLUSIONYYAScreening ÂSCREENING 2020-09-18.mRNA-1273-P301IEmRNA-1273-P301-US397-2199US3972199AEXC12AHas received systemic immunosuppressants or immune-modifying drugs for >14 days in total within 6 months prior to Screening (for corticosteroids = 20 mg/day of prednisone equivalent). EXCLUSIONYYAScreening ÂSCREENING 2020-09-18.mRNA-1273-P301IEmRNA-1273-P301-US397-2209US3972209AEXC14 Has donated >= 450 mL of blood products within 28 days prior to Screening. EXCLUSIONYYAScreening ÂSCREENING 2020-09-21.mRNA-1273-P301IEmRNA-1273-P301-US397-2212US3972166AEXC09AHas received or plans to receive a non-study vaccine within 28 days before/after any dose of IP (except for seasonal influenza vaccine which not permitted within 14 days before/after any dose of IP).EXCLUSIONYYAScreening ÂSCREENING 2020-09-15Á€mRNA-1273-P301IEmRNA-1273-P301-US397-2215US3972141AEXC09AHas received or plans to receive a non-study vaccine within 28 days before/after any dose of IP (except for seasonal influenza vaccine which not permitted within 14 days before/after any dose of IP).EXCLUSIONYYAScreening ÂSCREENING 2020-09-11ÂmRNA-1273-P301IEmRNA-1273-P301-US397-2220US3972220AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-28.mRNA-1273-P301IEmRNA-1273-P301-US398-2032US3982032AINC01 Adults, >= 18 years of age at time of consent, who are at high risk of SARS-CoV-2 infection. INCLUSIONNNAScreening ÂSCREENING 2020-08-27.mRNA-1273-P301IEmRNA-1273-P301-US398-2046US3982046AEXC12AHas received systemic immunosuppressants or immune-modifying drugs for >14 days in total within 6 months prior to Screening (for corticosteroids = 20 mg/day of prednisone equivalent). EXCLUSIONYYAScreening ÂSCREENING 2020-08-28.mRNA-1273-P301IEmRNA-1273-P301-US398-2056US3982056AEXC07 History of anaphylaxis, urticaria, or other significant adverse reaction requiring medical intervention after receipt of a vaccine. EXCLUSIONYY. . .mRNA-1273-P301IEmRNA-1273-P301-US398-2057US3982057AEXC12AHas received systemic immunosuppressants or immune-modifying drugs for >14 days in total within 6 months prior to Screening (for corticosteroids = 20 mg/day of prednisone equivalent). EXCLUSIONYYAScreening ÂSCREENING 2020-08-31.mRNA-1273-P301IEmRNA-1273-P301-US398-2064US3982064AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-09-01.mRNA-1273-P301IEmRNA-1273-P301-US398-2094US3982094AEXC11CImmunosuppressive or immunodeficient state, asplenia, recurrent severe infections (HIVpositive participants with CD4 count =350 cells/mm3 and an undetectable HIV viral load within the past year). EXCLUSIONYYAScreening ÂSCREENING 2020-09-03.mRNA-1273-P301IEmRNA-1273-P301-US398-2104US3982104AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-09-03.mRNA-1273-P301IEmRNA-1273-P301-US398-2154US3982154AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-11.mRNA-1273-P301IEmRNA-1273-P301-US398-2164US3982164AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-14.mRNA-1273-P301IEmRNA-1273-P301-US398-2176US3982176AINC07 Healthy adults or adults with pre-existing medical conditions who are in stable condition. INCLUSIONNNAScreening ÂSCREENING 2020-09-15.mRNA-1273-P301IEmRNA-1273-P301-US398-2177US3982177AINC02 Understands and agrees to comply with the study procedures and provides written informed consent. INCLUSIONNNAScreening ÂSCREENING 2020-09-15.mRNA-1273-P301IEmRNA-1273-P301-US398-2228US3982228AINC03 Able to comply with study procedures based on the assessment of the Investigator. INCLUSIONNNAScreening ÂSCREENING 2020-09-23.mRNA-1273-P301IEmRNA-1273-P301-US398-2254US3982254AEXC14 Has donated >= 450 mL of blood products within 28 days prior to Screening. EXCLUSIONYYAScreening ÂSCREENING 2020-09-30.